Pharmaceutical care practice : drug-related problems and opportunities for new services by Eichenberger, Patrick Marc
  
 
Pharmaceutical Care Practice – 
Drug-related Problems and Opportunities for New Services 
 
 
 
Inauguraldissertation 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
 
Patrick Marc Eichenberger 
aus Lenzburg (AG) 
 
Basel, 2010  
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
 
 
Prof. Dr. Kurt Hersberger 
Prof. Dr. Dr. Stephan Krähenbühl 
 
 
 
Basel, den 27. April 2010 
 
 
 Prof. Dr. Eberhard Parlow 
 Dekan 
 
Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 2.5 Schweiz
Sie dürfen:
das Werk vervielfältigen, verbreiten und öffentlich zugänglich machen
Zu den folgenden Bedingungen:
Namensnennung. Sie müssen den Namen des Autors/Rechteinhabers in der 
von ihm festgelegten Weise nennen (wodurch aber nicht der Eindruck entstehen 
darf, Sie oder die Nutzung des Werkes durch Sie würden entlohnt).
Keine kommerzielle Nutzung. Dieses Werk darf nicht für kommerzielle 
Zwecke verwendet werden.
Keine Bearbeitung. Dieses Werk darf nicht bearbeitet oder in anderer Weise 
verändert werden.
• Im Falle einer Verbreitung müssen Sie anderen die Lizenzbedingungen, unter welche dieses Werk fällt, 
mitteilen. Am Einfachsten ist es, einen Link auf diese Seite einzubinden.
• Jede der vorgenannten Bedingungen kann aufgehoben werden, sofern Sie die Einwilligung des 
Rechteinhabers dazu erhalten.
• Diese Lizenz lässt die Urheberpersönlichkeitsrechte unberührt.
Quelle: http://creativecommons.org/licenses/by-nc-nd/2.5/ch/  Datum: 3.4.2009
Die gesetzlichen Schranken des Urheberrechts bleiben hiervon unberührt. 
Die Commons Deed ist eine Zusammenfassung des Lizenzvertrags in allgemeinverständlicher Sprache: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ch/legalcode.de
Haftungsausschluss:
Die Commons Deed ist kein Lizenzvertrag. Sie ist lediglich ein Referenztext, der den zugrundeliegenden 
Lizenzvertrag übersichtlich und in allgemeinverständlicher Sprache wiedergibt. Die Deed selbst entfaltet 
keine juristische Wirkung und erscheint im eigentlichen Lizenzvertrag nicht. Creative Commons ist keine 
Rechtsanwaltsgesellschaft und leistet keine Rechtsberatung. Die Weitergabe und Verlinkung des 
Commons Deeds führt zu keinem Mandatsverhältnis.
  
 
 
 
 
 
 
 
 
 
 To my family 
 
Acknowledgements 
 4
Acknowledgements 
This work was carried out at the Pharmaceutical Care Research Group at the 
University of Basel and was supervised by Prof. Dr. sc. nat. Kurt E. Hersberger and 
Prof. Dr. med. Dr. pharm. Stephan Krähenbühl. 
 
My thanks belong to all the people who had contributed in any way to the 
accomplishment of this thesis. 
 
First of all, I would like to thank sincerely Prof. Dr. Kurt E. Hersberger for his 
unrestricted support, his enthusiasm and helpfulness during the whole thesis. I am 
very grateful for all the interesting and inspiring discussions, his valuable ideas and 
his untiring dedication. 
 
I wish to express my gratitude to Prof. Dr. Dr. Stephan Krähenbühl for supporting this 
thesis and for assuming the co-reference. His helpful suggestions contributed to the 
accomplishment of this thesis. 
 
Many thanks belong to Dr. phil. Markus Lampert and to Dr. med. Manuel Haschke for 
their support in several projects and to Prof. Dr. med. Rudolf Bruppacher for his 
support in analysis and for his helpful inspirations in the framework of the seminar in 
clinical pharmacy. 
 
My thanks go to Prof. Dr. Christoph Meier for accepting the function of representative 
of the Faculty. 
 
I would like to thank Senglet Foundation (Basel, Switzerland) and Förderinitiative 
Pharmazeutische Betreuung e.V. (c/o ABDA, Bundesvereinigung Deutscher 
Apothekerverbände) for the financial support. 
 
Many thanks go to all colleagues of the Pharmaceutical Care Research Group, 
especially to Seraina Mengiardi, Dr. Jörg Indermitte, Philipp Walter, Fabienne Böni, 
Acknowledgements 
 5
Esther Spinatsch, Dr. Vera Bernhardt, and Dr. Isabelle Arnet as well as to all 
colleagues of the Pharmacoepidemiology Unit and the Clinical Pharmacology and 
Toxicology, especially to Patrick Imfeld, Dr. Yolanda Brauchli, Dr. Birk Poller, Dr. 
Felix Hammann, Dr. Sabin Egger, Dr. Alexandra Rätz Bravo, Peter Mullen, Carmen 
Franz, Dr. Marcel Bruggisser, Cornelia Schneider, and Julia Spöndlin. 
 
I would like to thank Flavia Gregorini, Barbara Slejska and Romina Caluori for their 
excellent work in the framework of their master theses in our team. 
 
At this point I would like to express my gratefulness to my parents Silvia und Eugen 
and to my brother Reto for their great sympathy, always motivating encouragement 
and for giving me the opportunity to do these studies but above all for their deep love 
and incredible everlasting support. 
 
Abbreviations 
 6
Abbreviations 
ABDA Confederation of German pharmacists’ associations 
ADE Adverse drug event 
ADR Adverse drug reaction 
AFS Automated forms processing 
ANOVA Analysis of variance 
ASHP American Society of Hospital Pharmacy 
BP Blood pressure 
BPCS Behavioural pharmaceutical care scale 
cDUR Concurrent drug utilization review 
CH Switzerland (Confoederatio Helvetica) 
CHD Coronary heart disease 
CI Confidence interval 
CMR Clinical medication review 
CPCF Community pharmacy contractual framework 
CPD Continuing professional development 
CPS Cognitive pharmaceutical service 
CV(D) Cardiovascular (disease) 
DDI Drug-drug interaction 
DFI Drug-food interaction 
DK Denmark 
DMMR Domiciliary medication management review 
DRP Drug-related problem 
DRR Drug regimen review 
DUE Drug use evaluation 
DUR Drug utilization review 
EKBB Ethics Committee of Basel 
EQ-5DTM EuroQol 5D 
FVC Forced vital capacity 
GER Germany 
GP General practitioner 
Abbreviations 
 7
HF Heart failure 
HV Home visit 
HMR Home medicines review 
IQR Interquartile range 
MRR Medication regimen review 
MRRF Medication-related risk factor 
MTM Medication therapy management 
MUR Medicines use review 
NCCP-MERP 
National coordinating council for medication error reporting and 
prevention 
NHS National Health Service 
OTC Over-the-counter 
PAS® Problems, assessment, and solutions 
PBM Pharmacy benefit manager 
PC Pharmaceutical care 
PCNE Pharmaceutical Care Network Europe 
pDUR Prospective drug utilization review 
PI-Doc® Problem-Intervention-Documentation 
PIE Problem, Intervention, Ergebnis (Outcome) 
PMC Polymedication check 
POM Prescription-only medicine 
PQ Postgraduate qualification 
QC Quality circle 
rDUR Retrospective drug utilization review 
RCT Randomized controlled trial 
RMMR Residential medication management review 
SD Standard deviation 
SF-36 Short Form 36 
SHB-SEP The Health Base Foundation – subjective/objective, evaluation, plan 
SOEP Subjective, objective, evaluation, plan 
UK United Kingdom 
US United States 
V Version 
Table of contents 
 8
Table of contents 
Acknowledgements.................................................................................................. 4 
Abbreviations............................................................................................................ 6 
Table of contents...................................................................................................... 8 
Summary ................................................................................................................. 11 
1 General introduction ....................................................................................... 19 
1.1 Pharmaceutical care................................................................................... 19 
1.2 Drug-related problems................................................................................ 28 
1.3 Medication review....................................................................................... 35 
1.4 Rationale and approach ............................................................................. 45 
1.5 Synopsis of rationale and aims of the thesis .............................................. 51 
2 Provision of pharmaceutical care by community pharmacists................... 55 
2.1 Project A: Provision of pharmaceutical care by community 
pharmacists: a comparison across Europe (Euopean BPCS project).........57 
2.2 Project B: Provision of pharmaceutical care by Swiss and German 
community pharmacists: in-depth analysis of data from the European 
BPCS project and comparison with a sample of quality circle 
pharmacists ................................................................................................85 
3 Classification of drug-related problems...................................................... 129 
Project C: Classification of drug-related problems with new 
prescriptions using a modified PCNE classification system......................131 
Table of contents 
 9
4 Opportunities for pharmaceutical care........................................................ 159 
4.1 Project D: Patient knowledge and management of new prescribed 
medication: a pilot study ...........................................................................161 
4.2 Project E: Home visits of diabetes type 2 and solid organ transplant 
patients reveal opportunities for pharmaceutical care...............................175 
5 General discussion and conclusions .......................................................... 199 
6 References ..................................................................................................... 205 
7 Appendix ........................................................................................................ 227 
Curriculum vitae ................................................................................................... 258 
 
  
Summary 
 11
Summary 
Within the last decades, the role of the pharmacist and of pharmacy practice have 
moved from that of drug manufacturing and technical dispensing to a more cognitive 
role with patient orientation. The concept of pharmaceutical care focuses on the 
process of ‘using a drug’, bearing in mind that the dispensing of a drug is neither the 
beginning nor the end of this process. Pharmaceutical care is based on a relationship 
between the patient and the pharmacist who accepts responsibility for the patient. 
The concept implies the active participation of the patient in making decisions 
regarding his/her pharmacotherapy. Assessment of drug-related problems (DRPs), 
development of a care plan and its evaluation, as well as a continuous follow-up are 
important steps of the pharmaceutical care process. However, much of the impetus 
for pharmaceutical care provision has been driven by academics, and only limited 
published data on the extent to which pharmaceutical care has been adopted and 
implemented are available. This is particularly true for community pharmacy practice, 
at a national as well as international level. 
 
Drug-related problems are very common in primary care and in hospital settings. To 
evaluate the benefit of pharmaceutical care, we need tools to describe DRPs and 
measure their impact on patient outcomes. Pharmaceutical care practitioners need to 
be aware of common pattern of inappropriate care and the associated risk for 
adverse outcomes when they want to manage drug therapy successfully. In turn, our 
knowledge about the nature, prevalence, and causes of drug-related morbidity has to 
derive from practice. The classification of identified DRPs is useful to simplify the 
analysis, documentation, and prevention of further problems. However, no accepted 
standard tool for classification and documentation of DRPs has been made available 
so far. 
 
Clinical pharmacy is a commonly used term in pharmacy practice and pharmacy 
literature. The term includes all services performed by pharmacists practising in 
hospitals, community pharmacies, nursing homes, home-based care services, clinics, 
and any other setting where medicines are prescribed and used. The term ‘clinical’ 
does not necessarily imply an activity implemented in a hospital setting. A community 
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pharmacist as well as a hospital practitioner may perform clinical activities. Clinical 
pharmacists’ activities aim at maximising the clinical effect of medicines, minimising 
the risk of treatment-induced adverse events, and minimising the expenditures for 
pharmacological treatments. Medication reviews on individual patient level form a 
central part of this process. Although recent studies indicated that pharmacist-led 
medication reviews and home visits are potentially beneficial, it is still an open 
question if tailored medication reviews are needed. 
 
This thesis aimed to focus on different aspects of pharmaceutical care, i.e. 
 
- to investigate the provision of pharmaceutical care by community pharmacists 
across Europe and to closely examine the factors that could affect its 
implementation in Switzerland and Germany, 
- to explore the occurrence, nature, and the pharmacist’s management of DRPs 
with new prescriptions and to determine patients’ knowledge about newly 
prescribed medication shortly after the pharmacy visit, 
- to gain first experience with home visits of chronically ill patients. 
 
The concept of pharmaceutical care has been adopted by professional pharmacy 
associations and academic training programmes throughout the world and has 
redirected the focus of the pharmacist’s role within community practice from a 
traditional dispensing role to a more outcome-oriented, patient-centred practice. The 
aim of project A was to evaluate the current provision of pharmaceutical care by 
community pharmacists across 13 European countries and the impact of a range of 
factors that could affect its implementation. For this study, the behavioural 
pharmaceutical care scale (BPCS) was used. A total of 4,696 questionnaires were 
obtained (overall response rate of 25.3%). The mean total BPCS scores ranged from 
50.6 (Denmark) to 83.5 (Ireland). Ireland had significantly higher total scores than 
other countries. Denmark had the lowest mean total score, followed by Sweden. In 
general, pharmacists scored less well on ‘direct patient care activities’ (means 
ranged from 17.9% to 43.8% of the maximum achievable score) than on the ‘referral 
and consultation’ (means ranged from 39.4% to 70.1%) or the ‘instrumental activities’ 
dimension (means ranged from 50.6% to 70.3%). In England and Ireland, the 
provision of pharmaceutical care was more extensive if more pharmacists were 
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employed by a certain pharmacy. Furthermore, ‘referral and consultation activities’ in 
both countries increased with increasing number of employed pharmacists. The latter 
situation was also true for Switzerland and Belgium. In Sweden and Portugal, the 
total number of full-time pharmacists had a positive impact on the score obtained for 
‘direct patient care activities’ which specifically seeks to capture pharmacists’ efforts 
to provide pharmaceutical care. 
 
The results of project A suggest that the provision of pharmaceutical care in a 
comprehensive fashion is still limited within Europe. Pharmacists rarely documented 
activities related to patient care and did not often evaluated patients’ perceived status 
or engaged in implementing therapeutic objectives and monitoring plans. 
 
Because of the different healthcare systems in Germany (GER) and Switzerland (CH; 
several regions with dispensing doctors [DDs] in Switzerland), we used the 
opportunity to amend the BPCS questionnaire with specific questions. Our aim was 
to perform an in-depth analysis in project B and to compare these results with a 
sample of specialised quality circle (QC) pharmacists. After completion of our 
surveys among these three samples, we realised with surprise that Denmark (DK) 
had scored lowest although several pharmaceutical care services had already been 
implemented there. With this study, we aimed to explore differences between 
standard pharmacists, pharmacists participating in quality circles, and Danish 
pharmacists. Moreover, differences between Swiss pharmacists in regions with or 
without DDs were of interest, as well as discussion of the BPCS’ reliability and 
applicability as a research tool for pharmacy practice. Response rates ranged from 
10.1% (GER) to 59.9% (QC). The mean total score achieved by community 
pharmacists, expressed as a percentage of the total score achievable, ranged from 
31.6% (DK) to 45.8% (CH). The specialised QC and Danish pharmacists reached 
significantly lower scores in some dimensions and domains than Swiss and German 
pharmacists (e.g. dimension: direct patient care activities; domains: documentation, 
patient record screening, discussion of drug therapy, or verification of patient 
understanding). 
 
Our results show that pharmacies in all regions are adequately equipped to provide 
pharmaceutical care. However, the provision of pharmaceutical care mainly occured 
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when pharmacists were supported by their computer system, while individual patient 
approaches seem to be less frequent. Surprisingly, specialised QC pharmacists had 
lower scores than standard community pharmacies. This result casts doubt on the 
results of the whole BPCS study, and the question arises if the BPCS is a sensitive 
scale to enable a conclusion about the extent to which pharmaceutical care is 
provided to patients. 
 
Many studies have shown DRPs to be very common in primary care and hospital 
settings. Patients with at least one new prescribed drug represent a relevant 
population for the study of DRPs, especially for studying the applicability of a 
comprehensive classification system which includes technical DRPs. 
 
The aims of project C were to explore the occurrence of DRPs with new 
prescriptions and to analyse differences between primary care and hospital 
discharge as well as between electronically printed and handwritten prescriptions. 
Furthermore, we aimed to evaluate the applicability of a modified classification 
system. Prescriptions of 616 patients were analysed. The patients received a median 
of 3 (range 2−19) different drugs. In 121 (19.6%) prescriptions, 141 clinical DRPs 
were detected. The most frequent clinical DRPs were potential drug-drug interactions 
(DDIs; 37.6%), drug choice (24.8%), and drug use problems (15.6%). These clinical 
DRPs led to a total of 299 interventions. There were 222 prescriptions (36.0%) that 
contained 278 technical DRPs, resulting in a total of 417 interventions. The most 
frequent technical DRPs were missing or unclear package size or therapy duration 
(32.7%) and missing or unclear dosing/application instructions (30.9%).  
The results of this study showed that clinical and technical DRPs were frequently 
observed and that the number of prescribed drugs was the only factor with an 
influence on the frequency. The modified Pharmaceutical Care Network Europe 
(PCNE) classification system, especially the amendment with a technical DRP 
category, proved to be useful and allowed the classification of all DRPs. 
 
To get insight into the patients’ medication management and to identify DRPs, it may 
be useful to visit patients at home. Medication review has been shown to be an 
effective service to identify DRPs although some randomised controlled trials failed to 
prove effectiveness. With project D – a pilot study – we set the goal to explore 
Summary 
 15
patients’ knowledge about newly prescribed medication and to gain first experiences 
in performing home visits. We conducted 70 phone interviews with patients who 
received newly prescribed medications some days ago. Only 35% of drug names 
could be given by patients (10% of gastrointestinal and 20% of cardiovascular drugs). 
However, 92% of all stated purposes of drugs were correct (60% of cardiovascular 
drug purposes were known). Patients knew the duration of intake in 89% of cases, 
frequency or timing in 96% of cases, and the number of tablets of all drugs in 84% of 
cases. 
 
Out of 70 interviewed patients, 20 agreed to be visited at their home. The mean (SD) 
age of patients was 59.2 (16.2) years. The mean (SD) duration of a visit was 
42.9 min (24.3), ranging from 15 to 125 min. We recorded a mean (SD) number of 
4.6 (2.5) drugs per patient. Seventeen (85.0%) patients got their drugs from a single 
pharmacy. Two (10.0%) patients had drug use problems (e.g. big tablets), seven 
(35.0%) suffered from adverse drug events (e.g. gastro-intestinal problems, 
headache). No patient used a medicine cupboard. Seven (35%) patients experienced 
moderate or severe interactions. 
 
The patients’ knowledge a few days after receiving newly prescribed drugs was 
rather good (except for drug names and potential adverse effects). Home visits 
showed to be a feasible service, presumably also for community pharmacists. 
 
The structured interview guide for home visits developed for project D proved to be a 
useful tool. This pilot study gave important information on potential improvements of 
the interview guide, which were incorporated in the subsequent main study. In 
project E, we analysed the number and pattern of DRPs and assessed the patients’ 
knowledge. We also explored opportunities for pharmaceutical care at the patients’ 
home. Two investigators visited 54 diabetes type 2 (DM) and 22 solid organ 
transplant (Tx) patients in their homes, using a structured interview guide specifically 
developed for this study. We identified a mean of 7.4 ± 2.4 DRPs per visited patient, 
with significant differences between Tx and DM patients (6.3 ± 1.7 vs. 7.8 ± 2.5; 
p=0.010). All patients had at least one DRP. The most relevant DRPs in Tx and DM 
patients were uncertainty about one or multiple purposes or justification of drugs 
(36.4% and 48.1%), uncertainty about potential adverse effects (31.8 and 50.0%), no 
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basic knowledge about potential interactions such as with grapefruit, St. John’s wort, 
and/or beta-blockers (18.2% and 61.1%), no medication administration routine 
(36.4% and 37.0%), confusion of generic and trade names (27.3% and 74.1%), and 
risk for non-adherence (77.3% and 61.1%). In the case of a missed dose, 27.3% (Tx) 
and 61.1% (DM) of patients would ‘just ignore it’. The mean number of drugs was 
12.5 ± 4.4 (Tx) and 13.9 ± 5.4 (DM). Among all patients, 11 (14.5%) reported to have 
problems with their drugs (e.g. swallowing, opening of a bottle, use of a pipette). If 
interviews had been conducted at the pharmacies rather than the patient homes, we 
most probably would have detected only 3.6 ± 1.5 (48.6%) DRPs. Thus, we reason 
that 51.4% of all DRPs were only identified because we performed visits at the 
patient’s home. 
 
The results of this study indicated that home visits allowed to identify more DRPs 
than would have been detected with a medication review in the pharmacy and that 
more tailored interview guides for different diseases would enable more efficient 
home visits. 
 
In conclusion this thesis showed the following: 
 
- The provision of pharmaceutical care in a comprehensive fashion is still limited 
within Europe. Pharmacists routinely screened patient records and verified 
patient understanding but rarely documented activities related to patient care, 
evaluated patients’ perceived status, engaged in implementing therapeutic 
objectives and monitoring plans, or self-evaluated their performance in 
providing pharmaceutical care on regular basis. There is substantial room for 
improvements. 
 
- Pharmacies are adequately equipped to provide pharmaceutical care. 
However, the provision of pharmaceutical care mainly occured when 
pharmacists were supported by their computer system. If the results are 
presented in detail, they are much more meaningful than when aggregated in 
domains and dimensions. However, the question arises if the BPCS scale is 
sensitive enough to enable a conclusion about the extent to which 
pharmaceutical care is provided to patients. Thus, further efforts are needed to 
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develop valid assessment tools including indicators for pharmaceutical care 
activities. 
 
- Clinical and technical DRPs are frequently observed in new primary care and 
in hospital discharge prescriptions. Their occurrence was only influenced by 
the number of prescribed drugs. Therefore, management of DRPs in 
community pharmacies is a very important activity. The modified PCNE 
classification system proved to be useful and allowed the classification of all 
DRPs, but remained rather complicated to apply in pharmacy practice. 
 
- The patients’ knowledge a few days after receiving newly prescribed drugs 
was rather good (except for drug names and potential adverse effects), 
indicating that patients obtaining their drugs from a pharmacy were well 
informed. Home visits of such patients showed to be a feasible service, 
presumably also for community pharmacists. 
 
- Home visits of chronically ill patients allowed assessing more DRPs than 
would have been detected with an interview at the pharmacy. Transplant 
patients showed significantly less DRPs than diabetes patients who were often 
confused about generic and trade names, hoarded drugs, and had gaps in 
knowledge about interactions and purpose of drugs. These aspects represent 
important opportunities for pharmaceutical care. The interview guide 
developed specifically for the purpose of this study proved useful in the 
selected patient population. More tailored interview guides for different 
diseases would enable more efficient home visits. 
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1 General introduction 
1.1 Pharmaceutical care 
1.1.1 Development of pharmaceutical care 
Within the last decades, the role of the pharmacist and of pharmacy practice have 
moved from that of drug manufacturing and technical dispensing to a more cognitive 
role with patient orientation [1]. Pharmaceutical care was first defined by Mikeal et al. 
in 1975 [2] as “the care that a given patient requires and receives which assures safe 
and rational drug usage”. The concept of pharmaceutical care focuses on the 
process of ‘using a drug’, bearing in mind that the dispensing of a drug is neither the 
beginning nor the end of this process [3, 4]. According to the definition of Hepler and 
Strand [5, 6], pharmaceutical care is “the responsible provision of medicine therapy 
for the purpose of definite outcomes that improve a patient’s quality of life”. 
 
Pharmaceutical care is based on a relationship between the patient and the 
pharmacist who accepts responsibility for the patient. The concept implies the active 
participation of the patient in making decisions regarding his/her pharmacotherapy 
and the interdisciplinary cooperation of healthcare providers, and gives priority to the 
direct benefit of the patient. Assessment of drug-related problems (DRPs), 
development of a care plan and its evaluation, as well as a continuous follow-up are 
important steps of the pharmaceutical care process [4, 7]. Patient expectations and 
desired quality of life are important factors to ensure the best possible medication 
outcome, and to possibly prevent recurrence of disease. Pharmaceutical care is an 
indispensable element of patient centred healthcare and requires a change of 
traditional professional attitudes, a re-engineering of the pharmacy environment, the 
use of new technologies, and the acquisition of knowledge as well as skills in the 
areas of patient assessment, clinical information, communication, adult teaching, and 
psychosocial aspects of care [4]. 
 
The term ‘pharmaceutical care’ has established itself as a philosophy of practice, with 
the patient and the community as the primary beneficiaries of the pharmacist’s 
actions. The concept is particularly relevant to special groups such as the elderly, 
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mothers and children, and chronically ill patients. The model of pharmaceutical care 
is perhaps most advanced in the United Kingdom (UK) as evidenced by the new 
National Health Service (NHS) contractual frameworks for community pharmacy 
(CPCF) [8]. 
 
Clinical pharmacy is a commonly used term in pharmacy practice and in pharmacy 
literature. It is a health specialty which describes the activities and services of the 
clinical pharmacist to develop and promote the rational and appropriate use of 
medicinal products and devices [9]. The term includes all services performed by 
pharmacists practising in hospitals, community pharmacies, nursing homes, home-
based care services, clinics, and any other setting where medicines are prescribed 
and used. The term ‘clinical’ does not necessarily imply an activity implemented in a 
hospital setting. A community pharmacist as well as a hospital practitioner may 
perform clinical activities. Clinical pharmacists’ activities aim at maximising the 
clinical effect of medicines (i.e. using the most effective treatment for each type of 
patient), minimising the risk of treatment-induced adverse events (i.e. monitoring the 
therapy course and the patient’s compliance with therapy), and minimising the 
expenditures for pharmacological treatments [9] driven by the national healthcare 
systems and the patients (i.e. trying to provide the best treatment for the greatest 
number of patients). Medication reviews on individual patient level form a central part 
of this process. A literature review found that clinical pharmacy interventions in 
inpatient medical care contribute to improved patient outcomes [10]. A number of 
studies have demonstrated the clinical and economic benefits of clinical pharmacy 
interventions in hospital and primary care settings [11-15].  
 
The World Health Organization (WHO) and others consider community pharmacists 
to be ideally positioned to play important roles in facilitating improved patient 
adherence by, among others, providing patients with cognitive pharmaceutical 
services (CPS) that include the provision of appropriate health-related information 
and counselling to promote self-care and the correct use of medicines [16-19]. There 
is ample evidence that pharmaceutical care and CPS have been successfully applied 
by pharmacists across a range of disease entities and in different pharmacy practice 
settings [20-25]. Comprehensive or cognitive pharmacy services involve activities 
both to secure good health and to avoid ill-health in the population. When ill-health is 
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treated, it is necessary to assure quality in the process of using medicines in order to 
achieve maximum therapeutic benefit and avoid untoward side-effects. This 
presupposes the acceptance by pharmacists of shared responsibility with other 
professionals and with patients for the outcome of therapy [1]. 
1.1.2 Effectiveness of pharmaceutical care 
We found four reviews covering the period up to the end of 2003: a Cochrane review 
included 25 studies between 1966 and 1999 with more than 16,000 patients and was 
published in 2006 [26]. They compared 1. pharmacist services targeted at patients 
vs. services delivered by other health professionals; 2. pharmacist services targeted 
at patients vs. the delivery of no comparable service; 3. pharmacist services targeted 
at health professionals vs. services delivered by other health professionals; 
4. pharmacist services targeted at health professionals vs. the delivery of no 
comparable service. Comparison 1: scheduled service utilisation was slightly 
increased, whereas hospital admissions and emergency room admissions were 
decreased. Comparison 2: pharmacist services reduced the use of health services, 
the number of specialty physician visits, or the number and costs of drugs, compared 
to control patients. Improvements in the targeted patient condition were reported in 
10 of 13 studies that measured patient outcomes, but patients' quality of life did not 
seem to change. Comparison 3: the intervention delivered by the pharmacist was 
less successful than that delivered by physician counsellors in decreasing 
inappropriate prescribing. Comparison 4: all studies demonstrated that pharmacist 
interventions produced the intended effects on physicians prescribing practices. The 
authors concluded that only two studies compared pharmacist services with other 
health professional services. Both had some bias and did not allow drawing 
conclusions about comparisons 1 and 3. 
 
An evidence report issued in 2004 by the Danish College of Pharmacy Practice 
(Pharmakon) [27] about the follow-up on outcomes of drug therapy (Pharmaceutical 
Care) covered 44 studies between 1990 and October 2003 [28]. This report showed 
strong evidence that pharmaceutical care can positively influence clinical parameters 
(blood pressure [BP], blood sugar, and cholesterol) and that there is a positive 
influence on health-related quality of life of asthma patients and patients with 
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elevated cholesterol levels, hypertension, and diabetes. However, three out of five 
studies in elderly patients showed no difference between intervention and control 
groups. There is a tendency that programmes for the elderly do not affect drug use, 
and the authors found evidence for the cost effectiveness of pharmaceutical care 
programmes, patient satisfaction, and increased adherence (but not among the 
elderly), but evidence of improved knowledge was inconsistent. They concluded that 
pharmaceutical care programmes can contribute to solving DRPs of clinical 
significance and adverse drug events (ADE), that the acceptance rate among general 
practitioners (GPs) and patients is high, and that pharmaceutical care promotes more 
rational drug use among patients with elevated cholesterol levels and asthma 
patients. 
 
A critical review, published by Blenkinsopp et al. in 2005 [29], about enhanced 
community pharmacy-based diabetes care included 17 studies between 1990 and 
2003. They found only a few trials of community pharmacy-based interventions to 
improve diabetes care. However, the authors concluded that there is limited evidence 
of effectiveness of community pharmacy-based interventions in diabetes care. 
 
A systematic review by Roughead et al. [30] of 2005 looking at the effectiveness of 
pharmaceutical care services in the community or outpatient setting on patient 
outcomes included 22 randomised, controlled trials from 1990 to 2003 [30] and 
provided an evidence base for the improvement of medication use. Within this 
review, studies showed improved surrogate endpoints such as changes in blood 
pressure, glycosylated haemoglobin (HbA1C), lipids, and peak expiratory flow rates 
[23, 31-38]. However, improvement in other outcomes (e.g. morbidity and mortality 
[34, 36-44], knowledge or adherence [23, 33, 34, 39]) was less conclusive. The 
authors concluded that in future studies the outcome measure should be the 
resolution of medication-related problems as this is the focus of pharmaceutical care. 
 
To cover the subsequent period after these reviews, we conducted a literature search 
on the effectiveness of pharmaceutical care over the last 6 years conducted at the 
end of March 2010 using the National Library of Medicine MEDLINE database. With 
the Medical Subject Heading (MeSH) ‘pharmaceutical services’ (‘pharmaceutical 
care’ is comprised within ‘pharmaceutical services’) we located 380 articles with the 
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following limits: review, meta-analysis, or randomized controlled trial (RCT); English 
or German language; all adult (>18 years) and humans. Sixteen studies (Table 1) 
and 7 reviews (Table 2) considering the effectiveness of pharmaceutical care were 
identified. 
Out of 16 studies, 10 found positive effects with pharmaceutical care programmes 
[45-55]. However, the authors of 6 studies concluded that such programmes did not 
lead to reductions in hospital admissions [56], had no positive impact on clinical 
outcomes or quality of life [57], and were even associated with a significantly higher 
rate of hospital admissions [58]. Furthermore, Salter et al. [59] claimed that 
pharmacist interventions have the potential to undermine and threaten the patients’ 
assumed competence, integrity, and self-governance. Zermansky et al. [60] 
concluded that pharmacists’ recommendations by clinical pharmacists were usually 
accepted and that there was a reduction in the number of falls but no changes or 
improvements of costs, hospitalisations, and mortality. Bond et al. [11] reported that 
pharmacist-led services were more expensive than standard care and that no change 
in the proportion of patients receiving appropriate medication was observed. 
 
The reviews identified in the literature search that met the criteria found that there are 
significant positive effects on HbA1c levels [61, 62], systolic BP [63], and total 
cholesterol [64] as well as on low-density lipoprotein (LDL-) cholesterol and 
triglyceride levels. In addition, there is evidence that clinical pharmacy interventions 
can reduce the occurrence of DRPs [65]. However, no improvements on high-density 
lipoprotein (HDL-) cholesterol levels [64], diastolic BP, and adherence [63, 64, 66] 
were found. Moreover, no effects were found on mortality and all-case hospital 
admission [66], and there was unclear evidence about effects on quality of life [63, 
64, 66]. 
 
Overall, there the effectiveness of pharmaceutical care remains unclear. However, 
several studies and reviews could show benefit and evidence for different activities 
considering economic, clinical, and humanistic outcomes (ECHO). Furthermore, 
patients and pharmacists as well as physicians in many cases were satisfied with 
pharmaceutical care services. Further research with larger intervention studies with 
improved quality of design is needed. 
 
  
Table 1: Studies investigating the effectiveness of pharmaceutical care 
Study Design Participants Interventions Outcomes Conclusions 
Sorensen  
et al. 2004 
[55] 
RCT - 400 patients at risk of 
medication misadventure 
in the community 
- home visits (HVs) 
- pharmacist-led medication 
review 
- implementation of action 
plans in consultation with 
patients 
- quality of life (Short Form 36; SF-
36) and satisfaction 
- adverse drug events 
- no. of GP visits 
- hospital services 
- severity of illness 
- costs 
- positive trends in adverse drug 
events, severity of illness, and costs 
- no improvement of quality of life 
Holland  
et al. 2005 
[67] 
RCT  
(HOMER) 
- 872 patients 
- age ≥80 
- ≥2 drugs 
- 2 pharmacist-led HVs - hospital readmissions 
- death and quality of life (EuroQol 
5D; EQ-5D) 
- significantly higher rate of hospital 
admissions 
- no significant improvement of quality 
of life or reduction of no. of deaths 
Sadik  
et al. 2005 
[47] 
RCT - 104 patients 
- heart failure (HF) 
- pharmacist-led patient 
education and counselling 
- instruction for self-
monitoring 
- provision of booklet 
- daily exercise 
- exercise tolerance, pulse 
- BP 
- body weight 
- forced vital capacity (FVC) 
- quality of life (Minnesota living with 
heart failure questionnaire (MLHF); 
SF-36) 
- self-reported adherence 
- knowledge 
- improvements in exercise tolerance, 
FVC, quality of life (MLHF), and 
adherence 
- tendency to higher incidence of 
casualty department visits but a lower 
rate of hospitalization 
Zermansky  
et al. 2006 
[60] 
RCT - 661 residents 
- age ≥65 
- ≥1 drugs 
- pharmacist-led clinical 
medication review with 
patient and clinical records 
- no. of changes in medication 
- no. and cost of repeat 
medicines 
- mortality, falls, hospital admissions, 
GP consultations, Barthel index, 
Standardised Mini-Mental State 
Examination (SMMSE) 
- significant change in patients’ 
medication regimens without change in 
drug costs 
- significant reduction in the no. of falls 
- no significant change in GP 
consultations, hospitalisation, mortality, 
SMMSE or Barthel score 
- clinical pharmacists’ 
recommendations usually accepted 
Lee  
et al. 2006 
[48] 
RCT - 200 community-based 
patients 
- age ≥65 
- ≥ 4 chronic drugs 
- standardized pharmacist-
led medication 
education 
- regular follow-up 
- blister packs 
- proportion of pills taken (vs. 
baseline) 
- BP 
- LDL-C 
- improvement of medication 
adherence and persistence, systolic 
BP and LDL-C 
- discontinuation of the programme 
was associated with decreased 
medication adherence and persistence 
continued next page 
 
  
Study Design Participants Interventions Outcomes Conclusions 
Cabezas  
et al. 2006 
[45] 
Randomized 
clinical trial 
- 134 patients 
- HF 
- pharmacist-led patient 
education 
- telephone follow-up 
 
- hospital readmissions  
- days of hospital stay  
- treatment compliance  
- satisfaction and quality of life (EQ-
5D)  
- financial savings 
- improvement of treatment compliance 
and satisfaction 
- reduction of hospital readmissions 
and days of hospital stay 
- evidence for savings in hospital costs 
- no improvement of quality of life 
Wu  
et al. 2006 
[46] 
RCT - 442 patients 
- non-adherent  
- ≥5 drugs for chronic 
diseases 
- pharmacist-led phone 
counselling 
- all cause mortality 
- association between adherence and 
mortality 
- reduced mortality and improved 
compliance 
- poor compliance was associated with 
increased mortality 
Holland 
et al. 2007 
[56] 
RCT  
(HeartMed) 
- 293 patients 
- HF 
- 2 pharmacist-led HVs - hospital readmissions 
- mortality and quality of life (MLHF 
and EQ- 5D) 
- no reductions in hospital 
readmissions 
- improved quality of life with EQ-5D 
but not with MLHF 
Lenaghan  
et al. 2007 
[57] 
RCT  
(POLYMED) 
- 136 patients living at 
home 
- age >80 
- ≥4 drugs 
- ≥1 medicines-related 
risk factor 
- 2 pharmacist-led HVs and 
patient education 
- assessment of the need for 
adherence-aid 
- non-elective hospital admissions 
- no. of deaths 
- care home admissions  
- quality of life (EQ-5D)  
- impact of prescribed drugs 
- no reduction of hospital and care 
home admissions as well as no. of 
deaths 
- small decrease of quality of life 
- significant reduction of prescribed 
drugs 
Salter  
et al. 2007 
[59] 
Qualitative 
discourse 
analysis 
- 29 (out of 758) patients 
out of HOMER trial 
(2005) 
- age ≥80  
- patients admitted to 
hospital 
- pharmacist-led medication 
review 
- in-depth interviews before 
and after the review 
- extent to which advice given by 
pharmacists was accepted and 
acknowledged by patients 
- advice giving role of pharmacists 
during consultations has the potential 
to undermine and threaten the patients’ 
assumed competence, integrity, and 
self governance 
- caution is needed in assuming that 
commonsense interventions 
necessarily lead to health gain 
Bond  
et al. 2007 
[68] 
RCT 
(MEDMAN) 
- 1493 patients 
- coronary heart disease 
(CHD) 
- pharmacist-led medication 
management 
- appropriate treatment 
- quality of life (SF-36, EQ-5D) 
- economic evaluation 
- patient risk of cardiovascular (CV) 
death and satisfaction 
- no significant improvement of 
appropriate treatment and quality of life 
- no reduction of healthcare costs 
- improvement in satisfaction 
- no improved self-reported adherence 
Green  
et al. 2008 
[50] 
RCT - 778 patients 
- hypertension 
- age 25-75 
- home BP monitoring 
- online training 
- pharmacist care 
management 
- percentage of patients with 
controlled hypertension (<140/90) 
- changes in systolic and diastolic BP 
- increased percentage of patients with 
controlled BP 
- improved BP control 
continued next page 
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Mehuys  
et al. 2008 
[51] 
RCT - 201 patients 
- asthma 
- pharmacist-led patient 
education 
- level of asthma control (Asthma 
Control Test®; ACT) 
- significantly improvement of ACT 
score 
- reduction of reliever medication use 
and night-time awakenings due to 
asthma 
- significant improvement of inhalation 
technique and adherence to controller 
medication 
Mc Lean  
et al. 2008 
[52] 
RCT - 227 patients 
- diabetes type 1 or 2 
- BP >130/80 
- pharmacist-nurse-led 
patient education and 
counselling 
- BP measurement 
- referral to the GP 
- follow-up visits 
- systolic BP - clinically important improvement of 
BP even in relatively well controlled 
hypertensive diabetes patients 
Al Mazroui  
et al. 2009 
[53] 
RCT - 240 patients 
- diabetes type 2 
- pharmacist-led patient 
education and counselling 
- self-monitoring of 
glycaemic control 
- physical exercise 
- HbA1C 
- 10-year CHD risk score (British 
National Formulary and Framingham 
scoring) 
- significant reduction of HbA1C, systolic 
and diastolic BP as well as the 10-year 
CHD risk 
Hugtenburg  
et al. 2009 
[54] 
Controlled 
intervention 
study 
- 715 patients 
- discharged from a 
hospital 
- ≥5 drugs 
- extensive pharmacist-led 
medication review and drug 
counselling at patients’ 
home 
- changes in medication 
- discontinuation of drugs prescribed 
at discharge 
- mortality 
- medication cost savings 
- patient satisfaction 
- HVs resulted in the clearing of 
redundant home drug supplies 
- medication costs were slightly 
decreased 
- no reduction of mortality 
- patients were highly satisfied with the 
counselling at discharge from hospital 
by their community pharmacist 
 
  
Table 2: Reviews investigating the effectiveness of pharmaceutical care 
Study Design Studies Outcomes Results 
Hanlon  
et al. 2004 [65] 
Literature review - 3 databases 
- 14 studies 
- hospital admissions 
- resolution of DRPs 
- quality of life 
- knowledge 
- adherence 
- considerable evidence for a reduction of DRPs 
- limited evidence that interventions reduced morbidity, mortality or 
healthcare costs 
Royal  
et al. 2006 [69] 
Systematic review 
and meta-analysis 
- 14 databases 
- 38 studies 
- hospital admissions 
- preventable drug-related 
morbidity 
- reduction of falls 
- some evidence for reduction of hospital admissions through pharmacist-
led medication review 
- no evidence for other interventions with the aim to reduce admissions or 
preventable drug-related morbidity 
Machado  
et al. 2007 [61] 
 
Part I 
Systematic review 
and meta-analysis 
- 5 databases 
- 108 studies 
- levels of HbA1c - HbA1C is sensitive to pharmacists’ interventions 
- several potentially sensitive outcomes were identified, but too few 
studies were available for quantitative summaries 
Machado  
et al. 2007 [63] 
Part II 
Systematic review 
and meta-analysis 
- 4 databases 
- 98 studies 
- systolic and diastolic BP 
- quality of life 
- adherence  
- systolic BP is sensitive to pharmacist-led interventions 
- nonsensitive results in diastolic BP, quality of life, and adherence 
Machado  
et al. 2008 [64] 
 
Part III 
Systematic review 
and meta-analysis 
- 6 databases 
- 23 studies 
- LDL-cholesterol (LDL-C) 
- HDL-cholesterol (HDL-C) 
- triglycerides 
- total cholesterol 
- adherence 
- quality of life 
- total cholesterol is sensitive to pharmacist-led interventions 
- LDL-C and triglyceride levels are possibly sensitive to pharmacist-led 
interventions 
- no impact on HDL-C levels was found 
- unclear evidence for improvements in adherence and quality of life 
- clinically relevant but not statistically significant reduction in triglycerides 
Holland  
et al. 2008 [66] 
Systematic review 
and meta-analysis 
- 11 databases 
- 32 studies 
- hospital admission (all cause) 
- mortality 
- no. of prescribed drugs 
- no significant effect on all-cause hospital admissions 
- no significant improvement of mortality  
- slightly decrease of no. of prescribed drugs possible 
- interventions could improve knowledge and adherence 
- insufficient data to know whether or not quality of life is improved 
Wubben  
et al. 2008 [62] 
Systematic review - 5 databases 
- 21 studies 
- haemoglobin HbA1c 
- BP 
- lipids 
- clinical significance of reported improvements in HbA1c 
- greater effect when pharmacists were afforded prescriptive authority 
- reduction of long-term costs by improving glycaemic control 
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1.2 Drug-related problems 
1.2.1 Definition and terminology 
There are several definitions of a DRP in the literature but all of them are very similar. 
One of the first definition by Hepler and Strand was “an event or circumstance 
involving drug treatment that actually or potentially interferes with the patient’s 
experiencing an optimum outcome of medical care” [6]. In the same year, Strand 
redefined his own definition of a DRP into “an undesirable patient experience that 
involves drug therapy and that actually or potentially interferes with a desired patient 
outcome” [70]. Six years later, Segal defined a DRP as “a circumstance of drug 
therapy that may interfere with a desired therapeutic objective” [71]. Table 3 shows 
the definition and terms associated with problems of pharmacotherapy. 
 
Table 3: Definition and terms associated with problems of pharmacotherapy (DRPs) 
Adverse drug event Any injury related to the use of a drug, even if the causality of this 
relationship is not proven [72]. 
Adverse drug reaction Any response to a drug which is noxious and unintended and 
which occurs at doses normally used in humans for prophylaxis, 
diagnosis or therapy of diseases, or for the modification of 
physiological functions [73]. 
Medication error Any error in the medication process (prescribing, dispensing, 
administering of drugs), whether there are adverse consequences 
or not [72]. 
 
In 1999, the Pharmaceutical Care Network Europe (PCNE) defined a DRP as “an 
event or circumstance involving drug therapy that actually or potentially interferes 
with desired health outcomes” [74]. Only one year later, van den Bemt et al. [75] 
defined DRPs as “all problems, which can potentially affect the success of 
pharmacotherapy in a given patient, in particular medication errors, adverse drug 
events and adverse drug reactions (ADRs)”. In a review of DRPs in hospitals, 
published by Krähenbühl-Melcher et al. [76] in 2007, a DRP was defined as “all 
circumstances that involve a patient’s drug treatment that actually, or potentially, 
interfere with the achievement of an optimal outcome” (Fig. 1). The term medication-
related problem is often used in the definition of a DRP. 
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Fig. 1: Drug-related problems can be illustrated by the intersections of three circles 
representing medication errors, adverse drug events, and adverse drug reactions (Krähenbühl-
Melcher et al. [76]). 
1.2.2 Prevalence of drug-related problems 
Many studies have shown DRPs to be very common in primary care and in hospital 
settings [6, 76-91]. In both settings, there is evidence that pharmacists’ interventions 
can reduce the occurrence of DRPs [65, 76, 84, 89, 90]. A study in community 
pharmacies [92] showed that the detection rate of DRPs in community pharmacies 
was eightfold higher than in pharmacies that did not provide any pharmaceutical 
care. Studies in the hospital setting aimed at reducing the frequency of DRPs [93, 
94]. 
 
Tarn et al. [95] found that physicians stated the specific medication name for 74% of 
new prescriptions and explained the purpose of the medication in 87% of cases. 
Adverse effects were addressed for 35% and duration of intake for 34% of 
medications. Physicians explicitly instructed 55% of patients about the number of 
tablets to take and explained the frequency or timing of dosing in 58% of cases. 
Thus, patients receiving their prescribed drug at a pharmacy are likely to have 
substantial deficits in knowledge about their drugs. Therefore, counselling patients, in 
particular on a newly prescribed drug, seems to be very important. As shown in 
previous studies, patients who were more fully informed about their medication are 
more adherent [96]. Before patients start with their new drug therapy, pharmacies are 
the last ‘check point’ to ensure that the patient understands the prescribed drug 
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therapy. Pharmacists are in an optimal position to prevent, identify, and solve DRPs 
because of their education and regular contacts with patients because they are 
obliged by law to validate prescriptions before dispensing a drug. In addition to DRPs 
with prescription-only medicines (POM), risks by self-medication pose a further 
important problem as we could show in an earlier study [97]. 
 
A review issued in 2009 [98] included 40 research articles between 1993 and 2007 
and found counselling rates of community pharmacists between 8% and 100%: there 
were higher rates with new than with regular prescriptions and information about use, 
dose, medicine name, and indications were more frequently given than information 
on side effects, precautions, potential interactions, contraindications, and storage. 
Although such quoted rates may not be entirely reliable, pharmacists appear to have 
fulfilled the minimum legislative requirements or practice standards. 
 
The possible causes of DRPs may be identified by the prescriber, pharmacist, or 
patient. Thus, interventions to prevent adverse outcomes due to DRPs must take 
place at these levels [99]. Any deviation from the intended beneficial effect of a drug 
therapy results in a DRP [99, 100]. An optimal therapeutic outcome is only achieved 
with the absence of DRPs [6, 99]. Examples of DRPs are adverse drug events or 
reactions, inappropriate drug choice, dosage or drug therapy, or inappropriate use of 
a drug, such as handling problems, for example. 
1.2.3 Consequences of drug-related problems 
Problems with pharmacotherapy have consequences for the patient [75, 76, 101, 
102] resulting in costs for the hospitals [76, 103-105] and healthcare systems. 
Therefore, drug-related mortality and morbidity pose a major problem to healthcare 
systems. The costs of preventable drug-induced illnesses in the elderly population 
are substantial, with estimates of €7.5 billion annually in Canada and €131 billion in 
the United States [78, 106-108]. Costs associated with DRPs probably even exceed 
the expenditures for the cost of the medications themselves [109, 110]. In the elderly, 
10% to 31% of hospital admissions are associated with DRPs, such as inappropriate 
prescribing, ADRs, and non-adherence [108, 111-113]. The rates of drug-related 
hospital admissions found in two meta-analyses [109, 114] amounted to 5.3%, and 
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Winterstein et al. [115] found a median preventability rate of drug-related hospital 
admissions of 59%. A review published in 2008 [116] included 25 studies and 
involved 106,586 hospitalized patients. On average, 5.3% of hospital admissions 
were associated with ADRs. The results suggest higher prevalence rates than those 
shown in an earlier systematic review. Lazarou et al. [117] reviewed 21 prospective 
studies published between 1966 and 1996 and estimated that 4.7% of hospital 
admissions were associated with ADRs. This difference is possibly due to the fact 
that Kongkaew et al. [116] focused the review on prospective observational studies 
that have used a well-established and consistent ADR definition. 
 
In patients with ADRs, duration of hospital stays was increased by 2.2 to 3.2 days, 
and hospital costs were increased by €2400 to €3450, compared with patients who 
did not have any ADRs [118]. Antibiotics, anticoagulants, digoxin, diuretics, 
hypoglycaemic drugs, antineoplastic drugs, and nonsteroidal anti-inflammatory drugs 
(NSAIDs) are responsible for 60% of ADRs leading to hospital admission and 70% of 
ADRs occurring during hospitalization [119]. Pharmacists could play a crucial role in 
educating patients about potential ADRs so that they are not misinterpreted as 
another medical problem [120]. 
 
There is a need to reduce economic and medical burdens caused by DRPs by their 
identification, prevention, and solution in the process of pharmaceutical care [121]. 
The identification of patients at risk and an accurate management of their drug 
therapy are important challenges for healthcare professionals to avoid serious clinical 
consequences caused by ADRs [99]. This process of maximizing the benefits and 
minimizing the risks of a drug therapy for individual patients is complex and there are 
many steps where errors can occur [99]. The mission of healthcare providers is to 
provide systematic pharmaceutical care to reduce preventable drug-related morbidity 
and mortality [6]. 
1.2.4 Classification systems of drug-related problems 
One rationale for classification systems is that researchers and practitioners need 
better information about the nature, prevalence, and causes of drug-related morbidity 
[74], defined as the manifestation of a DRP, preventable or not, with clear adverse 
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consequences for a patient’s health [74]. This information will assist in creating 
awareness and identifying interventions to improve drug therapy outcomes [74]. 
Furthermore, to evaluate the benefit of pharmaceutical care, we need tools to 
describe DRPs and measure their impact on patient outcomes [74]. Pharmaceutical 
care practitioners need to be aware of common patterns of inappropriate care and 
the associated risk for adverse outcomes when they want to manage drug therapy 
successfully. [74]. In turn, our knowledge about the nature, prevalence, and causes 
of drug-related morbidity has to derive from practice. [74]. The classification of 
identified DRPs is useful to simplify the analysis, documentation, and prevention of 
further problems. 
 
Thus, (1) screening and documenting of DRPs, (2) structured assessment of the 
findings and the development of guidelines and indicators for quality improvement 
initiatives, and (3) their application in practice represent a self-learning system: the 
pharmaceutical care system [74]. Furthermore, together with the anatomical 
therapeutic chemical classification (ATC) code, a classification system can be used 
to develop national databases [122]. These databases could serve as the basis for 
epidemiological studies (e.g. to elucidate which drug classes or patient groups cause 
which problems) or to document the causes and solutions of certain problems [70, 
122]. In conclusion, a common, universally accepted, and practical reporting system 
for DRPs and drug-related morbidity is needed [74] for the development of 
pharmaceutical care practice [70, 123]. 
 
A number of classification systems are being used globally [121]. Fifteen different 
systems have been found in literature [121]: 
- ABC of DRPs (The Netherlands) 
- ASHP Classification (American Society of Hospital Pharmacists; USA) 
- Cipolle et al. (Drug-therapy problems; USA) 
- Granada Consensus (Spain) 
- Hanlon Approach (USA) 
- Hepler / Strand (USA) 
- Krska et al. System (UK) 
- Mackie Classification (UK) 
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- NCC-MERP Taxonomy of Medication Errors (National coordinating council for 
medication error reporting and prevention; USA) 
- PAS Coding System (Problems, assessment, and solutions; The Netherlands) 
- PCNE System (Europe) 
- PI-Doc (Problem-Intervention-Documentation; Germany) 
- PIE System (Problem, Intervention, Ergebnis; Germany) 
- SHB-SEP Classification (Health Base Foundation, subjective/objective, 
evaluation, plan; NL) 
- Westerlund System (Sweden) 
 
An overview with detailed information about the classification systems has been 
published by van Mil et al. in 2004 [121]. One of the first classification system was 
published In 1990 by Strand et al. [70] who defined eight categories of DRPs, all of 
them actually or potentially interfering with the patient’s drug therapy: 
 
1. The patient has a medical condition that requires drug therapy (a drug 
indication) but the patient is not receiving a drug for that indication. 
2. The patient has a medical condition for which the wrong drug is being taken. 
3. The patient has a medical condition for which too little of the correct drug is 
being taken. 
4. The patient has a medical condition for which too much of the correct drug is 
being taken. 
5. The patient has a medical condition resulting from an ADR. 
6. The patient has a medical condition resulting from a drug-drug, drug-food, or 
drug-laboratory interaction. 
7. The patient has a medical condition that is the result of not receiving the 
prescribed drug. 
8. The patient has a medical condition that is the result of taking a drug for which 
there is no valid medical indication. 
 
This classification system has no hierarchical structure and does not allow modifying 
any items. In 2002, eight criteria that define a suitable classification system have 
been described by Schaefer [124]. Out of them, van Mil et al. [121] elaborated five 
major requirements for DRP classifications: 
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1. The classification should have a clear definition, both for the DRP in general 
and for each DRP category. 
2. The classification should have a published validation. 
3. The classification should be usable in practice (has been used in a published 
study). 
4. The classification should have an open, hierarchical structure (with main 
groups, subgroups, and an open structure to include new problems, preferably 
on subgroup levels). 
5. The classification should have a focus on the drug use process and outcome 
and separate the problem itself from the cause. 
 
Most modern classifications have an open hierarchical structure, where higher levels 
are broadly defined and lower levels become more specific; new subcategories can 
be added in these systems as well [121]. The PCNE classification system comes 
closest to the above-mentioned criteria [121], and it is used on a European level in 
contrast to country-based systems, such as the PI-Doc or Westerlund systems 
although these are very elaborated, easy to use, and have proved useful in 
pharmacy practice [77, 81, 124-127]. However, in a study in 2007 [81] that employed 
the PI-Doc classification system, Hämmerlein et al. showed that 362 cases could not 
be classified with an extended version containing 27 new categories (in total 72). 
Krähenbühl et al. [83] developed a new classification system for DRPs, and in order 
to be comprehensive, technical problems related to prescriptions and clinical DRPs 
were analysed separately [83]. This allowed a complete classification of all DRPs 
found in the study. 
 
The PCNE system has a clear definition of a DRP, is hierarchical, and comprises 
separate codes for problems, causes, and interventions with the corresponding 
outcome. However, to our knowledge no validation has been published. The PCNE 
system was presented during a conference in 1999 [122] and since then, several 
updates have been developed by van Mil et al. It was designed to be used in 
research, as a process indicator in experimental pharmaceutical care studies, and as 
an instrument to help healthcare professionals to document information about DRPs 
in the pharmaceutical care process [99, 121, 128]. The current version 5.01, which 
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was used for the study within this thesis, is available online [128] and comprises four 
dimensions (problems, causes, interventions, and outcome) with several main 
categories. 
 
Validation is necessary to ensure that a code indeed reflects a unique DRP that is 
understood by practitioners and researchers alike [121]. Face validity of the PCNE 
classification scheme was tested in two ways: during a workshop conference, an 
expert group discussed items and domains with regard to conformity with the DRP 
definition, accuracy, redundancy, significance for its relationship to patient outcomes, 
comprehension, probability for report bias, homogeneity of domains, and 
comprehensiveness [74]. Secondly, every workshop participant independently coded 
a predefined set of 20 DRP patient cases [74]. If consensus on the selected codes 
was good, the codes were accepted but if not, the DRP items were refined 
accordingly [74]. Then, as part of the operational procedure, a report form that is 
based on the classification scheme was composed [74]. A set of guidelines for proper 
use of the report forms accompanies it [74]. Lastly, the sources for discovering DRPs 
were discussed [74]. The first source is the professional (the pharmacist), who either 
by talking to the patient or performing a drug use review would discover problems; 
the second source is the patients themselves [74]. Face validity is important for this 
kind of system because every problem can be understood in a different way by 
different persons who are working with the system. 
 
1.3 Medication review 
Several services with different characteristics are described as ‘medication review’ 
and different models of medication reviews, medication therapy management, and 
structured home visits with patients have been evaluated in several studies which 
differed in the design, setting, and type of intervention [129]. Table 4 shows a 
synopsis of different medication reviews developed in different countries. 
To perform medication reviews, several recommendations are available, such as to 
include patients with the largest chance for DRPs first [130], to conduct an MR 
preferably face-to-face, to use the same standardized systematic method for all 
patients in the practice, and to ensure appropriate training and continuing education 
of pharmacists.  
General introduction 
 36
Medication reviews can be provided by hospital or community pharmacists, GPs, 
nurses, and collaborative or multidisciplinary teams; possible settings for medication 
reviews are GP practices, hospital outpatient clinics, residential aged-care facilities, 
pharmacies, and patient homes, with limited or no access to clinical data. 
 
Experiences with medication reviews in the UK, USA, and Australia (AUS) showed 
how to apply CPS, which can be considered as a strategy to improve public health 
and the quality of drug therapy [131] in a meaningful way. The aims of an medication 
review are to prevent, reduce, or solve DRPs and thus, to improve a) healthcare 
outcomes (clinical outcomes), b) quality of life of patients (humanistic outcome), and 
c) utilization of resources (economic outcomes). The overall aim of a medication 
review is to optimize outcomes of a drug therapy. 
1.3.1 Models of medication review in the United Kingdom 
In the UK, medication reviews have been developed in the last decades from a four-
level concept [132] with an ad hoc, unstructured, and opportunistic review (level 0), a 
prescription or technical review of a list of the patient’s medicines (level 1), a 
treatment review, i.e. a review of medicines with the patient’s full notes (level 2), and 
a clinical medication review, i.e. a face-to-face review of medicines and conditions 
(level 3) to a standardized three-step concept in 2008 [133]: 
 
1. Prescription or technical review 
2. Compliance and concordance review (medicines use review, MUR) 
3. Clinical medication review 
 
The first step (prescription or technical review) is considered as the essential basic 
pharmaceutical service which should be done by every pharmacist during each 
dispensing process. A technical review is focused primarily on administrative aspects 
and the provision of the drug including information about dosage and basic 
knowledge. It is not mandatory for the patient to be present (e.g. if someone obtains 
drugs for a bed-ridden partner). 
  
Table 4: Definitions of different medication review services in different countries 
Medication review (MR) 
A structured, critical examination of a patient’s medicines with the objective of reaching an 
agreement with the patient about treatment, optimising the impact of medicines, minimising the 
number of medication-related problems and reducing waste [133]. 
Prescription review 
Level 1 
To address practical medicines management issues that can improve the clinical and cost-
effectiveness of medicines and patient safety. This type of review is usually conducted with one 
specific purpose in mind in the absence of the patient (only resulting changes to prescribed 
medicines must involve the patient) [133]. 
Concordance or compliance review  
(Medicines use review; MUR) 
Level 2 
A structured, concordance centred review with patients receiving medicines for long-term 
conditions, to establish a picture of their use of the medicines – both prescribed and non-
prescribed. The review should help patients understand their therapy and it will identify any 
problems they are experiencing along with possible solutions [133]. 
UK 
Clinical medication review (CMR) 
Level 3 
A process where a health professional reviews the patient, the illness, and the drug treatment 
during a consultation. It involves evaluating the therapeutic efficacy of each drug and the process 
of the condition being treated. Other issues, such as compliance, actual and potential adverse 
effects, interactions, and the patients understanding of the condition and its treatment are 
considered when appropriate [134]. 
Home medicines review (HMR) or 
Domiciliary medication management 
review (DMMR) 
A structured and collaborative healthcare service provided to consumers in the community setting 
to ensure their medicine use is optimal and fully understood and that continuity of care is 
enhanced [135]. 
AUS 
Residential medication management 
review (RMMR) 
A comprehensive medication review that is resident-focused involving the systematic evaluation of 
the resident’s complete medication regimen and management of that medication in the context of 
other clinical information and the resident’s health status [136]. 
continued next page 
  
Drug utilization review (DUR) or 
Drug use evaluation (DUE) 
A process to assess the appropriateness of drug therapy by engaging in the evaluation of data on 
drug use in a given healthcare environment against predetermined criteria and standards [137]. 
Drug regimen review (DRR) or 
Medication regimen review (MRR) 
A synonym for DUR in nursing home settings [138]. 
US 
Medication therapy management (MTM) 
Is designed to optimise therapeutic outcomes for targeted beneficiaries by improving medication 
use and reducing adverse drug events, including adverse drug interactions that may be furnished 
by a pharmacist [139]. 
Prescription validation 
A process to assess the appropriateness of drug therapy by engaging in the evaluation of data on 
drug use in a given healthcare environment against predetermined criteria and standards [137]. 
Composed of a) the delivery check which oblige the pharmacist to enter all relevant data into the 
computer system to be able to screen for interactions and accumulation and b) the drug check 
which aims at verify the dosage, interactions within the prescription, risk factors, contraindications, 
misuse, and others. 
CH 
Polymedication check (PMC) * 
A pharmacist-led review which is performed in the pharmacy together with the patient and which is 
remunerated by the Swiss healthcare system with the aim to instruct the patient on the use of all 
drugs taken (prescription and non-prescription) leading to a written data sheet which documents 
for each drug the dosing regimen, check for motivation, experiences and difficulties, counselling on 
potential side effects and interactions, discussion of adherence goals, and documentation of 
agreed objectives. After the discussion the pharmacist has the possibility to dispense a pill 
organizer managed by the pharmacy and paid by the healthcare system. No physician referral is 
necessary for this service. 
 
* At the time of printing this thesis, this cognitive pharmaceutical care service had only been elaborated but was not yet introduced in Swiss community pharmacy practice. 
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Medicines use reviews (MUR; compliance or concordance review) as the second 
step are carried out in pharmacies in the UK to assess and minimize non-adherence. 
The MUR was introduced in 2005 as the first ‘advanced service’ in the new NHS 
community pharmacy contractual framework for England and Wales [140]. The MUR 
was intended as a review focussing on patients’ use and understanding of their 
medicines, usually to be conducted in the pharmacy (definition in Table 4) [141]. The 
provision of MURs substantially increased during 2006 and 2007, in terms of both the 
proportion of provider pharmacies (two-thirds now providing) and the number of 
reviews conducted (a four-fold increase) [141]. The MUR is remunerated by the NHS 
(currently €33.5). 
 
A clinical medication review as described in the NHS guideline (definition in Table 4), 
represents the highest level of medication review [133] and requires a close 
coordination and cooperation with the responsible physician. This method is 
regarded as the most comprehensive method to analyse a patient’s drug regimen 
including clinically oriented aspects of a patient’s pharmacotherapy as, for example, 
the necessity of drug intake, dosage adjustments because of laboratory data, missing 
drugs but clear indications, or the appropriateness of the drugs. Such a review 
requires access to the patient’s medical records of the GP. 
1.3.2 Models of medication review in Australia 
In Australia, accredited pharmacists perform medication reviews for patients to 
identify and resolve DRPs [142]. The Australian government remunerates accredited 
pharmacists to formally review non-hospitalised patients in either Home Medicines 
Reviews (HMRs), also known as Domiciliary Medication Management Review 
(DMMR), or Residential Medication Management Reviews (RMMRs) [142]. Both the 
HMR and RMMR are remunerated by the Australian healthcare system with €108 
and €76 for pharmacists (€80 and €55 for physicians). HMRs are provided to patients 
living in their own home, whilst residential-care facility patients receive RMMRs. 
 
First, a GP who provides the majority of medical services to the patient assesses the 
need for a review [143]. Subsequently, a pharmacist performs the HMR or RMMR, 
conducts the clinical assessment of the information gathered during the patient 
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interview, and prepares the report for the GP [143]. The accredited pharmacist is 
responsible for the review overall [143]. The community pharmacist coordinating the 
service will either be an accredited pharmacist him- or herself, or will employ or 
contract an accredited pharmacist [143]. An accredited pharmacist is an experienced 
pharmacist who has undertaken specified education programmes and examinations, 
and undertakes continuing professional education and re-accreditation as approved 
by the Australian Association of Consultant Pharmacy, or an examination as 
approved by the Society of Hospital Pharmacists of Australia [143]. A patient can 
have a DMMR once every 12 months or sooner if there has been a significant 
change in the patient's condition or medication requirements [143]. 
1.3.3 Models of medication review in the United States 
The following models of medication review were identified in the United States (US) 
(definitions in Table 4: drug utilization review (DUR), drug regimen review (DRR), and 
medication therapy management (MTM). 
 
With a DUR, the appropriateness of drug therapy is evaluated through the 
assessment of all drugs and the medication history. A DUR can be prospective 
(pDUR), concurrent (cDUR), or retrospective (rDUR). If a DUR is performed in 
hospitals, it is called ‘drug use evaluation’ (DUE) [138], while the term used in nursing 
home settings is ‘drug regimen review’ (DRR) or ‘medication regimen review’ (MRR) 
[138]. The pDUR is comparable to the ‘prescription or technical review’ in the UK. 
 
American pharmacists are obliged to perform a pDUR, i.e. medication counselling, 
before a prescription is processed. There is no focus on a certain patient population, 
and the pDUR is intended to be used by every pharmacist, accredited or not [139]. 
No discussion or reporting with the responsible physician is required prior or after a 
pDUR. The pharmacist is not allowed to modify the prescription without permission of 
the physician [139]. To perform a drug-drug interaction (DDI) screening, over-the-
counter (OTC) drugs have to be included and the screening must include a check 
about potential DRPs (i.e. therapeutic duplication, contra-indications, DDI, wrong or 
inappropriate dosage, wrong or inappropriate duration of therapy, drug allergy, and 
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clinical abuse or misuse) [139]. There is no special remuneration for pharmacists 
providing pDURs [139]. 
 
‘Drug regimen review’ (DRR) or ‘medication regimen review’ (MRR) is intended for 
use in a long-term facility, and the pharmacist has the possibility to incorporate the 
staff of the facility or the resident [139]. The DRR has to be provided regularly for all 
residents at least once a month, and no referral from a GP is required. The review 
can be performed even more regularly, and no accreditation or level of education for 
pharmacists is specified [139]. An interview with the patient is recommended but not 
required [139]. The multidisciplinary approach is emphasised for this kind of review, 
considering the reviewing pharmacist, staff, and GP [139]. If a review has been 
performed, it is mandatory for the pharmacist to provide a report to the physician as 
well as the director of nursing of the care facility [139]. Decisions about 
recommended interventions with respect to the drug therapy are up to the physician 
who is responsible for the patient. However, interventions not relating to the drug 
regimen can be carried out by the staff or the pharmacist [139]. Medical records from 
the care facility are the main source of information to screen for DRPs. In addition, 
consultations with the physician or staff as well as patient interviews are possible 
[139]. DRP screening should include OTC drugs, POM, and herbal, plant, or 
complementary products [139]. 
 
‘Medication therapy management’ is targeted to certain beneficiaries and is 
performed by pharmacy benefit managers (PBMs) or other qualified providers (there 
are no national requirements for the level of education of providers) [139] who are 
obliged to provide such reviews. At national level, most process characteristics of the 
MTM are not regulated, and no guidelines exist. However, PBMs have to develop 
and to perform MTM services to certain primary-care as well as institutional 
beneficiaries of Medicare and to inform the Center for Medicare & Medicaid Services 
[139] about the procedure and performance [139]. MTMs should be developed in 
collaboration with pharmacists and physicians, and PBMs are responsible for the 
proper documenting of these services [139]. Possible beneficiaries for such a service 
are patients with multiple chronic diseases taking multiple drugs who are likely to 
incur annual costs of as much as €2500 (for 2009) [139]. The participation in a MTM 
programme is voluntary [139]. PBMs have the possibility to include further patients 
General introduction 
 42
for MTM programmes as well as to define the frequency of the service. Aspects 
discussed are the patient’s understanding and the importance of adherence, 
detection of ADEs, as well as patterns of over-use and under-use of medications 
[139]. Remuneration schemes for MTM services should be developed by PBMs. The 
costs are covered by Medicare, while the service is free for the beneficiary [139]. 
1.3.4 Medication review in Switzerland 
In Switzerland, the ‘prescription validation process’ [144] is comparable to the 
‘technical review’ (level 1) [132, 133] or the pDUR as defined by the US health 
system department [139] (Table 4). This service is remunerated at two different taxes 
by the Swiss healthcare system. Until now, no kind of advanced medication review 
which is remunerated by the Swiss healthcare system has been implemented in 
community pharmacy practice. 
 
To implement such a new service, we need to prove the effectiveness. Hence, a 
prerequisite is the selection of patients likely to benefit from medication reviews, both 
clinically and economically [145]. A study performed in Switzerland in 2008 [76] 
showed that the cost of a drug therapy is a simple criterion to identify patients eligible 
for a medication review. However, the authors also concluded that their selection 
method (cost of drug therapy exceeding €1400 over a 6-month period) could be 
improved by combining drug cost with the use of specific high-risk drugs or the 
occurrence of severe diseases [145]. 
 
It is anticipated that a pilot medication review will shortly be implemented in Swiss 
community pharmacies. The so called polymedication check (PMC) aims to identify 
any problems the patient may have with his/her pharmacotherapy, and to avoid or to 
minimize non-adherence [144]. This PMC will be remunerated by the healthcare 
system without a physician’s referral but after a pharmacist’s suggestion and with the 
patient’s agreement. The PMC is similar to the second level of the NHS guideline 
(‘compliance and concordance review’, MUR), but it is certainly not a clinical 
medication review. 
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Pharmaceutical care can be delivered on different levels which are mainly 
characterised through differences in the setting and the intensity of care: 
 
1. Ad hoc: unstructured, opportunistic, point of sale (POS) intervention 
2. Phone interview: structured counselling with respect to prior POS intervention; 
few days later 
3. Monitoring: structured medication review and screening for pharmaceutical 
care issues; periodic 1-4 times per year (scheduled) 
4. Home visits: comprehensive assessment of the patient’s self-management 
 
The PMC is a level 3 activity. The PMC was elaborated on behalf of the Swiss 
association of pharmacists (pharmaSuisse) by a working group consisting of 
research and community pharmacists. Taking into consideration the existing models 
of MR all over the world, in particular in the UK, US, and Australia, this service 
intended to be simple and easy to perform. Therefore, a single-page data sheet was 
developed to structure the procedure and to enable documentation. After a pilot 
phase, this service will be ready to be implemented in the Swiss healthcare system. 
The PMC is an opportunity for pharmacists to offer a simple MR to patients taking at 
least four drugs for a duration of at least 3 months. 
 
Further cognitive services (e.g. check of correct handling or self-injection) are not 
included in the PMC. Such services can be offered by the pharmacists [144], but the 
cost are not covered by the healthcare system, and up to now, no standard 
procedure has been defined. This first implementation of a remunerated CPS will 
represent a paradigm shift for Swiss community pharmacies and enables 
pharmacists assuming an integral role and an important step forward to take 
responsibility of a patient’s drug therapy with the purpose of achieving definite 
outcomes that improve a patient’s quality of life. 
1.3.5 Effectiveness of medication review 
Chronically ill and older people are often affected by multiple diseases, and it is no 
surprise that such patients may have to take numerous medications [66]. The 
complexity and toxicity of such drug regimens requires that care must be taken to 
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promote adherence, minimize harm, and overcome problems with storage and stock-
piling [66]. One method to solve problems or to identify risk factors are pharmacist-
led medication reviews which may have important benefits for older people [66]. 
However, there is conflicting evidence concerning these benefits [146]. A Cochrane 
review including studies conducted between 1966 and 1999 looked at the role of the 
pharmacist with outpatients but did not successfully draw any conclusions due to the 
limited quality of the research available at that time [147]. More recently, a systematic 
review of clinical pharmacists and inpatient medical care concluded that there was 
generally improved care and no evidence of harm, but the authors did not attempt to 
pool the results statistically [10]. Another meta-analysis looked at medication review 
in the primary care setting and identified only weak evidence for an effect on 
admissions [69]. An Australian study of home-based medication reviews has 
demonstrated a reduction in hospital admissions of 25%, and also a reduction in out-
of-hospital deaths [148]. 
 
When debating the usefulness and effectiveness of enhanced clinical pharmacy 
services, the question arises whether a specialised pharmacy service adds sufficient 
value to justify its costs. These considerations are critical to discuss such services 
with physicians or health insurances. Moreover, compelling arguments are needed to 
encourage colleagues to promote extended pharmacy practice services [149]. In the 
year 2005, Holland et al. (The HOMER RCT) [67] investigated the number of hospital 
(re)admissions and found significantly more readmissions in the intervention (n=415) 
than in the control (n=414) group (234 vs. 178) but fewer deaths in the intervention 
than in control group (49 vs. 63). Three years later, Holland et al. [66] concluded in a 
systematic review and meta-analysis that pharmacist-led medication review 
interventions do not have any effect on reducing mortality or hospital admission in 
older people, and can not be assumed to provide substantial clinical benefit. Such 
interventions may improve drug knowledge and adherence, but there are insufficient 
data to know whether or not quality of life is improved [66]. However, Krska [150] 
concluded in an RCT in 2007 that ‘hospital admission’ may not be a sufficiently 
sensitive outcome measure to evaluate the impact of pharmacist interventions. 
A review by Hanlon et al. [65] about the evidence of clinical pharmacy services and 
whether or not DRPs and the related health outcomes can be modified by providing 
clinical pharmacy services for the elderly in community-based settings included 28 
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studies from 1966-2003. The authors concluded that these studies provided 
considerable evidence that clinical pharmacy interventions reduced the occurrence of 
DRPs in the elderly but showed limited evidence that such interventions reduced 
morbidity, mortality, or healthcare costs. 
However, certain studies showed clinical pharmacy interventions to be associated 
with cost savings [12, 151, 152]. In 2008, Krähenbühl et al. [145] tried to estimate 
potential savings if all recommendations by pharmacists to solve DRPs and expense 
problems (defined as when a drug is not the least expensive alternative compared to 
others of equal effectiveness; [153]) were accepted. They reported a saving of 11% 
per day. To optimise patient benefits from such services, appropriate inclusion 
criteria, such as a high age (>70 years) in combination with at least 4 drugs, should 
be chosen. A randomised trial found that medication review by a pharmacist in 
general practice resulted in significant changes in prescribed medicines and saved 
more than the cost of the intervention without adversely affecting the workload of 
general practitioners [154, 155]. 
 
1.4 Rationale and approach 
1.4.1 Pharmaceutical care in the community pharmacy 
Much of the impetus for pharmaceutical care provision has been driven by 
academics [156], and only limited published data on the extent to which 
pharmaceutical care has been adopted and implemented are available. This is 
particularly true for community pharmacy practices, at a national as well as 
international level. In 1996, Odedina et al. [157] developed the Behavioural 
Pharmaceutical Care Scale (BPCS) in the United States. This scale measures the 
extent to which pharmaceutical care is provided to patients through assessing a 
community pharmacist’s recent behavioural activities. Later on, the BPCS scale was 
modified and used in 1998 by Bell et al. [158] to evaluate the provision of 
pharmaceutical care in community pharmacies of Northern Ireland. Both studies 
revealed low scores of pharmaceutical care activities at that time. In many European 
countries, there are no published data available about the provision of 
pharmaceutical care in community pharmacies. Rossing et al. [159] found in 2003 
that pharmaceutical care, as defined in policy documents in Denmark (DK), was not 
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evident in practice in Danish community pharmacies. While some aspects of 
pharmaceutical care were being performed, almost no documentation of efforts was 
taking place in community pharmacy. Major barriers to the general provision of 
cognitive services by pharmacists are their incomplete training in this regard, as well 
as the issue of reimbursement or compensation [160]. While some progress in 
addressing this problem has and is being made in a number of countries [20, 161, 
162], the willingness of patients to pay and third-party payment for cognitive services 
remains a challenge for the profession [19, 163-167]. 
 
To our knowledge, no study has investigated the extent to which pharmaceutical care 
has been implemented in Swiss and German community pharmacies. In 2006, 
Eickhoff et al. [161] reported that in Germany, CPS had been developed over the 
previous 10 years [161]. In 1993, the ABDA (Confederation of German pharmacists’ 
associations) issued a concept paper [161, 168]. This was the official starting point of 
the change that led to the community pharmacist moving from the image of a person 
primarily dispensing medicines toward a highly qualified advisor accepting 
responsibility for patients’ drug-related needs [161]. In Switzerland, pharmaceutical 
care has been integrated into the Swiss 5-year university pharmacy curriculum since 
2003 [4]. 
 
With this background, the PCNE initiated a research study across 13 European 
countries. As a partner of this network, we were in charge of conducting the survey in 
Switzerland and Germany, and contributed to the transnational analysis. 
( Project A: Provision of pharmaceutical care by community pharmacists: a 
comparison across Europe) 
 
Within this European project, we could use the opportunity to amend the BPCS 
questionnaire with specific questions with the intention to perform an additional 
analysis among German-speaking European community pharmacies.  
 
Germany has a single healthcare system: physicians are not allowed to dispense any 
drugs to their patients, in contrast to Switzerland where there are many regions with 
dispensing doctors. Using the BPCS scale, we tried to explore differences between 
these two countries and healthcare systems. In addition, we hypothesized that quality 
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circle (QC) pharmacists of the German state Bavaria would score higher than the 
ordinary Swiss and German pharmacists because the QC pharmacists meet each 
other 10 times a year with the aim to improve their pharmacy practice and to 
implement pharmaceutical care in a way that makes patients realize the desire of 
pharmacists to optimise the care of chronically ill patients. We therefore performed 
an additional survey with our German version of the BPCS questionnaire in a 
selected sample of these QC pharmacists. 
( Project B: Provision of pharmaceutical care by Swiss and German community 
pharmacists: in-depth analysis of data from the European BPCS project and 
comparison with a sample of quality circle pharmacists) 
1.4.2 Classification of drug-related problems 
In projects A and B, we analysed the extent to which pharmaceutical care is provided 
in community pharmacies in 13 European countries including Switzerland and 
Germany, and in a group of QC pharmacists who were specialised in providing 
pharmaceutical care [169]. Considering the previous 10 prescriptions (5 new and 5 
repeat prescriptions), pharmacists were asked a) if they checked for DRPs at all, and 
b) if they detected any DRPs for any of these prescriptions. Among all Swiss 
pharmacists, 334 (85.2%) reported to check regularly for DRPs, and in 135 (34.4%) 
prescriptions they had detected at least one. Among all German pharmacists, 652 
(89.9%) indicated to check regularly for DRPs as well as 85 (90.4%) QC and 80 
(58.4%) Danish pharmacists. They identified any DRP in 220 (30.3%; GER), 40 
(42.6%; QC), and 31 (22.6%; DK) prescriptions. This wide range of detected DRPs 
by community pharmacists was surprising. The lowest score was reached by Danish 
pharmacists who have already implemented several cognitive services in community 
pharmacies, while the highest score was obtained by QC pharmacists who are active 
in providing pharmaceutical care. Among all Swiss community pharmacists, more 
than one-third detected a DRP, but probably only few community pharmacists know 
the concept of pharmaceutical care, and even fewer are applying it in daily pharmacy 
practice. Therefore, we wondered if this result was true, or if social desirability led 
many pharmacists to report that they had detected a DRP, but in fact, they did not. 
The only way to challenge this assumption was to conduct our own study on 
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prescriptions and problems which are identified by community pharmacists in daily 
practice. 
 
Taking into consideration earlier studies [81, 83, 84] and the relevance of DRPs for 
healthcare systems, we aimed to explore the occurrence, nature, and pharmacist’s 
management of clinical and technical DRPs detected in Swiss community 
pharmacies using a modified PCNE classification system in new prescriptions. 
Further, we aimed to analyse possible differences between new primary-care and 
hospital-discharge prescriptions as well as differences between electronically printed 
and handwritten prescriptions, and to evaluate the usefulness of the modified 
classification system. 
( Project C: Classification of drug-related problems with new prescriptions using a 
modified PCNE classification system) 
1.4.3 Medication review 
In project C, we examined the frequency, nature, and pharmacist’s management of 
DRPs with primary-care and hospital-discharge prescriptions which contained at 
least one new drug. We found a high occurrence of clinical (19.6%) and technical 
(36.0%) DRPs. More than half of all prescriptions showed a clinical or technical DRP, 
or both. Compared to other studies, our numbers were quite high but in this study, we 
set out to use prescriptions which we considered likely to have a high prevalence, i.e. 
newly started drugs and prescriptions with at least two drugs. Our results were 
retrieved in daily practice while serving clients as usual. 
 
In order to achieve an optimal drug therapy, the absence of DRPs is essential. 
However, not all DRPs can be detected by a review in the pharmacy [170]. To get 
more information about the patient’s medication management, it may be useful to 
visit them at home. Home visits allow conducting a prescription review and observing 
the patient’s medicine-taking behaviour. In this way, insight into all aspects of self-
management of a drug regimen and the patient’s use of medicines in the context of 
their clinical condition may be possible [170]. 
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Systematic medication review carried out by pharmacists has been shown to be an 
effective cognitive service to identify medication-related risk factors (MRRFs) [170], 
to clear redundant home drug supplies, and to improve patient’s satisfaction with the 
counselling by their community pharmacist [54]. Sorensen et al. [170] monitored 
patients at their own home; most frequently, confusion of generic names and trade 
names was reported while poor adherence was reported with the second highest 
frequency. For the purpose of research, such medication reviews can be used to 
address the increasing number of DRPs experienced by chronically ill patients [65, 
145]. 
 
Considering the high detection rate of clinical and technical DRPs with new 
prescriptions in project C, we set the goal to explore patients’ knowledge a few days 
after receiving newly prescribed drugs using phone interviews. These interviews 
allowed assessing the knowledge and to recruit patients to be visited at home to gain 
first experiences in performing home visits. For the purpose of the main study, we 
had the aim to develop an interview guide specifically for home visits. 
( Project D: Patient knowledge and management of newly prescribed medication: a 
pilot study) 
 
Patients’ knowledge a few days after receiving newly prescribed drugs was rather 
good, except for drug names and potential adverse effects. Only 35% of drug names 
could be given by patients. However, 92% of all stated purposes of drugs were 
correct. Patients knew the duration of intake in 96% of cases, frequency or timing in 
96% of cases, and the number of tablets of all drugs in 84% of cases. Home visits 
showed to be a feasible service, presumably also for community pharmacists, and 
the structured interview guide developed in project D proved to be a useful tool. The 
pilot study gave important information on potential improvements of the interview 
guide which were incorporated in the subsequent main study. 
 
Because we observed a rather good knowledge in the pilot study, we presumed a 
less extensive knowledge and more frequent DRPs in patients on long-term 
treatments. Furthermore, we hypothesized that the severity of disease would 
influence the quality of self-management. We chose diabetes and transplant patients 
as ‘showcase’ patient groups and expected to observe more DRPs in diabetes 
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patients. We planned to perform pharmacist-led comprehensive home visits with the 
aim to analyse the number and pattern of DRPs, as well as the patients’ knowledge 
about the drugs and their management. We also aimed to explore opportunities for 
pharmaceutical care at the patients’ home. 
( Project E: Home visits of diabetes type 2 and solid organ transplant patients 
reveal opportunities for pharmaceutical care) 
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Synopsis of rationale and aims of the thesis 
 
Project A: Provision of pharmaceutical care by community pharmacists: a 
comparison across Europe (European BPCS project) 
Much of the impetus for pharmaceutical care provision has been driven by 
academics, and only limited published data on the extent to which pharmaceutical 
care has been adopted and implemented are available. This is particularly true for 
community pharmacy practices, at a national as well as international level. 
 
It was the aim of this study to investigate the current extent to which pharmaceutical 
care is being implemented into routine practice within community pharmacies of 13 
European countries, and to examine the impact of a range of factors that could affect 
its implementation. 
 
Project B: Provision of pharmaceutical care by Swiss and German community 
pharmacists: in-depth analysis of data from the European BPCS project and 
comparison with a sample of quality-circle pharmacists 
The objective of this project was to perform an in-depth analysis of data from 
Switzerland and Germany which had been collected for the European study for an 
additional comparison with specialised QC pharmacists and Danish BPCS data.  
 
The aims were to analyse in detail the extent to which pharmaceutical care is 
provided in these two countries, to compare the results with QC pharmacists of 
Bavaria (Germany) and data from Danish community pharmacies from the European 
sample because they scored lowest in the transnational survey, and to evaluate the 
behavioural pharmaceutical care scale (BPCS) as well as to discuss its usefulness 
as a research tool for pharmacy practice. 
 
Project C: Classification of drug-related problems with new prescriptions using 
a modified PCNE classification system 
Receiving a newly prescribed drug may be an extraordinary situation for a patient 
who was recently informed about a diagnosis or at least was confronted with a new 
drug in his/her regimen. The risk of DRPs may be increased when introducing new 
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drug treatments or changes within an established drug-treatment plan. There is no 
accepted standard tool for classification and documentation of DRPs, both in the 
primary care or hospital (discharge) setting. The usefulness of different systems is 
not yet clear, and many investigations conclude that further studies are needed, with 
the aim to provide a tool that allows a complete classification of all DRPs that arise 
during prescription processing in community pharmacies.  
 
The objectives of this study were to explore the occurrence, nature, and pharmacist’s 
management of DRPs detected in community pharmacies using a modified PCNE 
classification system in new prescriptions, to analyse differences between new 
primary-care and hospital-discharge prescriptions, as well as differences between 
electronically printed and handwritten prescriptions, and to evaluate the usefulness of 
a modified classification system. 
 
Project D: Patient knowledge and management of a newly prescribed 
medication: a pilot study 
For patients collecting their prescribed drug at a pharmacy, it is possible to have 
substantial deficits in knowledge about a new drug. Before patients start with their 
new drug therapy, pharmacies are the last ‘check point’ to ensure patients’ 
understanding and knowledge on prescribed drug therapy. 
 
The aims of this pilot study were to determine patients’ knowledge about newly 
prescribed medication shortly after the pharmacy visit, to explore the prevalence of 
drug use problems identified at patients’ homes, and to develop an interview guide 
for home visits which should be used in the subsequent main study. 
 
Project E: Home visits of diabetes type 2 and solid organ transplant patients 
reveal opportunities for pharmaceutical care  
Recent studies on pharmacist-led medication reviews and home visits indicated that 
such services have the potential to yield benefits, but some randomised controlled 
trials failed to prove effectiveness. It is still an open question if tailored medication 
reviews by specifically trained pharmacists are needed. Home visits allow observing 
the patient’s medication management and could therefore offer a possibility to gain a 
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more comprehensive insight into all aspects of self-management of a patient’s drug 
regimen and use of medicines. 
 
The aims of this study were to get insight into the self-management of medications of 
transplant and diabetes patients in the primary-care setting, to analyse drug-related 
problems as well as patients’ knowledge about the drugs and their management, and 
to explore opportunities for pharmaceutical care and the suitability of the interview 
guide developed specifically for home visits. 
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2 Provision of pharmaceutical care by community 
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Abstract 
 
Objective 
To investigate the provision of pharmaceutical care by community pharmacists 
across Europe and to examine the various factors that could affect its 
implementation. 
 
Methods 
A questionnaire-based survey of community pharmacies was conducted within 13 
European countries. The questionnaire consisted of two sections. The first section 
focussed on demographic data and services provided in the pharmacy. The second 
section was a slightly adapted version of the Behavioral Pharmaceutical Care Scale 
(BPCS) which consists of three main dimensions (direct patient care activities, 
referral and consultation activities and instrumental activities). 
 
Results 
Response rates ranged from 10–71% between countries. The mean total score 
achieved by community pharmacists, expressed as a percentage of the total score 
achievable, ranged from 31.6 (Denmark) to 52.2% (Ireland). Even though different 
aspects of pharmaceutical care were implemented to different extents across 
Europe, it was noted that the lowest scores were consistently achieved in the direct 
patient care dimension (particularly those related to documentation, patient 
assessment and implementation of therapeutic objectives and monitoring plans) 
followed by performance evaluation and evaluation of patient satisfaction. 
Pharmacists who dispensed higher daily numbers of prescriptions in Ireland, 
Germany and Switzerland had significantly higher total BPCS scores. In addition, 
pharmacists in England and Ireland who were supported in their place of work by 
other pharmacists scored significantly higher on referral and consultation and had a 
higher overall provision of pharmaceutical care. 
 
Conclusion 
The present findings suggest that the provision of pharmaceutical care in community 
pharmacy is still limited within Europe. Pharmacists were routinely engaged in 
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general activities such as patient record screening but were infrequently involved in 
patient centred professional activities such as the implementation of therapeutic 
objectives and monitoring plans, or in self-evaluation of performance. 
 
Keywords 
Pharmaceutical Care  Europe  Community Pharmacy  Pharmacists 
 
Impact on findings on practice 
 
- The overall level of pharmaceutical care provision as measured by this survey 
suggested that pharmacists across Europe still have much to achieve in order 
for the provision of pharmaceutical care to be considered as routine practice. 
 
- Community pharmacists were routinely engaged in general activities such as 
patient record screening but were infrequently involved in patient centred 
professional activities such as the implementation of therapeutic objectives 
and monitoring plans. 
 
- Community pharmacists who dispensed higher daily numbers of prescriptions, 
who were supported in their place of work by other pharmacists or who were 
participating in additional health services had higher overall provision of 
pharmaceutical care in several European countries  
Provision of pharmaceutical care by community pharmacists 
 60
Introduction 
 
The concept of pharmaceutical care, defined by Hepler and Strand as “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient’s quality of life” [6], has been adopted by professional 
pharmacy associations and academic training programmes throughout the world and 
has redirected the focus of the pharmacist’s role within community practice from a 
traditional dispensing role to a more outcome-oriented, patient-centred practice [70, 
171]. In addition to pharmacists’ commitment and effort, several changes in the 
organization of pharmacists’ work and payment systems are, however, required for 
implementation of pharmaceutical care to be realised [6, 157, 172, 173]. These 
include dealing with workplace issues such as heavy workload [174] and 
reimbursement systems, which are traditionally based on the number of products 
dispensed rather than on providing a holistic service [175]. There is also a need for 
pharmacists to collaborate with other health care professionals and patients in 
designing a therapeutic plan and to contribute to patient education on their 
medications and disease state [176]. 
 
A review of 22 randomised controlled trials of pharmaceutical care services from 
1990 to 2003 [30], provided an evidence base for the effectiveness of pharmaceutical 
care services provided by pharmacists in improving patient outcomes and medication 
use. Much of the impetus for pharmaceutical care provision has been driven by 
academicians [156], and to date, there have been limited published data, on the 
extent to which pharmaceutical care has been adopted and implemented, particularly 
within community pharmacy, at either national or international level. 
 
Rossing et al. [159] developed an instrument to measure the general provision of 
pharmaceutical care in all Danish community pharmacies (n=288) in 1999. Their 
results led the authors to conclude that pharmaceutical care, in its fullest sense, as 
defined in policy documents in Denmark, was not evident in practice. An earlier 
measure, known as the Behavioural Pharmaceutical Care Scale (BPCS), was 
developed by Odedina and Segal [157] in the United States (US) to measure the 
perceived provision of pharmaceutical care through assessing a pharmacist’s recent 
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behavioural activities. This scale (slightly modified) was used to investigate the extent 
of implementation of various aspects of pharmaceutical care in community pharmacy 
in Northern Ireland in 1996 [158]. The results of both the US and Northern Ireland 
studies indicated a low levels of provision of a comprehensive pharmaceutical care 
service at that time. 
 
The aim of the present study was to evaluate, using the BPCS scale, the current 
provision of pharmaceutical care by community pharmacists, across 13 European 
countries (including Northern Ireland), and the impact of a range of factors that could 
affect its implementation. 
 
Methods 
 
This study was initiated by researchers in Northern Ireland via their links with 
Pharmaceutical Care Network Europe (PCNE; www.pcne.org). Following 
expressions of interest from various PCNE members, data were collected in: 
Belgium, Denmark, England, Germany, Iceland, Malta, Northern Ireland, Portugal, 
Republic of Ireland, Scotland, Sweden, the German-speaking part of Switzerland and 
Wales. Ethical approval was not required for the project, following consultation with 
the relevant research governance bodies in the participating countries. 
 
Questionnaire / Instrument 
 
The questionnaire consisted of two sections; Section A contained 15 questions 
largely related to demographic information and services provided in the pharmacy; 
Section B had 34 questions and was a slightly adapted version of the BPCS [157, 
158] to account for differences in practice across countries. The latter scale contains 
three dimensions: direct care activities, referral and consultation activities and 
instrumental activities. Fourteen subscales or domains contribute to these three 
dimensions and provide a score which equates to the overall level of pharmaceutical 
care provided. The maximum score possible is 160 and the minimum is 15. 
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The questionnaire was checked for face and content validity by representatives from 
the different participating countries, in particular its applicability and relevance to the 
practice of community pharmacy in each respective country. Furthermore, the 
questionnaire was translated into the native language(s) in the different countries as 
required, according to Guillemin’s guidelines 
(http://ist.inserm.fr/basisateliers/atel127/guillemin.pdf). The questionnaire was piloted 
as a further check on validity with five community pharmacists in each country prior 
to general distribution. These pilot data were not included in the final analysis. 
 
Questionnaire distribution and data collection 
 
Addresses of community pharmacies in each of the participating European countries 
were obtained from their respective professional bodies/pharmaceutical associations. 
The sampling strategy was based on the number of community pharmacies in each 
participating country and was largely a pragmatic decision (Table 1). The research 
question was the degree of implementation of pharmaceutical care in each country. 
Using the findings of a previous study [158], pharmaceutical care implementation 
was assumed to be 21%. Assuming a 3% error estimate for a CI of 95% and using 
the total number of pharmacies in each of the participating countries as the 
population (e.g. Ireland = 1,339), the sample size was estimated accordingly (e.g. 
Ireland = 464). For each participant country, the response rate was assumed based 
on previous studies with a similar design, and accordingly, the number of 
questionnaires to be sent was calculated. In some cases, the questionnaire was sent 
to all community pharmacies, while in others, it was sent to a representative sample, 
based on the sample size calculation above. When less than 100% of pharmacies 
were surveyed, those surveyed were selected randomly (e.g. utilising a random 
number generator). Apart from Germany and Sweden, the questionnaire, along with 
a prepaid return envelope and covering letter, were sent to the selected pharmacies 
via regular mail with a second mailing to increase the response rate. In Germany, 
questionnaires were sent out only once, whereas in Sweden, the questionnaire was 
transformed into a web-based version and members were invited to participate 
online. The pharmacist who was most involved in patient care activities within the 
pharmacy was requested to respond and no identifiers were included to preserve 
anonymity. All mailings took place between November 2005 and December 2006. 
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Instrument validity and reliability 
 
The internal consistency of the instrument dimensions and domains was calculated 
for each country to obtain reliability estimates using Cronbach’s alpha test. Reliability 
estimates for single-item scales, however, could not be calculated using Cronbach’s 
alpha and were not reported in the present study. All reliability estimates >0.6 were 
considered acceptable as proposed by Robinson et al. [177]. To establish trait 
validity for the BPCS instrument, exploratory factor analysis (with Varimax rotation) 
was conducted for all dimensions and domains containing more than two items 
(since factors with fewer than three items are generally weak and unstable [178]). 
Five or more strongly loading items are desirable and indicate a solid factor. In the 
BPCS scale, dimensions and domains containing more than two items had at least 6 
items. The number of factors to be retained was decided upon using the Scree test 
as suggested by Costello and Osborne [178]; the test involved examining the plot of 
eigenvalues and counting the data-points above the natural ‘bend’ or ‘break’ in the 
data where the curve flattens out. If the number of factors was different from that 
projected by a priori factor structure, item loadings tables were compared and the 
one with the cleanest factor structure (item loadings >0.3, no or few item cross-
loadings, no factor with >3 items) was chosen as the best fit to the data. The 
adequacy of sample size was tested using the Kaiser–Meyer–Olkin (KMO) measure 
of sample adequacy and Bartlett’s test of sphericity. The value of KMO >0.5 indicates 
adequate sample. In addition, item-to-remainder correlations were calculated for 
each scale item belonging to a domain of activities with more than one item and were 
screened for extreme multicollinearity (i.e. highly correlated variables, r>0.8) and 
singularity (perfectly correlated variables, r>0.9). The determinant of the R-matrix 
was also calculated as a further check on multicolleniarity. If the determinant of the 
matrix is exactly zero, then the matrix is singular. 
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Data analysis 
 
Data analysis was performed using SPSS v15 (SPSS Inc., Chicago, IL, US). Scores 
for the BPCS three dimensions and 14 domains were calculated, by adding up 
individual item scores. Country specific total scores were calculated by adding the 
scores of the three dimensions. In addition, as in previous research involving this 
instrument [158], respondents were categorised into providers (top 20%) and non-
providers (bottom 20%) of pharmaceutical care at both country level and the overall 
sample level. Top/bottom 20% cut-off values were compared against another value 
(top/bottom 25%, i.e. upper/lower quartiles of BPCS scores) as a different form of 
categorisation. The data were analysed for significant relationships between the 
dimension or domain totals and the demographic data collected at country level. The 
Pearson’s correlation coefficient was used to test for correlation between continuous 
variables while the Student’s t test (independent samples) was used to assess 
differences in means between categorical variables. P-values for multiple pair-wise 
comparisons of BPCS dimensions and total scores between different countries were 
corrected as per the Bonferroni justification for multiple testing. P-values <0.05 were 
considered statistically significant. 
 
Results 
 
The response rates for participating countries ranged from 10.1 (Germany) to 70.9% 
(Sweden) (Table 1). There were generally more female than male respondents in all 
participating countries, apart from England and Iceland. In addition, there was a 
marked variation in the types and locations of pharmacy which predominated in each 
country. In Portugal, Denmark, Belgium, Germany, Switzerland, Malta and Ireland 
most respondents worked in an independent pharmacy, while in the United Kingdom 
(UK; England, Wales, Scotland and Northern Ireland), Sweden and Iceland many 
pharmacists worked in large multiples (chains), Table 2. For most pharmacies in the 
UK, Iceland, Ireland and Malta there was usually only one full-time equivalent 
pharmacist per pharmacy. This was in contrast to Denmark, Germany, Switzerland 
and Portugal where at least half of the pharmacies had two or more full-time 
equivalent pharmacists per pharmacy. Dispensing staff also varied across countries 
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with Denmark reporting a mean of 9.2 dispensing staff per pharmacy followed by 
Switzerland (mean of 4.4). In addition, a pre-registration student (a pharmacy 
graduate undergoing a training internship prior to professional registration) was 
employed to a greater extent in Denmark, Belgium and Iceland than in other 
countries. There was a variation across countries in terms of the number of items 
dispensed per day (the mean ranged from 62.2–884.5 prescriptions per day). The 
majority (at least 75%) of pharmacies in Sweden and Denmark did not participate in 
the health services surveyed (question A15; health screening, patient monitoring and 
domiciliary visiting). Furthermore, the majority of pharmacies in Sweden and 
Denmark did not have a private consultation area. Even thought the majority (≥53%) 
of responding pharmacists in all participating countries (apart from Switzerland) did 
not have a post-graduate qualification, most respondents (with the exception of those 
in Iceland) participated regularly in continuing professional development to maintain 
and improve their competency. The majority of respondents, however, did not 
participate in regular local multi-disciplinary team meetings in any of the countries 
surveyed. The BPCS showed acceptable Cronbach’s alpha values for BPCS 
dimensions and domains in all countries surveyed (Table 3) apart from 
‘documentation’ domain in Northern Ireland and Sweden and ‘instrumental activities’ 
dimension in Sweden. KMO values for each country and for the pooled data from all 
countries were greater than 0.5 (range, 0.715–0.874) indicating relatively compact 
pattern of correlations between scale items and, hence, higher probability of getting 
distinct and reliable factors from the analysis [179] The Bartlett’s test was significant 
(p<0.05) for all countries indicating that the r-matrix is not an identity matrix and, 
hence, adequate for performing factor analysis. The determinant of the r-matrix in all 
countries was non-zero and, hence, there was no problem of multicollinearity or 
singularity in the data. In addition, an examination of the correlation matrices did not 
yield any unreasonable values (i.e. all values were <0.8). Orthogonal rotation was 
chosen since BPCS domains were hypothesized to be uncorrelated when the scale 
was first developed [157] In addition, Scree test suggested the retention of 4 factors 
(Fig. 1) which was in accordance with the BPCS a priori factor structure (four 
domains contain [2 scale-items; ‘documentation’, ‘patient assessment’, ‘patient 
referral and consultation’ and ‘instrumental activities’). After rotation, item loadings on 
the extracted factors (with a specified minimum value of 0.3) resulted in a clean 
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structure that conformed with the distribution of BPCS items in the four domains 
mentioned above with very minimal cross-loadings. Average absolute itemloading on 
extracted factors for all countries ranged from 0.504–0.616. For a pooled data from 
all countries, item loading ranged from 0.306–0.829. Table 4 shows rotation sums of 
the squared factor loadings of the 4 extracted domains on the construct of 
pharmaceutical care behaviour as well as the proportion of variability explained by 
each domain. Convergent validity of the BPCS scale was demonstrated by adequate 
loadings of scale-items on the predicted factors and divergent validity was confirmed 
by the fact that correlations between factors were not so high (values were <0.85 for 
all countries). This indicated that predicted factors did not overlap significantly. 
Finally, an inspection of item communalities did not yield any spurious solutions (i.e. 
did not exceed 1.0) for any county. Average item communalities ranged from 0.421–
0.483 for the countries surveyed and from 0.26–0.70 for the pooled data. The mean 
total BPCS scores ranged from 50.6 (Denmark) to 83.5 (Ireland), Table 5. Total 
scores for Iceland could not be calculated due to missing data for most subscales of 
the ‘direct patient care activities’ dimension. Moreover, due to the small number of 
overall responses for Iceland (n=20), its scores could not be included in the 
subsequent analyses. Table 6 illustrates the categorisation of pharmacies within 
each country into two groups, ‘providers’ and ‘non-providers’ of pharmaceutical care 
according to the upper/lower quartiles of BPCS scores (as cut-off values of 
providers/non-providers, respectively) compared with the earlier categorisation of 
Odedina and Segal [157] i.e. top/lower 20% of BPCS scores). Ireland had 
significantly higher total scores than other countries (p<0.001). Denmark had the 
lowest mean total score (p<0.001) followed by Sweden (p<0.001; Fig. 2). In general, 
pharmacists scored less well on ‘direct patient care activities’ (means ranged from 
17.9 to 43.8% of the maximum achievable score) than on the ‘referral and 
consultation’ (means ranged from 39.4 to 70.1%) or the ‘instrumental activities’ 
dimension (means ranged from 50.6 to 70.3%). Ireland had the highest scores for 
‘direct patient care activities’ (p<0.001 when compared with the other countries apart 
from Switzerland). Pharmacists from Ireland scored well on documentation activities 
related to patient care, patient record screening, verification of patient understanding, 
patient consultation and implementation of therapeutic objectives and monitoring 
plans. In comparison with the rest of the group, the UK scored well on documentation 
and patient record screening but poorly on activities conducted to evaluate patients’ 
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perceived status (patient assessment subscale). Conversely, pharmacists in Malta 
and Portugal scored poorly on documentation and patient record screening but very 
well on patient assessment and verification of patient understanding. Wales, Malta 
and Portugal had the highest scores for ‘referral and consultation activities’ 
(p<0.001). Denmark had the lowest scores for that dimension (p<0.05) followed by 
Switzerland (p<0.005). The responding pharmacists in Ireland and the UK (apart from 
Wales) had the highest scores for the ‘instrumental activities’ dimension (p<0.001) 
despite the fact that they generally failed to evaluate patient satisfaction or their own 
performance in providing pharmaceutical care. In contrast, Wales, Malta and 
Portugal scored poorly for ‘instrumental activities’ but very well on evaluation of 
patient satisfaction and performance evaluation subscales. 
 
There were several significant relationships between the respondents’ demographic 
characteristics and their BPCS scores (Table 7). In England and Ireland, the 
provision of pharmaceutical care was more extensive when there was a higher 
number of pharmacists employed (p=0.001 and p=0.024, respectively). Furthermore, 
‘referral and consultation activities’ in both countries increased as the number of 
employed pharmacists increased (r=0.251, p<0.001 and r=0.155, p=0.002, 
respectively). The latter situation was also true for Switzerland (r=0.212, p<0.001) 
and Belgium (r=0.175, p<0.001). In Sweden and Portugal, the total number of full-
time pharmacists had a positive impact on the score obtained for ‘direct patient care 
activities’ which specifically seeks to capture pharmacists’ efforts to provide 
pharmaceutical care (r=0.123, p=0.008 and r=0.127, p=0.007, respectively). 
 
Pharmacists in England, Scotland, Northern Ireland and Ireland who employed a 
higher number of dispensing staff achieved higher scores on the validation of filled 
prescriptions compared to those who had fewer numbers of assistants (r=0.170, 
p=0.002; r=0.142, p=0.026; r=0.160, p=0.021 and r=0.131, p=0.005, respectively). In 
addition, there was a significant positive relationship between the total number of 
dispensing staff in Portugal and the verification of patient understanding (r=0.114, 
p=0.008). In Ireland, Germany and Switzerland, there was a further significant 
relationship between pharmacists’ BPCS total scores and the total number of 
dispensed items per day (p=0.008, p=0.002 and p=0.044, respectively; Table 7). The 
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pharmacists’ perception of the pharmaceutical care provided, as measured by the 
BPCS, was higher among those who worked in pharmacies with a higher prescription 
turnover. The number of dispensed items per day, however, had a negative impact 
on performance evaluation and the evaluation of patient satisfaction in Sweden (r=-
0.187, p<0.001 and r=-0.094, p=0.022, respectively). In all of the participating 
countries (except Malta and Wales), there was a statistically significant relationship 
between the provision of at least one of the health services (health screening; patient 
monitoring; domiciliary visiting; health promotion/education) and having higher BPCS 
total scores. The service that was related to the greatest increase in BPCS total 
scores was patient monitoring (mean difference ranged from 3.8 to 27.4 units) 
followed by the provision of health screening (mean difference was 6.1– 19.6 units). 
 
Discussion 
 
This is considered the first attempt to carry out a formal quantitative assessment of 
pharmacists’ efforts to provide pharmaceutical care across Europe. Even though 
there is an international consensus about the components and processes of 
pharmaceutical care, which have not changed since the BPCS was used in NI [158], 
the validity and reliability of this scale have been rechecked and examined in the 
present study. This enabled the use of BPCS scale as a valid tool for the purposes of 
comparison across a wide range of countries in the European context. In common 
with other research involving the instrument, pharmacists scoring in the top 20% on 
the BPCS were considered providers of pharmaceutical care while those scoring in 
the bottom 20% were considered non-providers. To be classified as providers of 
pharmaceutical care at the country level, pharmacists had to achieve different total 
BPCS scores across the different participating countries. For example, they had to 
have a total BPCS score of at least 66 (in Denmark) to be considered providers while 
at least 99 (in Ireland), representing only 41.3–61.9% of the maximum achievable 
BPCS score. To be classified as non-providers of pharmaceutical care, pharmacists 
had to score less than 21.9% (in Denmark) while less than 42.5% (in Ireland) of the 
maximum achievable score. Comparable results were found when upper/lower 
quartiles were applied as a method of classifying pharmacists into providers and non-
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providers, particularly in terms of the countries that have the highest and lowest 
percentages of providers/non-providers of pharmaceutical care. 
 
The mean total BPCS score achieved by pharmacists, expressed as a percentage of 
the total score achievable, ranged from 31.6% (Denmark) to 52.2% (Ireland). The 
overall level of pharmaceutical care provision as measured by this survey suggested 
that pharmacists across Europe still have much to achieve in order for the provision 
of pharmaceutical care to be considered as routine practice. It is apparent that the 
different aspects of pharmaceutical care were implemented to differing degrees 
across Europe. However, if the overall mean scores for BPCS domains and 
dimensions for all participating countries were considered, some general conclusions 
can be drawn. The lowest mean scores were achieved in the direct patient care 
dimension, particularly in those related to documentation, patient assessment and 
implementation of therapeutic objectives and monitoring plan domains; mean scores 
were under a third of the maximum possible score in the respective domains (23.0, 
31.5 and 26.2%, respectively). This could be explained by the fact that these 
activities tend to be more demanding and time-consuming. In addition, they would 
only be expected to be carried out if pharmacists were providing the full patient care 
aspects of pharmaceutical care [7]. Conversely, pharmacists scored higher on 
domains that related to more traditional areas of practice, such as verification of 
patient understanding (mean score, 73.8%) or patient record screening (mean score, 
61.1%). Similar trends were observed within the instrumental dimension where 
responding pharmacists had their lowest mean scores in evaluation of patient 
satisfaction and performance evaluation subscales (49.6 and 47.1%, respectively). 
Pharmacists with higher average daily prescription numbers in Ireland, Germany and 
Switzerland scored significantly higher in terms of their overall provision of 
pharmaceutical care. It is possible that more patient contact led to more consultation 
activities, documentation and patient record screening as suggested by the 
significant relationship between higher prescription turnover and increased direct 
patient care activities in these countries. One possible criticism of the BPCS could be 
that too high a weight is given to documentation (30 out of 85 points for the direct 
patient care dimension) and that such documentation may be more prevalent in 
larger pharmacies with more sophisticated computer systems. Even though some 
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authors have suggested that a pharmacist’s activity as a health care provider could 
be enhanced when prescription volume is low or when greater numbers of 
dispensing/support staff are employed, due to more time available for consultation 
activities [180], others have considered the ability to delegate and shift workload to 
other ancillary staff, as an overriding factor in determining the extent of 
pharmaceutical care provision [181]. The latter was supported, in part, by the fact 
that additional dispensing staff had a positive impact on pharmacists’ scores for filled 
prescription validation in England, Scotland, Northern Ireland and Ireland compared 
to those who undertook the dispensing role themselves, but did not have a significant 
impact on patient consultation or pharmaceutical care provision as a whole. 
 
In England and Ireland, pharmacists who were supported in their place of work by 
other pharmacists scored significantly higher on referral and consultation, which is a 
measure of collegial interaction, and had higher overall provision of pharmaceutical 
care. Lack of time, an important impediment to the provision of pharmaceutical care, 
could be overcome through employing additional pharmacists. However, employing 
and training extra staff requires an investment of both time and money. One solution 
is through reimbursement for services from third party payers. In Portugal, 
community pharmacists have recently obtained reimbursement for diabetes disease 
management [121]. In most of Europe, however, there is no consistent source of 
reimbursement for pharmacists’ pharmaceutical care services [20]. An alternative 
option would be to implement and maintain health services within a financially viable 
business model. In the present study, participating in extra health services (such as 
patient monitoring, health screening, domiciliary visiting and health 
promotion/education) was significantly associated with improved provision of 
pharmaceutical care in several European countries. In addition, another factor which 
may have an impact on the provision of pharmaceutical care in community pharmacy 
is the different pharmacy cultures and health service systems across different 
countries. Similar patterns of pharmaceutical care provision, as measured by the 
BPCS, are identifiable in areas with similar health care culture and systems; for 
example, Denmark and Sweden (Scandinavian countries in Northern Europe); 
Scotland, England and Northern Ireland (Western Europe); Malta and Portugal 
(Southern Europe); Germany and Switzerland (Central Europe). 
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One of the study limitations was the relatively low response rate in some countries 
(mainly Germany). However, the mean response rate across the different countries 
surveyed was around 40% which, in comparison with other published surveys of 
community pharmacy, can be considered a good response. In addition, a limited 
comparison of the demographics of respondents versus available published 
information on the demographics of the wider profession showed only minimal 
differences between respondents and overall profession demographics (data not 
shown). One reason for the different response rates achieved in the present study 
may have been the use of different types of administration methods. In Germany for 
example, the questionnaire was sent only once in a regular mailing package of the 
association which could explain, in part, the lowest response rate achieved in that 
country. On the other hand, the highest response rate in the current study (71%) was 
achieved in Sweden where the questionnaire was transformed into a web-based 
version and members were invited to participate online. Even though a lower 
response rate does not mean lower survey accuracy, it could introduce the possibility 
of bias in the data since those with a particular interest in the subject matter or the 
research itself are often more likely to return mailed questionnaires than those who 
are less interested [182]. For example, Portuguese respondents were quite young, 
therefore may have been more motivated to provide an enhanced pharmaceutical 
service. Only tentative conclusions were, therefore, derived from countries where the 
proportion of responding pharmacies was less than 10% (e.g. Germany). Due to the 
nature of the study, which was completely anonymous, it was not possible to contact 
non-respondents to carry out a non-respondent analysis. Anonymity was necessary 
to counteract the potentially strong social desirability bias which could otherwise have 
been introduced. A previous survey of pharmaceutical care provision in Danish 
pharmacies [159] has shown that 78% of non-respondents reported lack of time, lack 
of personnel or not participating in pharmaceutical care as reasons for not returning 
the questionnaire. Some of these reasons may also explain nonresponse to the 
present survey. 
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Conclusion 
 
The present study attempted to measure the general provision of pharmaceutical 
care in community pharmacies across 13 European countries using a slightly 
modified version of the BPCS. The findings suggest that the provision of this type of 
service in a comprehensive fashion is still limited within Europe. Pharmacists 
routinely screened patient records, verified patient understanding and validated filled 
prescriptions but infrequently documented activities related to patient care, evaluated 
patients’ perceived status, engaged in implementing therapeutic objectives and 
monitoring plans, evaluated patient satisfaction or self-evaluated their performance in 
providing pharmaceutical care on regular basis. 
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Tables and figures 
 
 
Table 1: Sampling strategy for each participating country and their response rates 
 
Countries No. of pharmacies to 
which questionnaire 
was distributed 
Sample as a % of 
total number of 
pharmacies in country 
Response rates  
n (%) 
Belgium 2,500 50% 623 (24.9) 
Denmark 321 100% 137 (42.7) 
England 1,096 10% 327 (29.8) 
Germany 7,151 33% 725 (10.1) 
Iceland 56 100% 20 (35.7) 
Ireland 897 67% 464 (51.7) 
Malta 202 100% 112 (55.4) 
N. Ireland 514 100% 213 (41.4) 
Portugal 2,698 100% 564 (20.9) 
Scotland 600 51% 250 (41.7) 
Sweden 1,010 100% 717 (70.9) 
Switzerland 814 100% 392 (48.2) 
Wales 718 100% 152 (21.2) 
Overall 18,577 40% 4,696 (25.3) 
  
Table 2: Demographic characteristics of participating pharmacists 
 continued next page 
  
 
  
Table 3: Reliability estimates of BPCS dimensions and domains by country 
 
 Reliability estimate (Cronbach’s alpha) 
 Belgium 
(n=623) 
Denmark 
(n=137) 
England 
(n=327) 
Germany 
(n=725) 
Ireland 
(n=464) 
Malta 
(n=112) 
N.Ireland 
(n=213) 
Portugal 
(n=564) 
Scotland 
(n=250) 
Sweden 
(n=717) 
Switzerland 
(n=392) 
Wales 
(n=152) 
Direct patient care 
activities  
(N of items = 17)  
0.85  0.84  0.86  0.87  0.83  0.88  0.81  0.88  0.82  0.81  0.83  0.84  
Documentation  
(N of items = 6)  
0.67  0.71  0.61  0.74  0.63  0.66  0.52  0.85  0.65  0.49  0.68  0.60 
Patient assessment  
(N of items = 6)  
0.85  0.78  0.87  0.84  0.81  0.84  0.87  0.85  0.85  0.83  0.81  0.87  
Referral and 
consultation  
(N of items = 8)  
0.70 0.79  0.79  0.76  0.79  0.80 0.79  0.73  0.78  0.67  0.74  0.77  
Instrumental activities 
(N of items = 7)  
n/a*  0.63  0.68  0.69  0.62  0.67  0.67  0.68  0.69  0.57  0.67  0.67  
 
*  Reliability estimate for instrumental activities could not be calculated for Belgium since item B34 was missing for all respondents 
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Table 4: Exploratory factor analysis of BPCS domains 
 
Domain  Rotation sums of  
squared loadings  
% of variance  
explained by domain  
Documentation  2.502  9.266  
Patient assessment  3.727  13.805  
Referral and consultation  4.228  15.658  
Instrumental activities 3.023  11.197  
 
 
 
 
  
Table 5: Respondents’ scores on modified behavioural pharmaceutical care scale 
 
continued next page  
  
 
 continued next page  
  
 
  
Table 6: Summary of providers and non-providers of pharmaceutical care by country based on BPCS scores 
 
Countries BPCS score 
range 
Score range of non-providersa 
(cut-off as % of maximum 
score) 
Score range of providersa 
(cut-off as % of maximum 
score) 
% of non-providers  
overallb 
% of providers 
overallb 
  Bottom 20% Bottom 25% Top 20% Top 25% Bottom 20% Bottom 25% Top 20% Top 25% 
Belgium 29–131 29–56 (35%) 29–60 (38%) 91–131 (57%) 88–131 (55%) 12.1% 11.7% 25.2% 28.9% 
Denmark 23–113 23–35 (22%) 23–37 (23%) 66–113 (41%) 63–113 (39%) 8.4% 6.4% 4.8% 6.0% 
England 18–140 18–55 (34%) 18–59 (37%) 93–140 (58%) 90–140 (56%) 8.2% 8.2% 26.7% 29.7% 
Germany 19–145 19–52 (33%) 19–55 (34%) 90–145 (56%) 86–145 (54%) 23.7% 22.4% 21.5% 26.0% 
Ireland 32–132 32–68 (43%) 32–73 (46%) 99–132 (62%) 97–132 (61%) 4.1% 4.5% 43.0% 49.0% 
Malta 43–113 43–64 (40%) 43–66 (41%) 85–113 (53%) 83–113 (52%) 1.0% 1.6% 11.6% 20.5% 
N. Ireland 29–129 29–58 (36%) 29–61 (38%) 91–129 (57%) 88–129 (55%) 4.7% 4.3% 25.0% 26.7% 
Portugal 27–130 27–66 (41%) 27–68 (43%) 86–130 (54%) 84–130 (53%) 2.9% 2.9% 17.4% 23.5% 
Scotland 32–152 32–58 (36%) 32–60 (38%) 87–152 (54%) 84–152 (53%) 4.0% 5.6% 19.6% 24.6% 
Sweden 23–124 23–50 (31%) 23–51 (32%) 77–124 (48%) 73–124 (46%) 21.7% 20.2% 6.2% 9.9% 
Switzerland 28–140 28–58 (36%) 28–60 (38%) 89–140 (56%) 86–140 (54%) 8.2% 9.7% 22.4% 27.1% 
Wales 39–105 39–62 (39%) 39–64 (40%) 81–105 (51%) 79–105 (49%) 1.8% 2.6% 9.9% 15.8% 
 
a Within top/bottom 20% at country level 
b  Within top/bottom 20% when all data from 13 countries are combined 
 
 
 
 
 
 
 
  
Table 7: Summary of relationships between demographic and practice characteristics and mean total BPCS score by country 
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Figure 1: Modified BPCS dimensions and total scores by country. Error bars represent means ± 
95% CI 
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Figure 2: Scree plot of the extracted components versus their eigenvalues for a pooled data 
from all European countries surveyed 
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Abstract 
 
Background and aims 
The purpose of the present study was an in-depth analysis of data regarding 
Switzerland and Germany from a previous study which investigated the provision of 
pharmaceutical care by community pharmacists across Europe using the behavioural 
pharmaceutical care scale (BPCS). The first aim was to analyse in detail the extent to 
which pharmaceutical care is provided in these two countries. We also compared 
data from quality circle pharmacists and data from Danish community pharmacies in 
the European sample, because they scored lowest in the transnational survey. The 
second aim was to evaluate the BPCS and to discuss its applicability as a research 
tool for pharmacy practice. 
 
Methods 
A questionnaire-based survey among community pharmacists was conducted in the 
German speaking part of Switzerland (CH) and in Germany (GER). The first section 
of the questionnaire focussed on demographic data and services provided in the 
pharmacy. The second section was an adapted version of the validated BPCS and 
consisted of three main dimensions (direct patient care activities, referral and 
consultation activities and instrumental activities). In a prospective way we used the 
same questionnaire for a survey among quality circle (QC) pharmacists of Bavaria 
(Germany), a specialised subgroup of community pharmacists who educate 
themselves regularly in pharmaceutical care. After the publication of the European 
results we amended our analysis with a comparison of our sample with the BPCS 
data from pharmacists of Denmark (DK). 
 
Results 
Response rates ranged from 10.1% (GER) to 59.9% (QC). The mean total score 
achieved by community pharmacists, expressed as a percentage of the total score 
achievable, ranged from 31.6% (DK) to 45.8% (CH). Even though different aspects of 
pharmaceutical care were implemented to different extent, it was noted that the 
lowest scores were achieved in the direct patient care dimension (particularly those 
related to documentation if not automatically done by the computer system, patient 
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assessment and implementation of therapeutic objectives and monitoring plans), 
followed by performance evaluation and evaluation of patient satisfaction. In addition, 
pharmacists who offer domiciliary visiting or health promotion and education scored 
significantly higher on total score. The specialised quality circle and Danish 
pharmacists reached significantly lower scores in some dimensions and domains 
than Swiss and German pharmacists (e.g. dimension: direct patient care activities; 
domains: documentation, patient record screening, discussion of drug therapy or 
verification of patient understanding). 
 
Conclusion 
The results show that pharmacies in all regions are adequately equipped to provide 
pharmaceutical care, however, the provision of pharmaceutical care mainly occurs 
when pharmacists were supported by their computer system, while individual patient 
approaches seem to be less frequent. Overall, there is much room for improvement.  
These results should stimulate further research and efforts at a local level to achieve 
a higher extent of provision of pharmaceutical care. Surprisingly, specialised 
pharmacists with regular meetings to improve pharmaceutical care in pharmacy 
practice have lower scores than standard community pharmacies. This result casts 
doubt on the results of the whole BPCS study, and the question arises if the BPCS 
tool is sensitive enough to enable a conclusion about the extent to which 
pharmaceutical care is provided to patients. Thus, further efforts are needed to 
develop valid assessment tools including indicators for pharmaceutical care activities. 
 
Keywords 
Pharmaceutical Care  Switzerland  Germany  Denmark  Quality circles  
Community Pharmacy  Pharmacists 
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Introduction 
 
Pharmaceutical care was first defined in 1975 by Mikael et al. [2]. In 1990, Hepler 
and Strand defined it as ‘the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve a patient’s quality of life.’ These outcomes 
are (i) cure of a disease; (ii) elimination or reduction of a patient’s symptomatology; 
(iii) arresting or slowing of a disease process; or (iv) preventing a disease or 
symptomatology [6]. Different services provided by community pharmacists have 
been developed or analysed in different countries (e.g. medication review [40, 183], 
pharmaceutical care programmes for diabetes [184-186], asthma [23, 31, 32, 38, 
187, 188], hypertension [189-192] or heart failure [47]; special services to terminally-
ill patients, compliance support [48, 193, 194], methadone services to drug misusers, 
detecting and preventing drug-related problems [77, 195-202], anti-smoking 
campaigns [203], and support of nicotine replacement (within a public health 
strategy) [54, 69, 142, 170, 194, 204-211]. However, pharmaceutical care models 
and practices differ in various countries [20]. Systematic reviews revealed in 2006 
[10, 194], 2007 [61, 63] and 2008 [64] that pharmaceutical care services can be 
effective in improving medication use and surrogate endpoints, but improvement in 
other outcomes is less conclusive [30, 66, 212, 213]. 
 
To measure pharmacists’ pharmaceutical care activities, Odedina et al. [157] 
developed and validated in 1996 a behavioural pharmaceutical care scale (BPCS) 
which was adapted two years later and used for a study in Northern Ireland [158] for 
a survey among community pharmacists. The scale measures three dimensions of 
pharmaceutical care: Direct patient care activities, referral and consultation activities 
and instrumental activities. Fourteen domains contribute to these dimensions and to 
the overall level of pharmaceutical care provided [158].  
 
With this background the Pharmaceutical Care Network Europe (PCNE) initiated a 
research study across 13 European countries. Within this European project we were 
in charge of conducting the survey in Switzerland and in Germany and we could use 
the opportunity to amend the BPCS questionnaire with specific questions with the 
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intention to perform an analysis among German speaking European community 
pharmacies. 
 
Switzerland features three main systems to dispense drugs: either the pharmacy is 
the unique channel to dispense drugs or both physicians and pharmacists have the 
permission to dispense drugs or the dispensing doctor (DD) is the main channel 
where patients have the possibility to receive their prescribed drugs. Therefore, 
Swiss community pharmacies dispense only 55.8% of all drug packages and they 
share this market with DDs (18.0%), hospitals (19.7%), and drug stores (6.5%) [214]. 
In Germany, physicians are not allowed to dispense any drugs. 
 
We imagined that different healthcare systems could influence the provision of 
pharmaceutical care; in particular, DDs could be a barrier for a broad implementation 
of pharmaceutical care. Therefore, we planned to use our Swiss and German data 
which we had collected for the survey across 13 countries for an in-depth analysis. In 
addition, we hypothesized that quality circle pharmacists (QC) of the German state 
Bavaria – who meet each other 10 times a year with the aim to improve their daily 
practice and implement pharmaceutical care in a way that patients realize the desire 
of pharmacists to optimise care of chronically ill patients – would score higher than 
the ordinary Swiss and German pharmacists. We therefore performed an additional 
survey with our German version of the BPCS questionnaire with a selected sample of 
these QC pharmacists. 
 
After completion of our surveys among these three samples, we saw in the survey 
across the 13 European countries that – surprisingly – Denmark scored lowest [169]. 
 
In Denmark several pharmaceutical care services have already been implemented 
such as medication review and home visits with clinical interventions related to 
assessment of individuals’ drug therapy at the pharmacy or in their homes [28]. 
These services currently are not provided by community pharmacists in Switzerland 
and Germany. Thus, we were very surprised to see the significantly lower scores of 
Danish pharmacists and we used the opportunity to compare our results of standard 
Swiss and German community pharmacists and the specialised quality circle 
pharmacists with BPCS data from Danish pharmacists (Fig. 1). 
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The first aim of this study was to analyse in-depth the extent to which pharmaceutical 
care is being implemented into routine practice within community pharmacies in the 
German speaking part of Switzerland and Germany. The second aim was to explore 
differences between standard pharmacists, pharmacists participating in quality 
circles, Danish pharmacists and between Swiss pharmacists in regions with or 
without DDs. The third aim was to evaluate the BPCS scale and to discuss its 
reliability and applicability as a research tool for pharmacy practice. 
 
Methods 
 
This prospective cross-sectional survey was part of a study across thirteen European 
countries [169]: Belgium, Denmark, England, Germany, Iceland, Ireland, Malta, 
Northern Ireland, Portugal, Scotland, Sweden, Switzerland and Wales.  
 
For all thirteen countries the same BPCS was used, although section A was adapted 
to specific interests with respect to demographic information and services provided in 
the pharmacy. Therefore, we could introduce some specific questions on the different 
healthcare systems in Germany and Switzerland. 
 
Data collection 
 
For the survey we used a German version of the questionnaire which was checked 
for applicability and relevance to the community pharmacy practice in Switzerland 
and Germany. Section B of the questionnaire was translated into German by two 
independent translators whose native language was German. The translated version 
was then back-translated into English. This process included the development of 
consensus versions resulting from the use of independent back and forward 
translators, according to Guillemin’s guidelines (http://ist.inserm.fr/basisateliers/ 
atel127/guillemin.pdf). The questionnaire was piloted with five community 
pharmacists as a further check of validity and comprehensibility prior to general 
distribution. These pilot data were not included in the final analysis. 
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The four-page questionnaire was sent by regular mail to all community pharmacies 
(n=814) in the German-speaking part of Switzerland. The mailer included a prepaid 
return envelope and a covering letter. In Germany, all 16 states were invited to send 
the questionnaire to their pharmacists (n=21,551) by regular mail. In Bavaria and 
North Rhine-Westphalia only a randomly selected sample of 29.2% and 13.4% was 
approached. All specialised quality circle pharmacists who participated in one of the 
20 quality circles in the German state Bavaria (Allgäu/Kempten, Ansbach, 
Aschaffenburg, Augsburg, Bad Tölz, Bamberg, Bayreuth, Cham, Dillingen, Ingolstadt, 
Landshut, München, Nürnberg, Nürnberger Land, Passau, Regensburg, Rosenheim, 
Schweinfurt, Traunstein, Würzburg) were invited to fill in the BPCS questionnaire. 
They received the BPCS questionnaire in their monthly meeting distributed by their 
circle facilitator. 
 
The covering letter explained the nature of the study. In establishments where 
several pharmacists were employed, we requested that the questionnaire was 
completed by the pharmacist with most patient contacts. In the hope of attaining a 
high response rate through preservation of anonymity, no identifiers were included on 
the questionnaire. In Switzerland, respondents could choose to give their name to 
enter an optional prize draw. As a further measure to increase the response rate, a 
second mailing of questionnaires, along with a new covering letter and prepaid return 
envelope, was undertaken in Switzerland one month after the first mailing. For 
logistical reasons it was not possible to send a reminder to German and quality circle 
pharmacists. 
 
To characterise non-responders in Switzerland (n=422), gender, year of registration, 
drug dispensing system and type of pharmacy of 100 (23.7%) randomly selected 
Swiss community pharmacists were assessed by telephone to establish their reasons 
for not participating. If a pharmacist had already filled in the questionnaire but not 
indicated his name for the raffle he was not interviewed and the next pharmacist in 
alphabetical order was contacted. German non-responders were not analysed. 
 
In Denmark the procedure of data collection was carried out as described in the 
European study [169]. 
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BPCS questionnaire 
 
The questionnaire consisted of two sections. Section A contained 15 questions 
largely related to demographic information and the characteristics of the pharmacies 
and different healthcare systems in Germany and Switzerland. 
 
Section B is validated in its original version [157]. Therefore, the adaptation process 
was restricted to linguistic adaptation and any change in structure was considered 
inappropriate. Section B included 34 questions and described the frequency of 
providing pharmaceutical care activities and was a slightly adapted version of the 
BPCS [157, 158]. The latter scale measures the provision of pharmaceutical care 
classified under three dimensions (direct patient care activities, referral and 
consultation) as well as instrumental activities. Fourteen subscales or domains 
contribute to these three dimensions and provide a score which equates to the 
overall level of pharmaceutical care provided. Prior the start of section B, a definition 
of pharmaceutical care was provided to avoid misunderstandings in the interpretation 
of these words. 
 
The first 17 questions of section B, which constituted the first dimension (direct 
patient care activities), required the pharmacist to indicate how many of their last five 
patients who presented a prescription for a chronic condition, were provided certain 
activities. For example, in one question, the pharmacist was asked to record the 
number of patients from the last five, with whom they had ‘discussed the patient’s 
drug therapy with him or her’. To calculate a total score on this dimension, all scores 
were summed. 
 
The last 15 questions of section B constituted the instrumental activities dimension 
and the referral and consultation dimension, and asked the pharmacist to indicate 
how often they carried out various activities over the last two weeks for all their 
patients, e.g. whether the pharmacist ‘Used a quiet location for patient counselling’. 
 
Two questions within the questionnaire asked how often pharmacists tried to provide 
pharmaceutical care and how often they consciously decided and made the effort to 
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provide pharmaceutical care, but responses did not contribute to any scores in any of 
the dimensions. Therefore, the maximum score possible is 160, the minimum is 15. 
 
Total scores for the three dimensions and the 14 domains were calculated, by adding 
up individual item scores, for each of the dimensions and domains. A total score was 
also calculated for the whole scale by adding together the scores of the three 
dimensions. Some demographic items were grouped for analysis purposes, e.g. year 
of registration and type of pharmacy. Respondents were further categorised into 
providers and non-providers of pharmaceutical care. In each case, pharmacies 
whose total scores fell in the top 20% were considered providers, while those in the 
bottom 20% were considered non-providers. Results are expressed as proportions 
and as means ± standard deviation (SD) or medians with the corresponding 
interquartile range (IQR). Main descriptive results are expressed as absolute 
numbers and percentages.  
 
Data analysis 
 
Data from all returned questionnaires was processed with the automated forms 
processing software Teleform® version 7.0 (Cardiff Software Inc., Vista, USA) at the 
study centre in Basel, Switzerland. Automated forms processing software was 
validated by Jorgensen et al. [215] who showed an improved quality of the data while 
reducing the processing time. To avoid potential errors, all numeric and letter 
recognitions were verified visually on data sheets and on screen. The data was 
directly transferred to a Microsoft Access® database. Distinct plausibility ranges were 
defined for each numeric variable and data were deleted when out of this range. Data 
entry was performed between September 2006 and October 2006 in Basel. Data 
were analysed with the SPSS® for Windows statistical package version 15.0 (SPSS, 
Inc, Chicago, IL, USA). 
 
The data were analysed for statistically significant relationships between any of the 
dimension or domain totals and the demographic data collected by country. In both 
cases (domains and dimensions), Pearson’s correlation coefficient and chi-square 
were used to test for correlation between continuous variables, and Student’s t test 
(independent samples) was used to assess differences in means between two 
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categorical variables. One-way analysis of variance (ANOVA) for multiple 
comparisons was run when appropriate. Non-parametric Mann-Whitney-U and 
Kruskal-Wallis-H-test were used for unpaired two-sample and multiple comparisons 
which were not normal distributed; normal distribution was tested with Kolmogorov-
Smirnov-test. p values less than 0.05 were considered statistically significant. Every 
dimension and domain was checked for reliability (Cronbach’s alpha). 
 
Results 
 
Response rate 
 
Out of the 814 pharmacies in the German-speaking part of Switzerland, 394 (48.4%) 
returned the BPCS questionnaire to the study centre. Out of them, 2 questionnaires 
had to be excluded from analysis due to missing data. Out of all 16 German states 
we received questionnaires from 8 states, resulting in a sample of 725 (10.1%) 
completed questionnaires; this largely pragmatic sample was used for the German 
analysis. Out of 157 quality circle community pharmacists in Bavaria, 94 (59.9%) sent 
back the BPCS questionnaire. In Denmark 137 (42.7%) out of the 321 community 
pharmacies sent back questionnaires. Consequently, the eligible study population 
included 392 CH, 725 GER, 94 QC and 137 DK questionnaires. 
 
Demographics 
 
Demographic characteristics of the respondents and of their pharmacies 
corresponding to each country are shown in Table 1. The fraction of female 
pharmacists differed significantly between Danish (82.5%) and other pharmacists: 
58.7% (QC) – 61.4% (CH). 
 
Only 37.8% of Swiss pharmacists worked in an independent pharmacy in contrast to 
77.4% QC, 77.7% GER and 100.0% of Danish pharmacists. In Denmark only 22.6% 
of pharmacies employed less than two pharmacists but 42.3% employed 2.0 – 2.9 
and 30.7% more than 3 pharmacists. Most other pharmacies in our sample only had 
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1.0 – 1.9 pharmacists employed (63.6% QC – 70.7% CH) and only 6.7% (CH) – 
9.1% (QC) pharmacies more than 3 pharmacists. 
 
The relation between the number of pharmacists and the number of dispensing 
assistants is 0.21 in Danish but 0.46 in Swiss and 0.67 in quality circle pharmacies. 
Sixty-seven percent (QC) – 81.0% (GER) of pharmacists indicated to have a private 
consultation area in their pharmacy, whereas only 46.0% of Danish pharmacists 
affirmed this question.  
 
Quality circle pharmacists participate significant more frequently in regular local multi-
disciplinary team meetings than Swiss (20.5%) or Danish pharmacists (29.9%). 
Danish pharmacists offer significantly fewer health services, such as health 
screening (20.4%) or patient monitoring (5.1%) than Swiss (84.9%; 76.3%), German 
(96.0%; 65.6%) or quality circle (95.7%; 51.1%) pharmacists. None of the Danish 
pharmacists reported to offer domiciliary visiting; 29.7% (CH) – 53.2% (GER) 
pharmacists provided this service.  
 
Assuming an average number of five items per prescription, Danish pharmacies 
process an average of 177 prescriptions per day in contrast to 62.2 (CH) and 107.3 
(GER). More detailed demographic characteristics of the respondents and of their 
pharmacies corresponding to each country are shown in Table 1. 
 
Respondents’ scores on the BPCS 
 
The respondents’ scores of the modified BPCS questionnaire of Swiss, German, 
quality circle and Danish pharmacists are shown in Table 2. Every dimension and 
domain was checked for reliability (Cronbach’s alpha). The values are shown in 
Table 9. 
 
Swiss pharmacists reached a mean of 45.8% (73.2 ± 18.7) of the maximum 
achievable total score, German pharmacists 44.3% (70.8 ± 22.0), quality circle 
pharmacists 38.2% (61.1 ± 20.1) and Danish pharmacists 31.6% (50.6 ± 17.8). The 
mean total score of Danish and quality circle pharmacists differed significantly from 
those of Swiss and German pharmacists (p<0.001; t test); mean total scores of 
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Danish and quality circles differed significantly (p<0.001; t test); there was no 
significant difference between the mean total scores of Swiss and German 
community pharmacists (p=0.057; Mann-Whitney-U-test) (Fig. 2). 
 
Drug-related problems 
 
Pharmacists had to indicate whether or not they had detected a drug-related problem 
(DRP) within the last 10 prescriptions (five new and five repeat prescriptions) they 
processed (Table 6 and Table 7). Two questions were not part of the validated BPCS 
total score (Section B: 18. How often did you try to provide pharmaceutical care to 
these patients? Section B: 19. How often did you consciously decide and make the 
effort to provide pharmaceutical care to these patients?); they referred to the self-
estimated extent of provision of pharmaceutical care by pharmacists (Table 8) in 
general, considering all the patients with chronic conditions that the pharmacist had 
seen in the previous six weeks. 
 
Providers and non-providers of pharmaceutical care 
 
Pharmacists scoring in the top 20% on the BPCS were categorized as providers of 
pharmaceutical care (score range 89 – 140 (CH), 90 – 145 (GER), 78 – 105 (QC), 
66 – 113 (DK)), those scoring in the bottom 20% as non-providers (score range 28 –
 58 (CH), 19 – 52 (GER), 24 – 41 (QC), 23 – 34 (DK)). According to this definition, we 
found in our study 17.9% (CH), 17.4% (GER), 18.1% (QC) and 13.1% (DK) 
pharmacists classified as providers and 18.9% (CH), 18.1% (GER), 17.0% (QC) and 
11.7% (DK) as non-providers, respectively. 
 
Overall (CH, GER, QC, DK; n=1348), the percentages of providers within top 20% 
(range 89 – 145) was 17.3% and the percentage of non-providers within bottom 20% 
(range 19 – 53) was 17.7%. 
 
Non-respondent analysis 
 
We could only perform a non-respondent analysis in Switzerland. A sample of non-
respondents among Swiss community pharmacists (n=100) was contacted by 
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telephone for a short interview to elicit reasons for not answering the questionnaire. 
The main reason for not participating was lack of time, indicated by 64%. Other 
reasons were a general policy not to answer to questionnaires (16%), absence of the 
responsible pharmacist (7%) and that the pharmacy did not practice pharmaceutical 
care (5%). In all characteristics (gender, year of graduation, type and geographic 
location of pharmacy and practicing in a region with dispensing doctors) non-
respondents did not differ from the study sample. 
 
Discussion 
 
This in-depth analysis of the Swiss, German and Danish BPCS study sample and the 
comparison with a sample of quality circle pharmacies tried to measure the general 
provision of pharmaceutical care in community pharmacies from the pharmacists’ 
perspective. This analysis resulted in valuable findings which enrich the published 
analysis across the 13 European countries [169] which showed that community 
pharmacies seem to be adequately equipped to provide pharmaceutical care but 
there is much room for improvement to intensify the provision of pharmaceutical care 
in the daily routine of community pharmacy practice. Results show that pharmacists 
are documenting patients’ data if they are supported by their computer system while 
information on patients’ health condition is not documented. Considering that 
pharmaceutical care is the ‘promise to do whatever possible to make sure the patient 
achieves positive outcomes from drug therapy’ [171] pharmacists should not only 
document details of prescription processing but also document follow-up activities for 
chronic patients. 
 
The low scores found in this study can be explained by known barriers to the 
provision of pharmaceutical care from the literature: excessive workload, lack of 
privacy, patient attitudes, store layout [174], lack of financially viable business models 
to implement care services, access to patients’ clinical and laboratory data, and 
motivation to implement care services [20]. Possible barriers to intensify collaboration 
with physicians are difficulties contacting them because of physicians’ workloads or 
negative physician attitudes toward pharmacists' recommendations [174]. 
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Through the in-depth analysis of our own results we found that the BPCS score has 
weaknesses, mainly in section A. In contrast to section B, this section is not validated 
and each country was free to add specific questions or to adapt to characteristics of 
the healthcare system (e.g. in Switzerland regions with or without dispensing 
doctors). We hypothesize that a considerable number of participants probably did not 
understand several questions or topics of the BPCS and therefore, results should be 
interpreted carefully. There is no opportunity for complex statistical analysis; the 
simple univariate analysis enables us to discuss potential influences coming from the 
healthcare system and is only a first attempt to elaborate hypothesis for a possible 
follow-up study. 
 
Demographics 
 
The structure of pharmacies differed a lot between our samples; these differences 
are important to consider if comparisons are made (Table 1). Pharmacies of different 
regions differed in the affiliation to chains, the service of domiciliary visiting as well as 
health screening, which is more frequently done by German standard and quality 
circle pharmacists than by Swiss or Danish pharmacists. Local multidisciplinary team 
meetings are arranged significantly more frequent by quality circle than by Swiss, 
German or Danish pharmacies. Swiss pharmacists indicated they more often verified 
patient understanding in contrast to German and Danish pharmacists. Danish 
pharmacists have fewest private consultation areas and they indicated they 
documented very rarely or never all patients’ medications; quality circle pharmacists 
also have significant fewer consultation areas than Swiss and German pharmacists. 
The lower scores of specialized than standard pharmacists in different variables (e.g. 
direct patient care activities, documentation, check for possible DRPs) are surprising 
and difficult to interpret. One possible explanation is that most quality circle 
pharmacists responded to the questionnaire but only a selected sample did so in 
Switzerland and Germany. 
 
There were twice as many prescriptions carried out per day in German than in Swiss 
community pharmacies. We checked the number of prescriptions in Swiss 
pharmacies with national data (RoKA – ‘Rollende Kostenanalyse Schweizer 
Apotheken’) of the Swiss pharmacists’ association and could verify our findings. 
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However, the number of prescriptions in German quality circle pharmacists is similar 
(p=0.682; Mann-Whitney-U-test) to the number in standard German pharmacies. 
 
In German pharmacies there are more pharmacists but fewer dispensing assistants 
employed than in Swiss pharmacies, and in quality circle pharmacies there are fewer 
pharmacists and dispensing assistants than in the other two countries. Danish 
pharmacies have a similar mean number of employed pharmacists than other 
countries but they have twice and four times as many employed dispensing 
assistants as other countries.  
 
In German and quality circle pharmacies the number of prescriptions per pharmacist 
and dispensing assistant was significantly higher than in Switzerland. Danish 
pharmacists seem to process many more prescriptions. Assuming to have an 
approximate number of five items per prescription there are about 177 prescriptions 
per day per pharmacy in contrast to 62.2 (CH) and 107.3 (GER). Considering the 
number of inhabitants in relation to the number of pharmacies in each country we find 
a ratio of more than 17,000 for Denmark, 4,500 for Switzerland and only 3,800 for 
Germany. Danish pharmacies seem to be very big with a high workload. 
 
For the survey it was not important if the pharmacy of the participating pharmacist 
was large or not; this did not influence the respondents’ score because we asked 
about pharmaceutical care activities of the last two or six weeks of one single 
pharmacist and not of the whole pharmacy. However, depending on the workload of 
each pharmacist, the willingness to provide pharmaceutical care could be influenced 
by the time available for each patient. 
 
Pharmacists of all countries indicated they participate very often in continuing 
professional development, with the lowest score for Danish pharmacists. In 
Switzerland the number of pharmacists who passed a postgraduate qualification 
(PQ) is significantly higher than in all other groups (Table 1). However, this 
postgraduate qualification was mostly achieved without attending a specific 
curriculum but through a temporary arrangement for pharmacists with at least 5 years 
of professional experience before the implementation of PQs for community 
pharmacists in 2004 by the Swiss association of pharmacists. 
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Participants had to indicate whether or not they check for possible DRPs during the 
prescription processing. About one third of all pharmacists of all countries reported 
they detect one or more DRP (Table 6). With 90.4%, quality circles pharmacists were 
most active and again, the Danish pharmacists had the lowest scores. But it is in 
question if all pharmacists – in particular Swiss and German pharmacists – are aware 
of a proper DRP definition and if they know how to recognize DRPs. We hypothesize 
that quality circle pharmacies are much more sensitised to screen for DRPs and the 
high frequency reflects their adoption of the philosophy of pharmaceutical care. A 
recently published study about self reported DRPs in Switzerland revealed that there 
are only 0.8 – 1.9% of clinical and technical DRPs in all prescriptions carried out in 
Swiss community pharmacies [83]. A survey of DRPs focussing only on new 
prescriptions in Switzerland showed that in 53.4% of all prescriptions at least one 
DRP could be detected [169]. Thus, it is very important to assess in section A of the 
questionnaire if repeat prescriptions are allowed; in Switzerland this is possible 
whereas in Germany not. To implement routinely the documentation of DRPs it would 
be important to have the possibility to document them electronically as in Sweden 
where all pharmacies have an information technology-based DRP documentation 
system [121]. 
 
Swiss pharmacists scored highest in the total score (Table 2) and the results differed 
significantly from those of Danish and quality circle pharmacists (Table 5); all total 
scores between all countries differed significantly from each other. Total scores were 
significantly higher if medical or clinical information was provided by the GP (apart 
from Denmark) and if domiciliary visits (apart from Denmark) or health promotion and 
education are offered by the pharmacy (Table 4). 
 
Comparison with quality circle and Danish pharmacists 
 
We expected quality circle pharmacists to reach higher scores in all items and 
dimensions than other pharmacists but the reverse was observed (Table 2). Quality 
circle pharmacies had the lowest scores for the instrumental activities and achieved 
in almost all items lower values for pharmaceutical care activities than standard 
German and Swiss community pharmacies. Danish pharmacists reached the lowest 
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scores for direct patient care and referral and consultation activities even if in 
Denmark different cognitive pharmaceutical care services are implemented as, for 
example, a medication review service, which the patients have to pay for themselves 
and a governmental paid technical service 'check the inhalation'. In Switzerland a 
new cognitive service paid by the health insurance providers is expected to start 
soon; no similar service is officially provided by German pharmacies. In Denmark, 
elaborated cognitive services (e.g. medication review) probably are provided to some 
few patients but basic PC elements which are asked for in the BPCS questionnaire 
(e.g. ‘documentation of therapeutic goals’, ‘carrying out a follow-up plan’) are not 
done. 
 
One explanation could be that quality circle and Danish pharmacists know better the 
philosophy and practice of pharmaceutical care. And, with additional services 
provided to patients they had experienced all the barriers and difficulties to 
implement pharmaceutical care into daily practice; therefore, they might have rated 
themselves very critically because of their individual knowledge. They are probably 
much more sensitised to screen their patients for pharmaceutical care issues and 
hereby experience all the difficulties of its provision in a comprehensive way. 
 
On the other hand, Swiss and German standard pharmacists with probably limited 
knowledge of and experience with the provision of pharmaceutical care rated 
themselves more positively because they think they are performing already 
pharmaceutical care very well. Such different appraisal of pharmaceutical care could 
be influenced by the extent of continuing education and specific training on 
pharmaceutical care. Pharmacists of both subgroups, Switzerland and Germany, 
participate very regularly in CPD; no significant differences could be found between 
Swiss, German and the quality circle pharmacists, but they existed between 
Denmark and all other samples. Only German community pharmacists reached 
significantly increased total scores if they participated regularly in CPD. 
 
Probably, this result among others is not well coded because there was too little 
explanation of the questioned services (e.g. check for DRPs: what is a DRP? carry 
out a follow-up plan: what is a follow-up plan? assessment of actual patterns of use 
of the medication: what is a pattern of use of the medication?). 
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Understanding of the BPCS questionnaire’s wording was tested through a pilot. The 
pilot concerned testing of the phrasing and understanding of questions. If necessary 
we changed the wording of questions in a way to make it more comprehensible for 
participants taking into account not to change the content of the questions because 
of its validation. Maybe we assumed by mistake that the meaning of questions was 
understandable for all pharmacists and in the BPCS survey we probably had not 
sufficiently explored, how providers and non-providers of pharmaceutical care would 
respond to our questions. Such a validation is lacking and the provision of the Hepler 
definition of pharmaceutical care in our questionnaire was supposably not enough. 
For a further use in research of the BPCS comprehensive definitions of discussed 
services and actions should be given to the responder. 
 
A further explanation could be that pharmacists who voluntarily participate in quality 
circles show a higher awareness of the benefits of pharmaceutical care activities and 
have higher expectations on themselves. It becomes obvious that both the 
comparison of pharmacists who work in different types of pharmacies in different 
countries and different regions and the interpretation of the results are very difficult. 
The social desirability of participants should not be underestimated even if we 
guaranteed anonymity of questionnaires. This is a potential source of bias which is 
well known [216-218]. 
 
Discussion in focus groups of the results of this questionnaire survey with community 
pharmacists might be a rational procedure to deepen these explanations as carried 
out by Odedina et al. [180]. In addition, such a survey needs very profound 
knowledge about respondents’ characteristics. Thus, section A of the questionnaire 
becomes very important. In the PCNE-BPCS project only questions in the section B 
were standardised and validated across all countries and section A could be freely 
modified. For future research much more emphasis should be placed on the 
development of adequate questions in section A. In addition, the nature and severity 
of the detected problems should be assessed to have the possibility to compare 
pharmaceutical care activities. 
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Different healthcare systems in Switzerland 
 
The comparison between the different healthcare systems in Switzerland revealed a 
trend towards higher (direct patient care and referral activities) or similar 
(instrumental activities) scores when prescribed drugs were exclusively dispensed 
through pharmacies. In half of all cantons of Switzerland this channel of drug 
dispensing is allowed, all over Germany regular drug dispensing through physicians 
is prohibited by law. There were no further differences. 
 
Reliability estimate 
 
Because the results in single items of all countries differed significantly from the 
composed result on domain or dimension level – in particular for the domain 
‘documentation’ (B2, B3, B5, B13, B14, B17) – we checked dimensions and domains 
for reliability using cronbach’s alpha resulting in values which indicate that some 
dimensions and domains may need a revision. Typically, [219] cronbach’s alpha 
values of at least 0.7 are considered to reflect sufficient reliability. Even if some 
domains or dimensions showed alpha values >0.7 (e.g. direct patient care activities, 
patient assessment), the remaining domains or dimensions should be re-evaluated in 
the case of a further use of this tool. 
 
Therefore, results should be analysed rather in detail than in dimensions or domains 
to be able to provide community pharmacists with helpful information about their 
current performance of pharmaceutical care and to show where possible gaps could 
be. The consideration only of dimensions and domains results in a possible 
undifferentiated view and this could lead to misinterpretations of pharmacists’ 
pharmaceutical care activities. Looking at single questions provides much more 
insight into differences of the practice of pharmaceutical care in different regions. At 
the same time they give important information about how to improve particular 
activities. Therefore we amended the way to present the results and listed every 
single item in contrast to the original BPCS study. 
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Limitations 
 
One major limitation of the study is the sample selection (‘response rate selection’). 
The response rate in Switzerland (48.2%) and Denmark (42.7%) are satisfactory but 
too low to represent pharmacists’ activities in general. 
 
In Germany most likely only pharmacists responded to the questionnaire with a 
positive attitude to pharmaceutical care or to scientific studies in general because of 
the low response rate (10.1%). Thus, it is not possible to make a valid statement 
about the extent of pharmaceutical care provision. However, 59.9% of the quality 
circles of Bavaria, within Germany, sent back their questionnaires, which allows a 
conclusion about the degree of the implementation of pharmaceutical care in these 
pharmacies. They meet each other ten times a year and elaborate pharmaceutical 
care tools for the community pharmacy practice. 
 
Because we did not reach a response rate of 60%, there is the limitation that only 
people participated in the survey who are interested in the field of pharmaceutical 
care [220]. Response rates in postal questionnaire surveys among healthcare 
professionals have been falling lasting recent years because of an increasing number 
of commercial requests and other reasons, such as increasing paperwork and time 
constraints [221]. In addition, the length of our questionnaire, 64 items on 4 pages, 
may not have motivated recipients to complete it.  
 
One of the most significant factors enhancing response rates is a monetary incentive 
[222]. However, such incentives are often not affordable for adequately powered 
analysis. Another effective method to increase response rates is sending several 
reminders [222]. In our study this was only possible in Switzerland. 
 
Outlook 
 
A possibility for a further use of the BPCS could be a tool to compare a sample of 
randomly selected pharmacists or regions over a certain time. If monitoring 
pharmacists’ efforts to provide pharmaceutical care, we suggest that the same 
pharmacists should answer in the same way and with the same extent of social 
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desirability if they complete the same questionnaire twice. However, a limitation could 
be that the BPCS tool is not sensitive enough and is not tested and validated for such 
a survey. 
 
A further possibility would be to conduct a survey with the BPCS questionnaire but 
instead of evaluating themselves they are evaluated by an other pharmacist. This 
allows one to reach a probably more realistic estimation of the provision of 
pharmaceutical care without any social desirability. In doing so the problem would be 
a low number of investigated pharmacists because of the huge effort. 
 
Some of the BPCS items assessing pharmaceutical care activities could be 
integrated in the pharmacy software. Each time the pharmacist is checking or 
entering certain data into the software, an electronic reminder could prompt them to 
provide more frequently pharmaceutical care services. An Australian study recently 
showed that computerized prompts are effective in changing the behaviour of health 
professionals in a variety of settings [223]. 
 
The advantage of electronic prompts is that activities carried out would be stored 
automatically in a database which could be used for an evaluation regarding 
pharmaceutical care as, for example, the BPCS. Social desirability would no longer 
be a potential bias because of the availability of objective data. Such databases 
already exist in Sweden for the documentation of DRPs [125]. 
 
Conclusion 
 
The results show that pharmacies of all regions are adequately equipped to provide 
pharmaceutical care. However, activities mainly occur when pharmacists were 
supported by their computer system while individual patient approaches like 
documentation of patients’ medical condition or desired therapeutic objectives for 
patients seem to be less frequent. Overall, much room for improvement in different 
activities is evident. Professional continuing education and advanced training in the 
topic of pharmaceutical care, as well as more explanations and definitions within the 
questionnaire, could be a possibility to avoid misunderstandings in the 
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comprehension of what is meant with ‘pharmaceutical care services’ by the 
responding pharmacists. Results should stimulate further research and efforts at 
local level to achieve a higher extent of provision of pharmaceutical care. Therefore, 
results presented in detail are much more meaningful than when aggregated in 
domains and dimensions. 
 
However, if the results are analysed in detail, the question arises if the BPCS tool is 
sensitive enough to enable a conclusion about the extent to which pharmaceutical 
care is provided to patients. Surprisingly, specialised pharmacists with regular 
meetings to improve pharmaceutical care in pharmacy practice have lower scores in 
several dimensions and domains than standard community pharmacies. This result 
questions on principle the results of the whole BPCS study. Thus, further efforts are 
needed to develop valid assessment tools including indicators for pharmaceutical 
care activities. The goals are to monitor regularly the extent to which pharmaceutical 
care is implemented in practice, to evaluate outcomes of this practice and to deduce 
the competences and skills required. 
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Tables and figures 
 
Table 1: Characteristics of study sample (n=1348) of Swiss (n=392), German (n=725), Danish (n=137) and quality circle pharmacists (n=94) as well 
as statistical comparisons between each group 
CH 
(n=392) 
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137) 
CH vs. 
GER 
CH vs. 
 QC 
CH vs. 
DK 
GER vs. 
QC 
GER vs. 
DK 
QC vs. 
DK 
  
  
No. (%) p values (95%; 2-sided) 
female 239 (61.4) 433 (60.6) 54 (58.7) 113 (82.5) Gender 
  missing 3 11 2 1 
p=0.796a p=0.628a p<0.001a p=0.719a p<0.001a p<0.001a 
mean ± SD 20.3 ± 9.8 21.0 ± 11.1 18.5 ± 9.5 19.5 ± 12.0 Years since 
registration missing 10 29 5 5 
p=0.498b p=0.157b p=0.881b p=0.071b p=0.663b p=0.249a 
independant 147 (37.8) 558 (77.7) 72 (77.4) 137 (100.0) p<0.001a p<0.001a p<0.001a p=0.948a p<0.001a p<0.001a 
member of a chain 47 (12.1) 18 (2.5) 1 (1.1) 0 (0.0) p<0.001a,b p<0.001a,b p<0.001a p=0.390a p=0.061a p=0.224a 
arranged in a group 195 (50.1) 142 (19.8) 20 (21.5) 0 (0.0) p<0.001a p<0.001a p<0.001a p=0.695a p<0.001a p<0.001a 
Type of pharmacy 
(group: ≥2 
independent 
pharmacies) missing 3 7 1 0 - - - - - - 
allowed 143 (36.5) † † † † † † † † † 
not allowed 110 (28.1) † † † † † † † † † 
mixed form 125 (31.9) † † † † † † † † † 
Dispensing doctors 
missing 14 (3.6) † † † † † † † † † 
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CH 
(n=392) 
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137) 
CH vs. 
GER 
CH vs. 
 QC 
CH vs. 
DK 
GER vs. 
QC 
GER vs. 
DK 
QC vs. 
DK 
  
  
No. (%) p values (95%; 2-sided) 
city or town centre 91 (23.2) 160 (22.1) 29 (30.9) 37 (27.0) p=0.754a p=0.102a p=0.342a p=0.055a p=0.217a p=.503a 
suburban 110 (28.1) 269 (37.1) 26 (27.7) 74 (54.0)) p=0.001a p=0.991a p<0.001a p=0.073a p<0.001a p<0.001a 
rural 150 (38.3) 248 (34.2) 35 (37.2) 24 (17.5) p=0.237a p=0.941a p<0.001a p=0.550a p<0.001a p=0.001a 
in a shopping 
centre 
39 (9.9) 34 (4.7) 2 (2.1) - p=0.001a p=0.016a p<0.001a p=0.255a p=0.009a p=0.083a 
Location 
missing 2 14 2 2 - - - - - - 
yes 33 (8.4) 157 (21.7) 12 (12.8) - 
Pharmacy integrated 
in a health centre or 
centre with several 
physicians 
missing 45 9 16 - 
p<0.001a p=0.152a p<0.001a p=0.180a p<0.001a p<0.001a 
1.0-1.9 275 (70.7) 491 (69.2) 56 (63.6) 31 (22.6) 
2.0-2.9 88 (22.6) 160 (22.1) 24 (27.3) 58 (42.3) 
≥3 26 (6.7) 59 (8.3) 8 (9.1) 42 (30.7) 
No. of full-time 
equivalent 
pharmacists 
missing 3 15 6 6 
p=0.013b p=0.616b p=0.001b p=0.104b p<0.001b p=0.041b 
0.0-0.9 5 (1.3) 52 (7.3) 7 (7.9) 5 (3.6) 
1.0-1.9 43 (11.1) 190 (26.5) 31 (34.8) 2 (1.5) 
2.0-2.9 80 (20.7) 191 (26.7) 25 (28.1) 4 (2.9) 
≥3 258 (66.8) 283 (39.5) 26 (29.2) 124 (90.5) 
No. of full-time 
equivalent 
dispensing assistants
missing 6 9 5 2 
p<0.001b p<0.001b p<0.001b p=0.120b p<0.001b p<0.001b 
continued next page 
 
  
CH 
(n=392) 
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137) 
CH vs. 
GER 
CH vs. 
 QC 
CH vs. 
DK 
GER vs. 
QC 
GER vs. 
DK 
QC vs. 
DK 
  
  
No. (%) p values (95%; 2-sided) 
median (IQR) 0.46 (0.30) 0.61 (0.57) 
0.67 
(0.68) 
0.21 (0.11) 
Number of 
pharmacists per 
number of 
dispensing assistants
missing 12 35 9 7 
p<0.001b p<0.001b p<0.001b p=0.043b p<0.001b p<0.001b 
mean (SD) 
median (IQR) 
36.7 ± 25.8 
30.9 (30.0) 
70.0 ± 53.4 
60.0 (42.0) 
63.5 ± 
25.4 
61.1 
(30.3) 
84.3 ± 28.3 
176.9 ‡ (-) 
No. of prescriptions 
per pharmacist 
missing 30 69 21 30 
p<0.001b p<0.001b ¦ p=0.970b ¦ ¦ 
median (IQR) 13.8 (13.6) 37.5 (27.7) 
45.2 
(33.5) 
102.5 ‡ (73.0) 
No. of prescriptions 
per dispensing 
assistant missing 35 75 20 35 
p<0.001b p<0.001b ¦ p=0.109b ¦ ¦ 
yes 59 (15.1) 73 (10.1) 13 (13.8) 37 (27.0) Pre-registration 
student employed missing 2 (0.5) 2 (0.3) 0 1 
p=0.013a p=0.751a p=0.002a p=0.267a p<0.001a p=0.016a 
yes 377 (97.2) 692 (95.7) 93 (98.9) 123 (89.8) Participating in 
continuing 
professional 
development (CPD) 
missing 4 2 0 0 
p=0.226a p=0.323a p<0.001a p=0.130a p=0.004a p=0.006a 
yes 302 (77.0) 587 (81.0) 63 (67.0) 63 (46.0) Private consultation 
area existing missing 0 0 0 1 
p=0.120a p=0.044a p<0.001a p=0.002a p<0.001a p=0.002a 
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CH 
(n=392) 
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137) 
CH vs. 
GER 
CH vs. 
 QC 
CH vs. 
DK 
GER vs. 
QC 
GER vs. 
DK 
QC vs. 
DK 
  
  
No. (%) p values (95%; 2-sided) 
yes 282 (71.9) 340 (46.9) 46 (48.9) 60 (43.8) 
Postgraduate 
qualification in 
community, hospital 
or clinical pharmacy 
or pharmacy practice 
missing 0 1 0 1 
p<0.001a p<0.001a p<0.001a p=0.717a p=0.542a p=0.471a 
yes 80 (20.5) 168 (23.2) 59 (62.8) 41 (29.9) 
Participation of 
regular local multi-
disciplinary team 
meetings  
missing 1 2 0 1 
p=0.288a p<0.001a p<0.021a p<0.001a p=0.085a p<0.001a 
yes 250 (67.2) 410 (57.7) 38 (42.2) 59 (43.1) Provision of 
medical/clinical 
information from GP missing 20 14 4 34 
p=0.002a p<0.001a p<0.062a p=0.005a p=0.941a p=0.037a 
yes 333 (84.9) 696 (96.0) 90 (95.7) 28  (20.4) Offering of health 
screening missing 0 0 0 6 
p<0.001a p=0.005a p<0.001a p=0.906a p<0.001a p<0.001a 
yes 297 (76.3) 472 (65.6) 48 (51.1) 7  (5.1) Offering of patient 
monitoring missing 3 5 0 9 
p<0.001a p<0.001a p<0.001a p=0.006a p<0.001a p<0.001a 
yes 115 (29.7) 384 (53.2) 38 (40.4) 0 (0.0) Offering of 
domiciliary visiting missing 5 3 0 7 
p<0.001a p=0.046a p<0.001a p=0.020a p<0.001a p<0.001a 
yes 350 (89.5) 589 (81.5) 59 (62.8) 67 (48.9) Offering of health 
promotion / education missing 5 2 0 2 
p<0.001a p<0.001a p<0.001a p<0.001a p<0.001a p=0.049a 
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a) Pearson’s chi-square 
b) Mann-Whitney-U-test (for variables not corresponding to the theoretical distribution) 
c) Student-t-test (for variables corresponding to the theoretical distribution) 
d) ANOVA 
† No data because drug dispensing through physicians is only allowed in some regions of Switzerland 
‡ The ‘number of prescriptions’ in Denmark corresponds to the number of prescription items dispensed in an average day (originally we received the number of 
prescription  
 Items dispensed per month) 
¦ No comparisons possible because of different data in different countries (CH/GER/QC: no. of prescriptions; DK: no. of prescription items) 
  
Table 2: Respondents’ scores (section B) of Swiss (n=392), German (n=725), Danish (n=137) and quality circle (n=94) pharmacists 
    Switzerland (n=392) Germany (n=725) Quality circles (n=94) Denmark (n=137) 
Dimension and Domain possible range Median (IQR) MD † Median (IQR) MD † Median (IQR) MD † Median (IQR) MD † 
Direct patient care activities (1-17) 0-85 35.6 ± 13.9 ‡ 38 31.9 ± 16.0 ‡ 54 24.7 ± 14.5 ‡ 6 15.2 ± 11.8 ‡ 33 
Documentation (2,3,5,13,14,17) 0-30 10 (10) 19 6 (9) 12 5 (7) 2 0 (2) 25 
Patient assessment (1, 4, 9-12) 0-30 9 (8) 12 12 (11) 7 9 (9) 1 6.5 (8) 11 
Implementation of therapeutic objectives and monitoring plans 
(15,16) 
0-10 2 (5) 22 2 (5) 37 2 (4) 4 0 (1) 23 
1: Assessment of medical condition 0-5 1 (2) 4 2 (3) 2 1 (2) 0 0 (1) 8 
2: Documentation of medical condition 0-5 0 (2) 4 0 (1) 1 0 (1) 0 0 (0) 8 
3: Documentation of all medications 0-5 5 (1) 3 3 (3) 1 2 (4.3) 0 0 (0) 8 
4: Assessment of patient’s expectations of drug therapy 0-5 0 (1) 6 0 (2) 2 0 (1) 0 0 (1) 9 
5: Documentation of desired therapeutic  
    objectives for the patient 
0-5 0 (0) 6 0 (0) 3 0 (0) 0 0 (0) 9 
6: Patient record screening 0-5 5 (1) 3 3 (3) 1 3 (4) 0 0 (0.8) 9 
7: Discussion of drug therapy 0-5 4 (2) 4 2 (3) 2 2 (3.3) 0 2 (3) 10 
8: Verification of patient understanding 0-5 5 (2) 5 4 (3) 4 2 (4) 0 2 (3) 10 
9: Assessment of actual patterns of use of the medication 0-5 2 (3) 5 3 (3) 1 3 (3) 0 2 (2) 6 
10: Check for possible DRPs 0-5 2 (2) 5 2 (3) 0 2 (2) 0 1 (1.8) 5 
11: Assessment of perceived effectiveness of drugs already used 0-5 2 (2) 4 2 (2) 1 1 (3) 0 1 (2) 5 
12: Assessment of achievement of therapeutic goals 0-5 1 (2) 7 2 (3) 3 1 (3) 1 1 (2) 6 
13: Documentation of DRPs 0-5 1 (5) 8 0(2) 2 0 (2) 0 0 (0) 21 
14: Documentation of therapeutic goals for each DRP identified 0-5 0 (1) 13 0 (0) 5 0 (0) 2 0 (0) 22 
15: Implementation of a strategy to resolve DRPs 0-5 1 (3) 8 2 (3) 2 1 (3) 1 0 (1) 21 
16: Carrying out follow-up plan 0-5 0 (2) 22 0 (2) 37 0 (1) 4 0 (0) 23 
17: Documentation of interventions 0-5 2 (4) 9 1 (3) 2 0 (2) 0 0 (0) 22 
continued next page 
 
  
    Switzerland (n=392) Germany (n=725) Quality circles (n=94) Denmark (n=137) 
Dimension and Domain possible range Median (IQR) MD † Median (IQR) MD † Median (IQR) MD † Median (IQR) MD † 
Referral and consultation activities  
(20-26,33) 
8-40 17 (7) 12 20 (8) 24 19 (7) 1 15 (6.3) 19 
20: Consultation with other pharmacists 1-5 3 (1) 1 3 (2) 11 3 (2) 0 2 (1) 10 
21: Made referrals to other pharmacists 1-5 2 (2) 3 3 (2) 14 3 (2) 1 2 (2) 14 
22: Made referrals to a GP 1-5 4 (2) 1 4 (1) 1 4 (2) 0 3 (0) 8 
23: Communication with GP 1-5 2 (2) 1 2 (1) 2 2 (2) 0 1 (1) 9 
24: Initiation of discussion with GP 1-5 2 (1) 1 2 (1) 1 2 (2) 0 2 (2) 8 
25: Provided the GP with a written summary 1-5 1 (1) 1 1 (1) 1 1 (1) 0 1 (0) 9 
26: Made referrals to help groups 1-5 2 (1) 1 2 (2) 1 2 (2) 0 1 (1) 9 
33: Provision of written copies to professional colleagues 1-5 1 (1) 4 1 (1) 2 1 (1) 0 1 (1) 7 
Instrumental activities (27-32, 34) 7-35 20 (6) 12 19 (6) 37 17 (6) 5 20 (5) 24 
27: Counseling location 1-5 3 (1) 0 3 (2) 0 2 (1) 1 3 (1) 4 
28: Filled-prescription validation 1-5 2 (3) 3 1 (1) 25 1 (1) 4 4 (2) 3 
29: Informational support 1-5 4 (1.8) 0 3 (2) 5 3 (1) 0 4 (2) 2 
30: Evaluation of patient satisfaction 1-5 2 (2) 0 2 (2) 4 2 (2) 0 1 (1) 6 
31: Competency improvement 1-5 4 (1) 4 4 (1) 5 4 (1) 1 3 (3) 21 
32: Performance evaluation 1-5 2 (2) 6 1 (1) 5 1 (1) 0 1 (1) 9 
34: Provision of medical information 1-5 3 (1) 1 3 (1) 0 3 (1) 0 4 (1) 6 
Provision of pharmaceutical care (18, 19) 2-10 6 (3) 6 6 (3) 3 5.5 (2) 0 6 (3) 9 
18: Tried to provide pharmaceutical care 1-5 3 (1) 5 3 (2) 0 3 (1) 0 3 (1) 9 
19: Made the psychological commitment and effort to provide 
pharmaceutical care 
1-5 3 (2) 6 3 (2)  3 2.5 (1)  0 3 (2) 8 
Total score (1-17, 20-34) 15-160 73.2 ± 18.7 ‡ 53 70.8 ± 22.0 ‡ 101 61.1 ± 20.1 ‡ 12 50.6 ± 17.8 ‡ 54 
Achieved range by country - 28-140 19-145 24-105 23-113 
†  MD: missing data 
‡  Mean ± SD (standard deviation) for variables corresponding to the theoretical distribution 
  
Table 3: Respondents’ scores (section B) of two sub-groups of Swiss pharmacists (regions with dispensing doctors vs. without dispensing 
doctors) 
    
Switzerland 
(dispensing doctors; n=143) 
Switzerland 
(no dispensing doctors; n=110) 
Dimension and Domain Possible Range Median (IQR) MD † Median (IQR) MD † 
Direct patient care activities (1-17) 0-85 32.7 ± 14.9 ‡ 14 37.2 ± 13.0 ‡ 11 
Documentation (2,3,5,13,14,17) 0-30 8.7 ± 6.3 ‡ 8 11.6 ± 5.8 ‡ 4 
Patient assessment (1, 4, 9-12) 0-30 9.8 ± 7.0 ‡ 7 10.4 ± 6.5 ‡ 2 
Implementation of therapeutic 
objectives and monitoring plans (15,16) 
0-10 2 (5) 7 2 (5.5) 5 
1: Assessment of medical condition 0-5 1 (2) 4 1 (2) 0 
2: Documentation of medical condition 0-5 0 (1.75) 3 0 (1) 1 
3: Documentation of all medications 0-5 5 (4) 3 5 (0) 0 
4: Assessment of patient’s expectations of drug therapy 0-5 0 (1.25) 5 0 (1) 0 
5: Documentation of desired therapeutic objectives for the patient 0-5 0 (0) 3 0 (0) 2 
6: Patient record screening 0-5 5 (2) 2 5 (0) 1 
7: Discussion of drug therapy 0-5 4 (2) 2 4 (2) 2 
8: Verification of patient understanding 0-5 5 (1) 3 5 (1) 2 
9: Assessment of actual patterns of use of the medication 0-5 2 (2) 4 3 (3) 1 
10: Check for possible DRPs 0-5 2 (2) 4 2 (3) 1 
11: Assessment of perceived effectiveness of drugs already used 0-5 2 (2) 3 2 (2) 1 
12: Assessment of achievement of therapeutic goals 0-5 2 (3) 3 1 (2) 2 
13: Documentation of DRPs 0-5 1 (3) 3 2 (5) 1 
14: Documentation of therapeutic goals for each DRP identified 0-5 0 (0) 7 0 (1) 1 
15: Implementation of a strategy to resolve DRPs 0-5 1 (3) 2 1 (3) 1 
16: Carrying out follow-up plan 0-5 0 (2) 7 0 (2.5) 5 
17: Documentation of interventions 0-5 1 (5) 3 3 (4) 1 
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Switzerland 
(dispensing doctors; n=143) 
Switzerland 
(no dispensing doctors; n=110) 
Dimension and Domain Possible Range Median (IQR) MD † Median (IQR) MD † 
Referral and consultation activities (20-26,33) 8-40 17.3 ± 4.4 ‡ 4 18.1 ± 4.6 ‡ 5 
20: Consultation with other pharmacists 1-5 2 (2) 0 3 (2) 0 
21: Made referrals to other pharmacists 1-5 2 (2) 0 2 (2) 2 
22: Made referrals to a GP 1-5 4 (2) 0 4 (2) 1 
23: Communication with GP 1-5 2 (2) 0 2 (2) 1 
24: Initiation of discussion with GP 1-5 2 (1) 0 2 (1) 1 
25: Provided the GP with a written summary 1-5 1 (0) 1 1 (1) 0 
26: Made referrals to help groups 1-5 2 (1) 1 2 (1) 0 
33: Provision of written copies to professional colleagues 1-5 1 (1) 2 1 (1) 0 
Instrumental activities (27-32, 34) 7-35 20.3 ± 4.5 ‡ 5 19.8 ± 4.0 ‡ 5 
27: Counseling location 1-5 3 (2) 0 3 (1) 1 
28: Filled-prescription validation 1-5 2 (3) 1 2 (2) 0 
29: Informational support 1-5 4 (2) 0 4 (1) 0 
30: Evaluation of patient satisfaction 1-5 2 (2) 0 2 (2) 3 
31: Competency improvement 1-5 4 (1) 0 4 (1) 2 
32: Performance evaluation 1-5 2 (2) 3 2 (1) 1 
34: Provision of medical information 1-5 3 (1) 1 3 (1) 0 
Provision of pharmaceutical care (18, 19) 2-10 6 (3) 4 6 (2) 1 
18: Tried to provide pharmaceutical care 1-5 3 (1.75) 3 3 (1) 1 
19: Made the psychological commitment and 
effort to provide pharmaceutical care 
1-5 3 (2) 4 3 (1) 1 
Total score (1-17, 20-34) 15-160 69.6 ± 19.8 ‡ 17 74.5 ± 16.7 ‡ 19 
Achieved range by country - 28-135 37-120 
†  MD: missing data 
‡ Mean ± SD (standard deviation) for variables corresponding to the theoretical distribution 
  
Table 4: Relationship between BPCS total score and items of section A (Student t test) among Swiss (n=392), German (n=725), Danish (n=137) and 
quality circle (n=94) pharmacists and 2 sub-groups of Swiss community pharmacists: regions with dispensing doctors (DD; n=143) and regions 
without dispensing doctors (no DD; n=110) 
 Switzerland (n=392) Germany (n=725) Quality circles (n=94) 
Denmark 
(n=137) 
Switzerland (DD)  
(n=143) 
Switzerland (no DD) 
(n=110) 
Gender 
male vs. female 
p=0.021 
70.4 vs. 75.2 
p=0.034 
68.5 vs. 72.3 
p=0.333 
58.4 vs. 62.9 
p=0.986 
50.9 vs. 50.8 
p=0.165 
66.4 vs. 71.6 
p=0.361 
72.5 vs. 75.8 
Independence of pharmacy 
yes vs. no 
p=0.107 
74.5 vs. 73.0 
p=0.760 
70.8 vs. 70.2 
p=0.080 
59.2 vs. 68.6 
‡ 
p=0.825 
70.0 vs. 69.2 
p=0.960 
74.9 vs. 74.7 
Affiliation to a chain 
yes vs. no 
p=0.118 
77.7 vs. 72.7 
p=0.752 
69.0 vs. 70.7 
p=0.562 
73.0 vs. 61.1 
‡ 
p=0.496 
73.3 vs. 69.2 
p=0.891 
74.0 vs. 74.9 
Affiliation to a group 
yes vs. no 
p=0.709 
72.9 vs. 73.7 
p=0.853 
70.4 vs. 70.7 
p=0.104 
68.4 vs. 59.4 
‡ 
p=0.504 
68.3 vs. 70.6 
p=0.975 
74.8 vs. 74.7 
Dispensing doctors 
yes vs. no 
p=0.059 
69.6 vs. 74.5 
† † † † † 
location: city or town centre 
yes vs. no 
p=0.140 
75.9 vs. 72.4 
p=0.798 
70.2 vs. 70.7 
p=0.501 
58.9 vs. 62.2 
p=0.184 
53.6 vs. 48.1 
p=0.920 
69.3 vs. 69.7 
p=0.696 
75.8 vs. 74.0 
location: suburban 
yes vs. no 
p=0.545 
72.3 vs. 73.6 
p=0.767 
70.3 vs. 70.8 
p=0.984 
61.3 vs. 61.2 
p=0.278 
47.8 vs. 51.9 
p=0.346 
75.0 vs. 69.1 
p=0.792 
73.9 vs. 74.8 
location: rural 
yes vs. no 
p=0.821 
72.9 vs. 73.4 
p=0.500 
71.4 vs. 70.2 
p=0.467 
63.3 vs. 59.9 
p=0.866 
49.0 vs. 49.9 
p=0.160 
67.3 vs. 72.2 
p=0.440 
76.4 vs. 73.5 
location: integrated in a 
shopping centre 
yes vs. no 
p=0.429 
 
70.9 vs. 73.5 
p=0.732 
 
69.2 vs. 70.7 
p=0.742 
 
56.5 vs. 61.3 
‡ 
p=0.182 
 
75.2 vs. 68.6 
p=0.096 
 
62.2 vs. 75.1 
location: integrated in a 
health centre 
yes vs. no 
p=0.121 
 
77.5 vs. 72.0 
p=0.984 
 
70.8 vs. 70.7 
p=0.205 
 
68.0 vs. 59.2 
‡ 
p=0.136 
 
78.7 vs. 68.4 
p=0.288 
 
82.2 vs. 73.5 
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 Switzerland (n=392) Germany (n=725) Quality circles (n=94) 
Denmark 
(n=137) 
Switzerland (DD)  
(n=143) 
Switzerland (no DD) 
(n=110) 
No. of prescriptions° p=0.346 p=0.009 p=0.446 p=0.890 p=0.694 p=0.697 
Pre-registration student 
employed 
yes vs. no 
p=0.599 
 
74.5 vs. 73.0 
p=0.009 
 
77.7 vs. 70.0 
p=0.009 
 
71.7 vs. 59.6 
p=0.324 
 
47.3 vs. 51.7 
p=0.953 
 
70.0 vs. 69.7 
p=0.712 
 
75.8 vs. 74.1 
Continuing professional 
development 
yes vs. no 
p=0.053 
 
73.5 vs. 61.2 
p<0.001 
 
71.7 vs. 53.2 
p=0.250 
 
61.4 vs. 38.0 
p=0.732 
 
50.3 vs. 52.3 
p=0.261 
 
69.9 vs. 54.0 
p=0.192 
 
75.0 vs. 63.8 
Postgraduate qualification in 
community / hospital / clinical 
pharmacy or pharmacy 
practice 
yes vs. no 
p=0.734 
 
 
87.6 vs. 88.1 
p=0.966 
 
 
82.5 vs. 82.5 
p=0.322 
 
 
81.3 vs. 78.4 
p=0.595 
 
 
52.0 vs. 49.8 
p=0.215 
 
 
84.6 vs. 87.7 
p=0.652 
 
 
89.2 vs. 90.5 
Participation in multi- 
disciplinary team meetings 
yes vs. no 
p<0.001 
 
82.1 vs. 70.9 
p<0.001 
 
80.1 vs. 68.0 
p=0.105 
 
63.9 vs. 56.5 
p<0.001 
 
63.7 vs. 45.7 
p=0.033 
 
77.7 vs. 67.9 
p=0.004 
 
84.8 vs. 71.9 
Private consultation area 
available 
yes vs. no 
p=0.030 
 
74.5 vs. 69.3 
p<0.001 
 
72.6 vs. 63.3 
p=0.459 
 
62.3 vs. 58.7 
p=0.177 
 
53.4 vs. 48.1 
p=0.285 
 
70.6 vs. 66.0 
p=0.075 
 
76.3 vs. 70.3 
Provision of medical and 
clinical information from GP 
yes vs. no 
p=0.001 
 
75.6 vs. 68.3 
p<0.001 
 
73.8 vs. 67.0 
p=0.006 
 
68.7 vs. 56.2 
p=0.255 
 
53.3 vs. 48.2 
p=0.134 
 
72.0 vs. 66.5 
p=0.673 
 
75.2 vs. 73.4 
Health screening 
yes vs. no 
p=0.028 
74.1 vs. 67.8 
p<0.001 
71.6 vs. 52.0 
p=0.159 
61.7 vs. 45.0 
p=0.451 
53.5 vs. 49.4 
p=0.050 
70.6 vs. 57.9 
p=0.085 
75.5 vs. 69.7 
Patient monitoring 
yes vs. no 
p<0.001 
75.4 vs. 66.9 
p<0.001 
75.0 vs. 62.3 
p=0.195 
63.9 vs. 58.1 
p<0.001 
75.0 vs. 47.6 
p=0.005 
73.2 vs. 62.8 
p=0.079 
76.3 vs. 69.1 
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 Switzerland (n=392) Germany (n=725) Quality circles (n=94) 
Denmark 
(n=137) 
Switzerland (DD)  
(n=143) 
Switzerland (no DD) 
(n=110) 
Domiciliary visiting 
yes vs. no 
p=0.004 
77.8 vs. 71.3 
p<0.001 
75.3 vs. 65.7 
p=0.001 
69.5 vs. 54.6 
‡ 
p=0.132 
74.7 vs. 68.3 
p=0.174 
77.5 vs. 72.4 
Health promotion / education 
yes vs. no 
p=0.001 
74.4 vs. 63.3 
p<0.001 
73.3 vs. 60.3 
p=0.010 
65.4 vs. 53.7 
p=0.027 
55.5 vs. 46.5 
p=0.006 
71.3 vs. 55.4 
p=0.078 
75.4 vs. 64.5 
 
† no data because drug dispensing through physicians is only allowed in some regions of Switzerland 
‡ no data because there is no data for at least one group 
° ANOVA instead of Student t test 
 
  
Table 5: Comparison of section B items between countries and within subgroups 
 
CH vs.  
GER 
CH vs. QC 
CH vs.  
DK 
GER vs.  
QC 
GER vs.  
DK 
QC vs.  
DK 
CH DD vs. CH 
nonDD 
Direct patient care activities (1-17) p<0.001c p<0.001c p<0.001c p<0.001c p<0.001b p<0.001c p=0.017c 
  Documentation (2,3,5,13,14,17) p<0.001b p<0.001b p<0.001b p=0.003b p<0.001b p<0.001b p<0.001b 
  Patient assessment (1, 4, 9-12) p<0.001b p=0.777 b p<0.001b p=0.003b p<0.001b p=0.001b p=0.249b 
  Implementation of therapeutic objectives and  
  monitoring plans (15,16) 
p=0.802b p=0.185b p<0.001b p=0.118b p<0.001b p<0.001b p=0.203b 
    1: Assessment of medical condition p<0.001b p=0.583b p<0.001b p=0.001b p<0.001b p<0.001b p=0.974 b 
    2: Documentation of medical condition p<0.011b p=0.002b p<0.001b p=0.057b p<0.001b p<0.001b p=0.671b 
    3: Documentation of all medications p<0.001b p<0.001b p<0.001b p=0.002b p<0.001b p<0.001b p<0.001b 
    4: Assessment of patient’s expectations  
        of drug therapy 
p<0.001b p=0.285b p=0.039b p=0.002b p<0.001b p=0.561b p=0.491b 
    5: Documentation of therapeutic objectives p=0.046b p=0.081b p=0.104b p=0.007b p=0.005b p=0.722b p=0.167b 
    6: Patient record screening p<0.001b p<0.001b p<0.001b p=0.006b p<0.001b p<0.001b p=0.002b 
    7: Discussion of drug therapy p<0.001b p<0.001b p<0.001b p=0.008b p=0.001b p=0.957b p=0.969b 
    8: Verification of patient understanding p<0.001b p<0.001b p<0.001b p<0.001b p<0.001b p=0.160b p=0.978b 
    9: Assessment of actual patterns of medication’s use p<0.001b p=0.083b p=0.011b p=0.120b p<0.001b p=0.001b p=0.029b 
    10: Check for possible DRPs p=0.006b p=0.479b p<0.001b p=0.020b p<0.001b p=0.033b p=0.201b 
    11: Assessement of perceived effectiveness of  
          drugs already used 
p=0.225b p=0.090b p=0.002b p=0.020b p<0.001b p=0.398b p=0.427b 
    12: Assessment of achievement of therapeutic goals p=0.065b p=0.639b p<0.001b p=0.129b p<0.001b p=0.019b p=0.313b 
    13: Documentation of DRPs p<0.001b p<0.001b p<0.001b p=0.257b p<0.001b p<0.001b p<0.001b 
    14: Documentation of therapeutic goals p=0.459b p=0.057b p<0.001b p=0.108b p<0.001b p=0.058b p=0.334b 
    15: Implementation of a strategy to resolve DRPs p=0.437b p=0.477b p<0.001b p=0.226b p<0.001b p<0.001b p=0.402b 
    16: Carrying out follow-up plan p=0.664b p=0.093b p<0.001b p=0.125b p<0.001b p<0.001b p=0.103b 
    17: Documentation of interventions p<0.001b p<0.001b p<0.001b p=0.195b p<0.001b p<0.001b p=0.002 
  
 
CH vs. 
GER 
CH vs. QC CH vs. DK GER vs. QC GER vs. DK QC vs. DK 
CH DD vs. CH 
nonDD 
Referral and consultation activities (20-26,33) p<0.001b p=0.166b p<0.001b p=0.003b p<0.001b p<0.001b p=0.223b 
    20: Consultation with other pharmacists p<0.001b p=0.057b p=0.562b p=0.656b p=0.002b p=0.055b p=0.001b 
    21: Made referrals to other pharmacists p<0.001b p=0.003b p=0.067b p=0.422b p<0.001b p<0.001b p=0.048b 
    22: Made referrals to a GP p<0.001b p=0.054b p<0.001b p=0.106b p<0.001b p<0.001b p=0.267b 
    23: Communication with GP p<0.001b p=0.710b p=0.001b p<0.001b p<0.001b p=0.043b p=0.979b 
    24: Initiation of discussion with GP p=0.072b p=0.009b p<0.001b p<0.001b p<0.001b p=0.344b p=0.983b 
    25: Provided the GP with a written summary p=0.394b p=0.115b p<0.001b p=0.040b p<0.001b p=0.005b p=0.003b 
    26: Made referrals to help groups p<0.001b p=0.032b p=0.388b p=0.027b p<0.001b p=0.048b p=0.106b 
    33: Provision of written copies to  
          professional colleagues 
p=0.453b p=0.542b p=0.789b p=0.856b p=0.871b p=0.794b p=0.816 b 
Instrumental activities (27-32, 34) p<0.001b p<0.001b p=0.258b p<0.001b p=0.089b p<0.001c p=0.491b 
    27: Counselling location p=0.058b p<0.001b p=0.001b p<0.001b p<0.001b p=0.300b p=0.038b 
    28: Filled-prescription validation p<0.001b p<0.001b p<0.001b p=0.217b p<0.001b p<0.001b p=0.856b 
    29: Informational support p<0.001b p<0.001b p=0.006b p<0.001b p<0.001b p<0.001b p=0.598b 
    30: Evaluation of patient satisfaction p=0.856b p=0.037b p<0.001b p=0.044b p<0.001b p<0.001b p=0.719b 
    31: Competency improvement p=0.719b p=0.052b p<0.001b p=0.059b p<0.001b p<0.001b p=0.799b 
    32: Performance evaluation p=0.002b p=0.002b p=0.030b p=0.129b p<0.725b p=0.322b p=0.661b 
    34: Provision of medical information p<0.001b p=0.533b p<0.001b p<0.001b p<0.001b p<0.001b p=0.064b 
1-17; 20-34: BPCS total score p=0.057b p<0.001c p<0.001c p<0.001c p<0.001c p<0.001c p=0.059c 
 
a) Pearson’s chi-square 
b) Mann-Whitney-U-test (for variables not corresponding to the theoretical distribution) 
c) Student-t-test (for variables corresponding to the theoretical distribution) 
d) ANOVA 
 
 
  
Table 6: Check for possible DRPs (Switzerland, Germany, Denmark, Quality circles) as well as comparisons between different samples (chi-square) 
 
 CH 
(n=392) 
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137) 
CH vs. GER CH vs. QC CH vs. 
DK 
GER vs. QC GER vs. DK QC vs. DK 
Check for 
DRPs 
85.2% 
(n=334) 
89.9% 
(n=652) 
90.4% 
(n=85) 
58.4% 
(n=80) 
p=0.300 p=0.465 p<0.001 p=0.853 p<0.001 p<0.001 
DRP detected 34.4% 
(n=135) 
30.3% 
(n=220) 
42.6% 
(n=40) 
22.6% 
(n=31) 
p=0.091 p=0.233 p=0.013 p=0.019 p=0.120 p=0.003 
missing 11+2 1+2 0+1 6+0 - - - - - - 
  
Table 7: Check for possible DRPs (Switzerland; regions with and without dispensing doctors) as well as comparisons between samples (chi-
square) 
 
Switzerland 
(n=392)* 
DD (n=143; 36.5%) 
prescriptions: 37.7±31.8  
p-value 
(95%; 2-sided) 
no DD (n=110; 28.1%) 
prescriptions: 83.2±48.7  
Check for DRPs 114 (79.7%) 0.121 95 (86.4%) 
DRP detected 37 (25.9%) 0.016 44 (40.0%) 
 
*  regions in Switzerland with a mixed system (regions with DD and without DD): n=125 (31.9%) not analysed; missing=14 
 
 
  
Table 8:  Extent of provision of pharmaceutical care considering all the patients with chronic conditions seen in the previous 6 weeks 
 
 CH (n=392) GER (n=725) QC (n=94) DK (n=137) CH (DD) (n=143) CH (no DD) (n=110) 
frequently or always tried to provide 
pharmaceutical care 
166 (42.3%) 310 (42.7%) 17 (18.1%) 31 (22.7%) 59 (41.3%) 49 (44.6%) 
frequently or always consciously decided and 
made the effort to provide extensive services 
121 (30.9%) 237 (32.7%) 15 (15.9%) 38 (27.7%) 48 (33.6%) 32 (29.1%) 
Provision of pharmaceutical care by community pharmacists 
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Table 9:  Reliability estimates of dimensions and domains of all groups 
 
Dimension and domain 
CH 
(n=392)
GER 
(n=725) 
QC 
(n=94) 
DK 
(n=137)
CH (DD) 
(n=143) 
CH (no DD) 
(n=110) 
Dimension: Direct patient care 
activities 
0.830 0.874 0.863 0.840 0.861 0.812 
Domain: Documentation 0.683 0.742 0.574 0.705 0.690 0.650 
Domain: Patient assessment 0.807 0.837 0.823 0.775 0.865 0.819 
Domain: Implementation of 
therapeutic objectives and 
monitoring plans  
0.677 0.674 0.634 0.798 0.771 0.757 
Dimension: Referral and 
consultation activities 
0.740 0.755 0.791 0.791 0.682 0.745 
Dimension: Instrumental 
activities 
0.673 0.691 0.701 0.626 0.701 0.658 
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Fig. 1: In-depth analysis using own data from Switzerland, Germany and quality circles and 
comparison with data from the Danish BPCS study cohort 
 Switzerland 
(DD  no DD) 
Germany Quality circles 
Denmark 
Own data collected for the BPCS survey
Data from Denmark taken from the BPCS-study 
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Fig. 2: Boxplots of BPCS dimensions and total scores by subgroup: Switzerland (CH; n=392), 
Germany (GER; n=725), quality circles (QC; n=94), Denmark (DK; n=137). Dimensions: direct 
patient care activities (0-85), referral and consultation activities (0-40), instrumental activities 
(0-35) and total score (15-160). 
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Abstract 
 
Objectives 
To explore and classify drug-related problems (DRPs) with new prescriptions 
detected in community pharmacies using a modified PCNE (Pharmaceutical Care 
Network Europe) classification system. 
 
Setting 
Sixty-four Swiss community pharmacies offering internships for pharmacy students. 
 
Main outcome measures 
Occurrence, nature and pharmacist’s management of DRPs. 
 
Methods 
Fifth year pharmacy students collected consecutively hospital discharge and primary 
care prescriptions. After training, they documented clinical and technical DRPs, 
causes and interventions. 
 
Results 
Prescriptions of 616 patients (43.0% discharged from hospital) were analysed. The 
patients’ median age was 56 years and they received a median of 3 (range 2−19) 
different drugs. In 121 (19.6%) prescriptions 141 clinical DRPs were detected. The 
most frequent clinical DRPs were potential drug-drug interactions (DDIs) (37.6%), 
drug choice (24.8%) and drug use problems (15.6%). These clinical DRPs led to a 
total of 299 interventions. There were 222 prescriptions (36.0%) that showed 278 
technical DRPs, resulting in a total of 417 interventions. Most frequent technical 
DRPs were missing or unclear package size or therapy duration (32.7%) and missing 
or unclear dosing/application instructions (30.9%). Most DRPs (75.4%) could be 
managed by the pharmacist alone. The number of prescribed drugs was the main 
factor with an influence on the frequency of clinical and technical DRPs. 
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Conclusion 
Clinical and technical DRPs are frequently observed in primary care as well as in 
hospital discharge prescriptions. The modified PCNE classification system, especially 
the amendment with a technical DRP category, proved to be useful and allowed the 
classification of all DRPs. Neither the setting (hospital discharge vs. primary care) nor 
the quality of electronically printed prescriptions, but only the number of prescribed 
drugs influenced the occurrence of clinical or technical DRPs. 
 
Keywords 
Drug-related problems  Pharmaceutical care  PCNE  Classification system  
Community pharmacy  Hospital discharge  Primary care  Switzerland 
 
Impact of findings on practice 
 
- In Switzerland, half of all new prescriptions show a DRP; two-thirds are 
technical DRPs. 
 
- The PCNE classification V5.1 needs to be amended, to include technical 
DRPs. 
 
- The occurrence of clinical or technical DRPs is only influenced by the number 
of prescribed drugs. It is not relevant if the prescriptions were electronically 
printed. 
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Introduction 
 
Many studies have shown drug-related problems (DRPs) to be very common in 
primary care and in hospital settings [76-91]. In both settings there is evidence that 
pharmacists’ interventions can reduce the occurrence of DRPs [65, 76, 84, 89, 90]. 
 
Receiving a newly prescribed drug is most likely an extraordinary situation for a 
patient who was recently informed about a diagnosis or at least was confronted with 
a new drug in his regimen. Because the risk of DRPs may be increased on the 
initiation of new drug treatments or changes within an established drug-treatment 
plan, a thorough consultation with a pharmacist is required to consider the new 
medication and, in particular, to make an accurate check for DRPs to achieve desired 
health outcomes [80, 224]. Thus, patients with at least one newly prescribed drug 
represent a relevant population to study DRPs and especially for studying the 
applicability of a comprehensive classification system which includes technical DRPs. 
 
Usually, patients discharged from hospital also have new drugs prescribed and are at 
increased risk of experiencing DRPs [80]. Therefore, we decided to focus on both 
prescriptions from hospital discharge and new primary care prescriptions, expecting 
that there are differences between these two settings (e.g. pattern and number of 
DRPs) as well as differences between electronically printed and handwritten 
prescriptions. To our knowledge, no previous study focused on new primary care and 
hospital discharge prescriptions processed in Swiss community pharmacies in 
everyday life. 
 
In different studies, different detection rates of DRPs were found because of 
variations in the methods used to identify DRPs, the classification systems and the 
inclusion criteria. There is no accepted standard tool for classification and 
documentation of DRPs, for the primary care or hospital (discharge) settings. The 
applicability of different systems is not yet clear, and many studies conclude that 
further studies are needed, with the aim to provide a tool that allows a complete 
classification of all DRPs that arise during prescription processing in community 
pharmacies. 
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From different pilot studies we had experience in the use of the PCNE classification 
(PCNE Classification V 5.01) [128]. This system attributes at least four items to each 
observation: (a) coding for the problem itself, (b) the actual or suspected cause(s) of 
the problem, (c) the intervention(s) required to resolve the DRP and (d) its outcome. 
We recognised as a probably important deficiency the lack of possibilities to classify 
technical DRPs, which arise frequently from prescription processing in community 
pharmacies (e.g. missing or unclear specification of drug dosage form, drug dosage 
and dosage regimen). In a very recent study on pharmacists’ interventions during the 
prescription dispensing process of new prescriptions for acute respiratory tract 
infections, we observed a need for addition of specifications in 11.6% of all 
prescription items [225]. Therefore, we planned to amend the existing PCNE 
classification accordingly. 
 
The first objective of this study was to explore the occurrence, nature and 
pharmacist’s management of drug-related problems (DRPs) detected in community 
pharmacies using the modified PCNE classification system in new prescriptions. The 
second aim was to analyse possible differences between new primary care and 
hospital discharge prescriptions as well as differences between electronically printed 
and handwritten prescriptions. The third aim was to evaluate the applicability of the 
modified classification system. 
 
Methods 
 
Setting and participants 
 
This prospective observational study was conducted from January to April 2007 in 64 
Swiss community pharmacies offering internships for fifth-year pharmacy students. 
Prescriptions of patients aged 18 years or older were eligible for the study if they 
comprised at least two prescribed drugs and if at least one drug was new (a new 
drug was defined as a new drug, drug form or dosage or a generic drug but not a 
new package size). In Switzerland not every prescription contains a new drug 
because the healthcare system allows physicians to issue repeat prescriptions and 
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thus enable patients to get their medications up to 12 months without further visit of 
the physician. Prescriptions issued by primary care physicians, physicians from 
ambulatory care centres or outpatient clinics of hospitals were classified as ‘primary 
care prescriptions’; ‘hospital discharge prescription’ was defined as a prescription 
issued by a hospital after the patient had been admitted for least one night.  
 
Data collection 
 
Sixty-four fifth-year pharmacy students had the mandatory mission from the 
university to collect five hospital discharge and five primary care prescriptions in a 
consecutive way during their pharmacy internships, leading to a convenient sample 
of prescriptions with at least one new medication. They were free to select one day to 
do so within the designated study period. While serving clients as usual they only had 
to identify if they were in possession of a prescription with a new drug and to check 
for inclusion criteria regardless whether they identified any problem or not. Then they 
were to check for DRPs with all the information available in a standard pharmacy, 
including the patient’s medication history. The software used in all Swiss community 
pharmacies performs computerized screening and alerts the attending employee of 
potential drug-drug interactions (DDIs). Whether a potential DDI was documented as 
a DRP or not depended on the student and the pharmacist: if the DDI was seen as a 
problem for the patient they had to complete a classification form. 
 
Thereafter, prescription validation was performed as usual by a pharmacist. 
Accordingly, the pharmacist or the student could detect a DRP or a problem that 
arose during patient counselling or processing the prescription. After they had 
included the first prescription they were obliged to collect the subsequent nine 
prescriptions fulfilling the inclusion criteria leading to five hospital and five primary 
care prescriptions. This consecutive collecting enabled the estimation of the 
incidence of DRPs with new prescriptions and the compilation of a randomized, 
convenient sample to reflect the daily life setting in Swiss community pharmacies. 
For each prescription at least one data sheet had to be filled out and if multiple 
problems were detected in the same prescription for each problem a new data sheet 
was used. To each problem multiple causes and interventions could be attributed. 
Students were instructed to document each case shortly after dispensing the 
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prescribed drugs. We retrieved the number of prescribed drugs per prescription from 
copies of prescriptions and verified plausibility of students’ documentation. Students 
anonymised all documents before delivery to the study centre. 
 
Students were trained during a lecture at the university. Three case studies were 
used to test their performance in documenting problems, causes and interventions 
resulting in a proportion of 91.9% of correct coding. In addition, ongoing support was 
assured by the study team being in contact by e-mail or phone. 
 
Classification of DRPs 
 
We used the PCNE classification system for DRPs (version 5.01) [128]. This system 
distinguishes four dimensions: problems, causes, interventions and the 
corresponding outcome. 
 
The six main categories of clinical DRPs are: (P1) adverse reaction(s), (P2) drug 
choice problem, (P3) dosing problem, (P4) drug use problem, (P5) interactions and 
(P6) other. We added a seventh category (P7) ‘technical DRP’ with the aim to be 
able to classify and to distinguish between “clinical DRPs” (P1−P6) and ‘technical 
DRPs’. A technical DRP is related to prescription quality and impedes to 
unambiguously dispense a drug in the correct dose, dosage form and package size 
(e.g. unreadable prescription, missing specifications). Accordingly, we created a 
seventh category of causes: C7 prescription quality (e.g. unreadable prescription, 
missing or unclear drug form, dosage, package size or therapy length). The pre-
existing categories of causes were: (C1) drug/dose selection, (C2) drug use process, 
(C3) information, (C4) patient/psychological, (C5) (pharmacy) logistics and (C6) 
other. Categories in the intervention domain remained unchanged: (I0) ‘no 
intervention’, (I1) at prescriber level, (I2) at patient level, (I3) at drug level, (I4) other. 
Unchanged outcome categories were: (O0) outcome unknown, (O1) problem solved, 
(O2) problem partially solved, (O3) problem not solved. 
 
We created a one-side data sheet with four dimensions, 20 categories and a total of 
95 items (24 problem codes, 41 causes, 23 interventions and 7 outcome codes) to 
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enable easy data collection, including patients’ age and sex, number of medications 
on the prescription and whether it was a primary care or a hospital discharge 
prescription. In total, 14 items and one main category (technical DRP) were added to 
the existing classification system (Table 1). 
 
Users’ opinion on the usability of the tool 
 
To evaluate usability of and satisfaction with the modified classification system, an 8-
item questionnaire used in a prior published study [123] was administered to the 
students who used this tool. They were asked about the extent to which they agree 
or disagree (five-point scale) with statements regarding the usability and usefulness, 
satisfaction and their willingness to use the tool in their practice in the future. 
 
Statistical analysis 
 
All returned data sheets were processed with the automated forms processing 
software TeleForm® version 7.0 from Cardiff Software Inc., Vista, USA. To avoid 
potential errors, all numeric and letter recognitions were verified visually on data 
sheets and on screen.  
Results are expressed as proportions and as medians with the corresponding 
interquartile range (IQR). The non-parametric Mann-Whitney test was used for 
unpaired two-sample comparisons, if data was normal distributed with Student’s t 
test. Statistical significance was defined as a p value <0.05. To check for possible 
risk factors, McNemar’s chi-square test was used. To investigate factors with 
influence on problems, different methods were tried, such as univariate analysis of 
variance, analysis of discriminance, logistic regression and correlation (bivariate, 
Spearman). We cite only results that proved robust in different methods of analysis. 
To consider the difference of prescribed number of drugs in primary care and hospital 
prescriptions, we analyzed influences of the setting only for a subgroup of 
prescriptions with ≤5 prescribed drugs. This subgroup was chosen because our 
sample contained few primary care prescriptions with >5 drugs and because the 
relationship between the number of prescribed drugs and the error rate changes 
significantly for >5 drugs (Fig. 1). Statistical analyses were performed using SPSS for 
Windows version 15.0 (SPSS Inc., Chicago, USA). 
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Results 
 
During the study period (January to April 2007) 625 prescriptions were collected. 
Nine cases did not fulfil the inclusion criteria (in one case only one drug was 
prescribed, eight cases had an age below 18), resulting in a sample of 616 
prescriptions (57.0% primary care) equal to 616 patients receiving a total of 2,309 
prescribed drugs. Table 2 shows basic study characteristics. 
 
Drug-related problems 
 
During prescription processing in the community pharmacies, 419 clinical and 
technical DRPs (or both) were detected in 329 prescriptions. In relation to the total 
number of prescribed drugs (n = 2309) we found 6.1% (n = 141) clinical and 12.0% 
(n = 278) technical DRPs. All problems could be classified with the modified PCNE 
classification system. 
 
Multiple clinical problems were present in 12 prescriptions, multiple technical DRPs in 
49 prescriptions and 14 prescriptions showed both clinical and technical DRPs. 
 
The analysis of the clinical problems revealed that 52 (36.9% of all clinical DRPs) 
were potential interactions (PCNE code P5), 35 (24.8%) drug choice problems (P2) 
and 22 (15.6%) drug use problems (P4). The most frequent technical DRPs were 
missing or unclear package size or therapy length (32.7%) and missing or unclear 
dosing/application instruction (30.9%). The details of clinical and technical DRPs, are 
shown in Table 3 and Table 4, respectively. 
 
The main contributing factor for presentation of clinical and technical DRPs was the 
number of drugs per prescription. Other variables had no significant influence in our 
dataset (univariate analysis of variance, analysis of discriminance, logistic regression 
and correlation). 
 
The probability for a clinical DRP was similar in prescriptions between two and five 
drugs; if >5 drugs were prescribed then the probability increased (see Fig). The 
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number of drugs is correlated with the chance of a clinical DRP (r=0.220; p<0.001; 
bivariate correlation, Spearman) and with ‘any problems’ (r=0.132; p=0.001; bivariate 
correlation, Spearman) but not with technical DRPs (r=0.012; p=0.775; bivariate 
correlation, Spearman). 
 
The mean number of prescribed drugs was significantly higher for prescriptions from 
hospital discharge than from primary care (5.1 vs. 2.7; p<0.001; t test). This higher 
number of prescribed drugs in hospital discharge prescriptions caused more clinical 
but not more technical DRPs. To analyse the influence of the setting (primary care 
and hospital discharge), we only considered prescriptions with ≤5 prescribed drugs 
because primary care prescriptions rarely included >5 prescribed drugs. We 
observed significantly more technical DRPs among prescriptions from primary care 
(p=0.043; chi-square; 95%; 2-tailed) but no influence of the setting for any problem 
(p=0.080; chi-square; 95%; 2-tailed) or clinical DRPs (p=0.924; chi-square; 95%; 2-
tailed). There was no association between gender and problems. Because the 
relationship between the number of prescribed drugs and technical DRPs is not 
linear and we do not have sufficient data we could not statistically correct for this 
effect. 
 
Causes 
 
To each problem a maximum of three causes could be attributed. Overall, 166 
causes for clinical DRPs were reported, with a majority (50.0%, n = 83) that was 
related to the selection of the drug and/or dosage schedule (C1). The second and 
third most common causes with 15.7% (n = 26) involved the information process (C3) 
and the drug use process with 14.5% (n = 24) (C2) (see Table 5). 
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Interventions 
 
A total of 716 interventions (see Table 6) were reported for all prescriptions (1.2 per 
616 prescriptions / 2.2 per 329 prescriptions with problems). All 141 clinical DRPs 
induced 299 (41.8% out of 716) interventions (2.1 per clinical DRP / 2.5 per 
prescription with clinical DRPs / 0.5 per 616 prescriptions; range 1−7) and 278 
technical DRPs induced 417 (58.2% out of 716) interventions (1.5 per technical DRP 
/ 1.9 per prescription with a technical DRP / 0.7 per 616 prescriptions; range of 0−6). 
 
To manage all problems a total of 81 (13.1% out of 616 prescriptions) direct contacts 
to the prescriber (call / conversation) were necessary: 42 (6.8% out of 616) 
prescriptions with one or more clinical DRPs and 46 (7.5% out of 616) prescriptions 
with one or more technical DRPs led to a direct contact with the prescriber (7 
prescriptions with both a clinical DRP and a technical DRP). One hundred and 
seventy-five (63.0% of 278) of technical DRPs could be solved by the pharmacy 
together with the patient, but only 56 (39.7% out of 141) of clinical DRPs were solved 
in cooperation with the patient. 
 
The 299 interventions induced by clinical DRPs involved 178 drugs (in 48 cases 2 
drugs were related to one problem, e.g. interaction). Cardiovascular drugs (C; 21.9%, 
n = 39) were most often involved, followed by nervous system (N; 21.3%, n = 38) and 
musculo-skeletal system drugs (M; 10.1%, n = 18). 
 
Users’ opinion 
 
After training and data collection, observers were asked 8 questions about the 
acceptability and usability of the classification system they had used in this study 
(see Table 7). Most of the users think that it is important to have an opportunity to 
document the efforts of the pharmacies but only one third agreed that the tool is easy 
to use and practical. 
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Discussion 
 
This study examined the frequency, nature and pharmacist’s management of DRPs 
with primary care and hospital discharge prescriptions which comprised at least one 
new drug. We found a high occurrence of clinical (19.6%) and, in particular, of 
technical DRPs (36.0%). More than 50% of all prescriptions showed a clinical or a 
technical DRP or both. Compared to other studies our numbers are quite high but in 
this study we set out to use prescriptions which we considered likely to have a high 
prevalence i.e. newly started drugs and prescriptions with at least two drugs. In 2007 
Hammerlein found only 0.93 DRPs per 100 patients and 1.16 DRPs per 100 
prescriptions [81]. Westerlund conducted a survey on DRPs in prescription-only 
medicines in 1999 and found 2.8 DRPs per 100 patient contacts [77]. A recent Swiss 
study detected 0.74 clinical DRPs per 100 prescriptions with the need of an 
intervention and 1.9 technical DRPs per 100 prescriptions [83]. These figures 
illustrate the problem that such comparisons are hampered by different settings, 
measurements methods and classification systems. Paulino [80] found in a study in 
six European countries even more DRPs than we did (103.7 DRPs per 100 patients 
discharged from hospital; 63.7% out of all patients had at least one DRP). 
Uncertainty or lack of knowledge about the aim of the drug (29.5%), side effects 
(23.3%) and practical problems (7.6%) were the most common DRPs. However, only 
few DDIs (4.0%) were detected, probably because most of them did not have access 
to patient medication histories. In Switzerland every pharmacy is equipped with 
software that includes an automatic DDI screening system and participants in our 
study probably indicated every possible potential interaction, even if not clinical 
relevant. Therefore, the most frequently reported clinical DRPs in our study were 
DDIs (37.6% of all clinical DRPs; 7.0% of all patients). In the German study [81] DDIs 
were also most frequent but the fraction was only 8.5% of all DRPs. In another 
primary care study DDIs were the third most common problem with 3.2%, and in a 
study performed in hospital setting they observed 17.0% DDIs [83, 84]. Paulino et al. 
found 60.0% of patients after hospital discharge with a potential interaction [80]. 
 
However, the comparison of the study’s findings with those of other studies is difficult 
due to differences in setting and aim [77, 80, 81, 83, 84, 226]. Furthermore, the 
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frequency of detected problems can be influenced by the systematic screening under 
study conditions, which differs significantly from daily practice (Hawthorne effect 
[227]). In our study, students and pharmacists probably had a more positive attitude 
towards the provision of pharmaceutical care (e.g. check for DRPs) and they 
probably detected most possible problems. This may explain our high detection rate 
of 22.9. If DDIs are as frequent as found in this or other studies more emphasis 
should be placed on best management of potential DDIs in community pharmacies. 
However, if we omit all interactions we still found a detection rate of 14.3. 
 
Using fifth year pharmacy students for data collection during their internship and 
collecting primary care as well as hospital discharge prescriptions in a continuous 
way, enabled us to compile a randomized, convenient sample and to estimate the 
prevalence of DRPs with new prescriptions. We had instructed the students to 
perform prescription processing as usual. Thus, every prescription was checked by a 
pharmacist before dispensing and we were not depending on inferior competencies 
of students. Factors associated with clinical and technical DRPs were tested with 
several statistical methods and the main factor influencing the presence of any 
clinical problems was the number of drugs. Older people showed both more clinical 
and technical DRPs, but this was to be expected because the number of drugs 
increased with age. In addition, we expected the setting to have an influence on the 
occurrence of DRPs but different statistical tests did not show any relationship. More 
clinical DRPs were found in hospital discharge than in primary care prescriptions but 
the mean number of prescribed drugs was higher on these prescriptions, which 
explains the higher frequency of problems. Surprisingly, more technical DRPs were 
found in primary care prescriptions with fewer prescribed drugs than in hospital 
discharge prescriptions. 
 
Most problems were caused by drug selection and/or drug dose selection and many 
problems were solved after discussion with patients or family members. More than 
two-thirds of technical but less than half the clinical DRPs could be solved by the 
pharmacy together with the patient. Pharmacists should therefore actively involve 
patients and relatives in the screening and solving process for DRPs. Almost two 
thirds of all interventions and 50% of all contacts with the prescriber were related to 
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technical DRPs which shows their importance and frequency in daily life practice in 
community pharmacies. Therefore, inclusion of technical DRPs into the classification 
is strongly recommended. Looking at the intervention part, pharmacists indicate the 
importance of the detected clinical DRPs, in particular activities at prescriber and 
drug level. The high frequency of interventions is related to the high detection rates of 
DRPs. 
 
We amended in this study the original PCNE system with 80 items by addition of 15 
items (incl. technical DRPs as one new main category) resulting in a total of 95 items. 
This new problem category was specified with seven items to receive enough 
information. As suggested by Lampert [84] and Allenet [228], we further added two 
items in the category ‘drug use problem’ to categorise wrong or improper use of a 
drug and wrong or improper time of applying a drug. A previous study showed a 
documentation rate of 97.8% in a hospital setting without any modification of the 
classification system but they reported a lack of certain items for in-patients [84]. 
Therefore, an important result of this study is the fact that our modified system 
allowed a complete classification of all problems. In contrast, a study [81] with the PI-
Doc system with 72 items was amended with 27 items but 362 out of 10,427 (3.5%) 
cases still could not be classified. Our study found twice as many technical DRPs as 
clinical ones. Most of the documentation systems do not separate technical from 
clinical DRPs and give them the same level of importance, or they have integrated 
technical DRPs in ‘prescribing errors’ or ‘other’ [77, 124, 128, 195, 229]. Often there 
is only a definition for clinical but not for technical DRPs. The German study of 2007 
reported 8.3% (out of 10,427) of technical DRPs and difficulties to classify technical 
DRPs in over 50% of the cases [81]. Our results strongly support the inclusion of a 
new problem category ‘technical DRPs’ with enough further possibilities to specify 
them. Furthermore, different classification systems should feature at least the same 
main categories with the possibility to change single items to be able to compare 
results from different studies. 
 
Our study has strengths and limitations. We selected prescriptions from primary care 
during prescription processing in a daily-life setting. We could ascertain the reported 
problems with the copies of the prescriptions and we could retrospectively 
differentiate between handwritten and electronically written prescriptions. All 
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problems could be coded with our modified PCNE classification system. However, 
we did not assess the level of severity and the clinical or economic impact of clinical 
and technical DRPs. Furthermore, we cannot assure that the prescriptions selected 
were consecutive ones and the diversity of persons who documented clinical and 
technical DRPs could lead to variability in coding for the same problem, even though 
the participant observers were trained with specific and detailed instructions. In our 
study the PCNE system showed to be easy to use for a majority of the users and 
took little time, as it has been created for the documentation of DRPs in the 
community pharmacy setting. However, one quarter of students evaluated the PCNE 
tool as not comprehensive although they had classified all problems. Our students 
rated very critically all questions if comparing with the study from which the questions 
were retrieved [123]. 
 
Our study reflects only the situation in Switzerland. A recent multinational study by 
Mc Elnay et al. investigated the extent to which pharmaceutical care has already 
been implemented into daily community pharmacy practice across Europe (Mc Elnay 
J, Hughes C. Provision of pharmaceutical care by community pharmacists: a 
comparison across Europe). The behavioural pharmaceutical care scale was used 
and the mean of all 13 countries was 72.1 ± 8.5 (mean ± SD) with a range of mean 
scores from 50.6 to 83.5 (possible score: 15−160) reflecting a considerable variation 
between countries. Switzerland had a score of 73.2 ± 18.7 (mean ± SD) indicating 
that Swiss pharmacists behave most probably not very differently from their 
counterparts in other European countries. Furthermore, this study revealed an 
important lack of documentation activities throughout Europe: only 25.2% of all 
possible documentation possibilities were used. Thus, a documentation and 
classification system is urgently needed. Intensive training can increase the number 
of interventions without increasing the time spent on documentation. [92, 230]. As 
Lampert [84] reported, the PCNE system with its classification of each DRP on four 
different levels gives enough detail to allow qualitative and even economic analyses. 
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Conclusion 
 
In the delivery process of new prescribed medications, clinical and technical DRPs 
are frequently observed in new primary care and in hospital discharge prescriptions. 
Neither the setting (hospital discharge vs. primary care) nor the quality of 
electronically printed prescriptions, but only the number of prescribed drugs 
influenced the occurrence of clinical or technical DRPs in this study. Most DRPs 
could be managed by the pharmacist alone or after discussion with the patient but 
without any contact to the prescriber. Therefore, the management of DRPs in 
community pharmacies is a very important activity which should be explored more 
intensively in further studies. The modified PCNE classification system, especially the 
amendment with a technical DRP category, proved to be useful and allowed the 
classification of all DRPs, but still rather complicated to apply in pharmacy practice. 
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Tables and figures 
 
Table 1: Added items to the original PCNE classification system V5.01 
Problems (P) Causes (C) Interventions (I) 
 C7 prescription quality  
P4.3 wrong or improper 
application method of drug 
(e.g. tablets without break 
score cut into halves) 
C7.1 unreadable prescription 
I2.5 patient asked for further 
information 
P4.4 wrong or improper 
time of application or intake 
C7.2 missing or unclear drug 
name, though readable 
I2.6 more information retrieved 
from patient‘s history 
P7.1 technical DRP 
C7.3 missing or unclear drug form 
if multiple forms are available 
I3.7 adaptation of amount of drug 
dispensed 
 
C7.4 missing or unclear drug 
potency if multiple forms are 
available 
I4.3 information retrieved from 
literature 
 
C7.5 missing or unclear package 
size or therapy length 
I4.4 information retrieved from 
toxicology or drug information 
centre 
 
C7.6 missing or unclear dosage or 
application instruction 
 
 
C7.7 missing prescription of 
necessary applications aids 
 
 
  
Table 2: Basic study characteristics 
 Primary care Hospital discharge  Total p-values 
Prescriptions (=patients) – n (%) 351 (57.0) 265 (43.0) 616 (100.0) - 
Age – mean years (SD, median)  
(IQR*, range) 
53.3 (19.0;53)  
(28.5; 18−98) 
59.3(18.6; 62)  
(27.3; 19−94) 
55.9 (19.0; 
56)  
(32; 18-98) 
p<0.001 a
Female − n (%) 212 (60.4) 139 (52.5) 351 (57.0) p=0.069 b
Electronic prescriptions – n (% of prescriptions) 36 (10.3) 143 (54.0) 179 (29.1) p<0.001 b 
Total number of prescribed drugs – n (%) 962 (41.7) 1347 (58.3) 2309 p<0.001 b 
Number of drugs per prescription − median (IQR, range) 2 (1; 2−10) 4 (5; 2−19) 3 (2; 2−-19) p<0.001 a
Clinical DRPs – n (% of prescriptions) 55 (15.7) 86 (32.5) 141 (22.9) p<0.001 b 
Technical DRPs – n (% of prescriptions) 175 (49.9) 103 (38.9) 278 (45.1) p=0.007 b 
Prescriptions with clinical DRPs –n (% of prescriptions) 52 (14.8) 69 (26.0) 121 (19.6) p=0.001 b
Prescriptions with technical DRPs – n (% of prescriptions) 135 (38.5) 87 (32.8) 222 (36.0) p=0.149 b
Prescriptions without any problem – n (% of prescriptions) 167 (47.6) 120 (45.3) 287 (46.6) p=0.572 b
a) p-values for comparisons with t test (2-tailed, 95%) 
b) p-values for comparisons with chi-square (2-tailed, 95%) 
 
  
Table 3: Clinical DRPs (n=141) in 121 prescriptions, classified according to PCNE classification V5.1 
Primary domain Code Detailed classification Primary care Hospital discharge Total 
    n (% of 141) n (% of 141) n (% of 141) 
Adverse reactions P1 Total   3 (2.1) 
  P1.1 Side effect suffered (non-allergic) 1 (0.7) 1 (0.7) 2 (1.4) 
  P1.2 Side effect suffered (allergic) 1 (0.7) - 1 (0.7) 
  P1.3 Toxic effects suffered - - - 
P2 Total     35 (24.8) Drug choice problem 
P2.1 Inappropriate drug (not most appropriate for indication) 6 (4.3) 5 (3.5) 11 (7.8) 
  P2.2 Inappropriate drug form (not most appropriate for indication) 4 (2.8) 3 (2.1) 7 (5.0) 
  P2.3 Inappropriate duplication of therapeutic group or active ingredient 1 (0.7) 3 (2.1) 4 (2.8) 
  P2.4 Contra-indication for drug (incl. pregnancy/breast feeding) 2 (1.4) - 2 (1.4) 
  P2.5 No clear indication for drug use 6 (4.3) 4 (2.8) 10 (7.1) 
  P2.6 No drug prescribed but clear indication - 1 (0.7) 1 (0.7) 
Dosing problem P3 Total     18 (12.8) 
  P3.1 Drug dose too low or dosage regimen too long 2 (1.4) 2 (1.4) 4 (2.8) 
  P3.2 Drug dose too high or dosage regimen too frequent 1 (0.7) 7 (5.0) 8 (5.7) 
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Primary domain Code Detailed classification Primary care Hospital discharge Total 
  P3.3 Duration of treatment too short 2 (1.4) 2 (1.4) 4 (2.8) 
  P3.4 Duration of treatment too long 1 (0.7) 1 (0.7) 2 (1.4) 
Drug use problem P4 Total     22 (15.6) 
  P4.1 Drug not taken/administered at all - - - 
  P4.2 Wrong drug taken/administered - 1 (0.7) 1 (0.7) 
  P4.3 Wrong/not appropriate drug use/application 5 (3.5) 4 (2.8) 9 (6.4) 
  P4.4 Wrong/not appropriate time of use/application 8 (5.7) 4 (2.8) 12 (8.5) 
Interactions P5 Total     53 (37.6) 
  P5.1 Potential interaction 10 (7.1) 42 (29.8) 52 (36.9) 
  P5.2 Manifest interaction 1 (0.7) - 1 (0.7) 
Others P6 Total     10 (7.1) 
  P6.1 Patient dissatisfied with therapy despite taking drug(s) - - - 
  P6.2 Insufficient awareness of health and diseases 4 (2.8) 6 (4.3) 10 (7.1) 
  P6.3 Unclear complaints, further clarification necessary - - - 
  P6.4 Therapy failure (reason unknown) - - - 
Total   55 (39.0) 86 (61.0) 141 (100.0) 
  
Table 4: Technical DRPs (n=278) in 222 prescriptions 
Technical DRPs a Primary care Hospital discharge Total 
 n (% of 278) n (% of 278) n (% of 278)
Missing prescription of necessary application aids 1 (0.4) 2 (0.7) 3 (1.1) 
Missing/unclear drug name though legible 6 (2.2) 8 (2.9) 14 (5.0) 
Missing/unclear drug form, if several available 17 (6.1) 6 (2.2) 23 (8.3) 
Missing/unclear drug potency, if several available 15 (5.4) 13 (4.7) 28 (10.1) 
Unreadable prescription 26 (9.4) 7 (2.5) 33 (11.9) 
Missing/unclear dosing/application instruction 64 (23.0) 22 (7.9) 86 (30.9) 
Missing/unclear package size and/or therapy length 46 (16.5) 45 (16.2) 91 (32.7) 
Total 175 (62.9) 103 (37.1) 278 (100.0) 
 
a) 1 technical DRP per prescription possible 
  
Table 5: Top ten of the most frequently reported causes (n=166) induced by clinical DRPs (n=141), classified according to PCNE classification V5.1 
Primary domain Code Detailed classification Primary care Hospital discharge Total 
      n (% of 166) n (% of 166) n (% of 166) 
C1 Total     83 (50.0) Drug/dose 
selection C1.1 Inappropriate drug selection 17 (10.2) 38 (22.9) 55 (33.1) 
 C1.2 Inappropriate dosage selection 5 (3.0) 9 (5.4) 14 (8.4) 
 C1.4 Pharmakokinetic problems, incl. ageing/deterioration in organ 
function and interaction 
3 (1.8) 7 (4.2) 10 (6.0) 
C2 Total     24 (14.5) Drug use process 
C2.1 Inappropriate timing of administration and/or dosing intervals 5 (3.0) 8 (4.8) 13 (7.8) 
 C2.3 Drug overused/over-administered 2 (1.2) 3 (1.8) 5 (3.0) 
  C2.6 Patient unable to use drug (form) as directed 3 (1.8) 1 (0.6) 4 (2.4) 
Information C3 Total     26 (15.7) 
 C3.1 Instructions for use/taking not known 9 (5.4) 6 (3.6) 15 (9.0) 
 C3.2 Patient unaware of reason for drug treatment - 4 (2.4) 4 (2.4) 
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Primary domain Code Detailed classification Primary care Hospital discharge Total 
      n (% of 166) n (% of 166) n (% of 166) 
Patient / 
Psychological 
C4 Total   14 (8.4) 
 C4.8 Burden of therapy 2 (1.2) 3 (1.8) 5 (3.0) 
C5 Total     5 (3.0) (Pharmacy) 
Logistics C5.1 Prescribed drug not available 1 (0.6) 3 (1.8) 4 (2.4) 
 
  
Table 6: Top ten of the most frequently reported interventions (n=716) induced by clinical or technical DRPs, classified according to PCNE 
classification V5.1 
Primary domain Code  Detailed classification Primary care Hospital discharge Total 
   clinical  
DRPs 
technical 
DRPs 
clinical  
DRPs 
technical 
DRPs 
all DRPs 
   n (% of 716) n (% of 716) n (% of 716) n (% of 716) n (% of 716) 
I1 Total      102 (14.2) 
I1.1 Prescriber informed only 2 (0.3) 3 (0.4) 7 (1.0) 2 (0.3) 14 (2.0) 
I1.2 Asked prescriber for further information 7 (1.0) 26 (3.6) 14 (2.0) 6 (0.8) 53 (7.4) 
At prescriber level 
I1.3  Intervention proposed, approved by 
prescriber 
6 (0.8) 11 (1.5) 8 (1.1) 3 (0.5) 28 (3.9) 
I2 Total       171 (23.9) 
I2.1 Patient (medication) counselling 25 (3.5) 66 (9.2) 63 (8.8) 42 (5.9) 196 (27.4) 
I2.5 Patient asked for further information 21 (2.9) 83 (11.6) 25 (3.5) 28 (3.9) 157 (21.9) 
At patient/ carer level
  
I2.6 Further information retrieved from patient 
history 
4 (0.6) 20 (2.8) 21 (2.9) 9 (1.3) 54 (7.5) 
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Primary domain Code  Detailed classification Primary care Hospital discharge Total 
   clinical  
DRPs 
technical 
DRPs 
clinical  
DRPs 
technical 
DRPs 
all DRPs 
   n (% of 716) n (% of 716) n (% of 716) n (% of 716) n (% of 716) 
I3 Total       94 (13.1) 
I3.1 Drug changed 4 (0.6) 9 (1.3) 5 (0.7) 3 (0.4) 21 (2.9) 
I3.2 Dosage changed 4 (0.6) 4 (0.6) 4 (0.6) 1 (0.1) 13 (1.8) 
I3.4 Instructions for use changed 9 (1.3) 9 (1.3) 3 (0.4) 3 (0.4) 24 (3.4) 
At drug level 
  
I3.7 Amount of drug to dispense changed 5 (0.7) 5 (0.7) 4 (0.6) 4 (0.6) 18 (2.5) 
 
  
Table 7: Users’ opinion (n=64) of the tool. 1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree 
  Mean score ± SD Agree or 
strongly agree
Neutral Disagree or 
strongly 
disagree 
  n (%) n (%) n (%) 
1. The classification system was comprehensive and included all drug-related 
problems I identified. 
3.4 ± 1.1 29 (45.3) 18 (28.1) 17 (26.6) a 
2. I did not have problems finding out the proper classification of drug-related 
problems I identified. 
2.9 ± 1.0 18 (28.1) 23 (35.9) 23 (35.9) a 
3. The classification system was easy to use and practical. 3.1 ± 0.9 22 (34.4) 28 (43.8) 14 (21.9) a 
4. I will use the classification system in my practice in the future. 2.3 ± 1.3 5 (7.8) 14 (21.9) 41 (64.1) b 
5. In general I am satisfied with the classification system. 3.3 ± 1.0 30 (46.9) 19 (29.7) 15 (23.4) a 
6. The expenditure of time to classify the problems was adequate. 3.7 ± 1.0 42 (65.6) 12 (18.8) 10 (15.6) a 
7. I think it is important to have an opportunity to classify the effort of pharmacies. 4.4 ± 0.7 56 (87.5) 7 (10.9) - 
8. The PCNE classification would be a good tool to document the activities of 
pharmacies. 
3.1 ± 1.1 21 (32.8) 22 (34.4) 19 (29.7) a 
a) No user answered this question with ‘strongly disagree’ 
 
b) Twenty users answered this question with ‘strongly disagree’  
Classification of drug-related problems 
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Fig. 1: Probability for prescriptions to present ‘any’ problems (n=329), clinical (n=121) or 
technical DRPs (n=222) according to the number of prescribed drugs 
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Background and aims 
 
Medications have to be applied correctly to act effectively [95]. Misuse of medication 
can lead to progression of disease or treatment failure; non-adherence (NAH) can 
cause adverse drug events, drug over- or underdose, unnecessary hospitalizations, 
additional newly prescribed drugs, and higher costs [95]. Therefore, counselling 
patients on a newly prescribed drug is important [95]. In an earlier study we found 
that in Switzerland, half of all new prescriptions show a drug-related problem (DRP). 
Potential drug-drug interactions (DDIs; 37.6%), drug choice (24.8%), and drug use 
problems (15.6%) were the most frequent DRPs. 
 
Using the medication communication index (MCI), Tarn et al. [95] showed that during 
consultation, physicians mentioned the name of the medication in 74% of the 
prescribed drugs, stated the purpose or justification for taking a medication in 87%, 
the duration of intake in 34%, the number of tablets or sprays in 55%, the frequency 
or timing of intake in 58%, and adverse effects in 35%. The study did not assess the 
patient’s knowledge but only the physician’s information given to the patient (Fig. 1). 
Thus, patients collecting their prescribed drug from a pharmacy are likely to have 
substantial deficits in knowledge about a new drug. Before patients start with their 
new drug therapy, pharmacies are the last ‘check point’ to ensure patients’ 
understanding and knowledge on prescribed drug therapy. 
 
Medication review by community pharmacists has been shown to be an effective 
service to identify medication-related risk factors (MRRFs) [170]. However, not all 
DRPs can be detected by a review in the pharmacy [170]. To get more information 
about the patient’s medication management, it is useful to visit them at home [170]. 
Sorensen et al. [170] visited 204 patients in their own homes in Australia. Confusion 
of generic and trade names was reported most frequently (56%), followed by risk for 
non-adherence (53%). Such risk factors may be associated with adverse drug events 
or hospital (re)admission [170]. 
 
Using this information, we set the goal to address patients with newly prescribed 
medication and to gain first experience in performing home visits.  
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The aims of this pilot study were to assess the patients’ knowledge about newly 
prescribed medication shortly after their pharmacy visit and to identify the prevalence 
of MRRFs and problems associated with the use of the drugs at patients’ homes. 
 
Methods 
 
Twenty community pharmacies in the region of Basel, Switzerland, participated in 
this pilot study. After counselling patients with a newly issued prescription, all staff 
members were instructed to refer these patients to the investigator who was present 
in the pharmacy during one working day. The investigator explained the nature and 
aim of the study to each patient, and he arranged a telephone interview within the 
coming two days. 
 
Newly prescribed medications were defined as those that had not been used in the 
previous 12 months or those prescribed at a different dosage or for a different route 
of administration. Drugs that were replaced by generics at the same dosage and for 
the same route of administration were not included. To qualify for the phone 
interviews, patients had to be at least 18 years old. Moreover, they had to fluent in 
German, and the medication had to be intended for the person who had come to the 
pharmacy. Parents getting a new drug for a child (≤12 years old) were also included. 
For patients who did not agree to take part, the reason was recorded. Questionnaires 
for the interview as well as the prescriptions were made anonymous.  
 
At the end of each completed phone interview, all patients were asked to be visited at 
their home by an investigator. For this home visit, we developed a 36-item interview 
guide. We assessed patients’ characteristics; patients’ knowledge about drugs based 
on the MCI by Tarn et al. [95];  the prevalence of MRRFs by Sorensen et al. [170], 
i.e. risk for non-adherence using the self-reported medication-taking scale of Morisky 
[231], expired medications present, hoarding of over-the-counter (OTC) drugs and 
prescription-only medicines (POMs) (one or more drugs no longer required but 
retained at home), therapeutic duplications (two or more drugs containing the same 
active ingredient that were taken concomitantly), multiple locations of medication 
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storage, no medication administration routine (e.g. no pill organizers used), 
discontinued medication repeats retained, and the patient’s confusion of generic and 
trade names), and additional risk factors (e.g. drugs belonging to other individuals 
living in the same household, any problems with using or handling the drugs, or any 
suspected ADR since starting to take the drug).  
 
After the visit, the patients’ drugs were screened for potential drug interactions using 
Pharmavista® [232]. They were noted as ‘interactions present’ if at least one 
interaction was documented as ‘moderate’ (frequent therapeutic problems; 
combination can be administered but close monitoring required) or ‘severe’ (life-
threat / intoxication / permanent harm). 
 
Results are expressed as proportions. Statistical significance was defined as a p 
value <0.05. Statistical analyses were performed using SPSS for Windows version 
15.0 (SPSS Inc., Chicago, USA). 
 
Results 
 
Phone interview 
 
Out of 252 patients with a newly prescribed drug, 80 (31.7%) agreed to participate in 
the phone interview. Seventy interviews could be completed (four patients were not 
reachable, two felt too ill, two did not want to participate anymore, and two had given 
the wrong phone number). The mean (SD; range) number of newly prescribed drugs 
was 1.3 (0.6; 1-3). Forty (70%) patients received more than one drug. The mean (SD; 
range) age was 51.5 years (19.2; 19-89). Six interviews were performed with the 
parents of a child. The mean (SD) MCI score was 3.4 (0.8) on a 5-point scale (68%). 
The MCI ranged from 2.8 (cardiovascular drugs) to 4.3 (psychiatric drugs) (Table 1). 
 
We asked patients what they would do in the case of adverse effects. Patients gave 
the following answers (multiple answers were possible; missing=3): 
- ask the physician (n=55, 57.3%) 
- discontinuing the medicines (n=20; 20.8%) 
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- ask the pharmacist (n=7; 7.3%) 
- lowering the dosage (n=1; 1.1%) 
- other (n=13; 13.5%) 
 
Further, we wanted to know what patients would do in the case of a missed dose (no 
multiple answers were possible; missing=1). 
- missed dose just ignore (n=42; 60.0%) 
- missed dose taken later (n=8; 11.4%) 
- will never occur (n=7; 10.0%) 
- inconsistent action (n=5; 7.1%) 
- read the package insert (n=2; 2.9%) 
- ask the physician or pharmacist (n=2; 2.9%) 
- next dose doubled (n=1; 1.4%) 
- other (n=2; 2.9%) 
 
Home visits 
Out of 70 interviewed patients, 20 (65.0% female, 55.0% retired) agreed to be visited 
at their home. The mean (SD) age of patients was 59.2 (16.2) years, and the mean 
(SD) duration of a visit was 42.9 min (24.3) with a range of 15 to 125 min. We 
observed a mean (SD) number of 4.6 (2.5) drugs per patient. Seventeen (85.0%) 
patients got their drugs mostly (90-100%) from only one pharmacy. Two (10.0%) 
patients had any drug use problems (e.g. big tablets), seven (35.0%) suffered from 
any adverse drug events (e.g. gastrointestinal problems, headache). Most patients 
kept their drugs in the kitchen (75%), followed by the bathroom (50%) and the 
bedroom (35%). Multiple answers were possible. No patient used a medicine 
cupboard. Seven (35%) patients showed moderate or severe interactions. Fig. 2 
shows the medication-related risk factors. 
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Discussion 
 
Phone interviews 
 
Few people could remember the drug’s name (35%), especially patients receiving 
gastrointestinal (10%) or cardiovascular (20%) drugs. Patients with psychiatric drugs 
could recall the name of the newly prescribed drug best (63%). Tarn et al. [95] 
showed that 74% of the physicians mentioned the name. Maybe patients cannot 
remember the names of the drugs because these are often hard to memorise. Akici 
et al. [233] showed that only 3% (out of 385) of patients with a newly prescribed drug 
could remember the drug’s name when leaving the physician’s office. Perhaps the 
patients in our study could better remember the names because they had already 
used the drug for 2-3 days. How important is it to know the name? If a pharmacist or 
a physician asks for other medications during counselling, it is very important for a 
patient to know the name because of safety reasons, but, for the everyday life it 
seems to be not very important. 
 
More important than knowing the name is to know the purpose of intake. Overall, 
92% could name the reason why to take the drugs. Amazingly, 40% of purposes of 
cardiovascular drugs were not known by patients. In particular for patients suffering 
from cardiovascular diseases it would be important to know the reason of intake 
because often no direct effect can be noticed by the patient himself whether or not 
he/her takes the drugs. Overall, 92% of all stated purposes of drugs were correct. 
Compared with the results of Tarn et al., patients in our study were well informed. 
Tarn reported that 87% of physicians talked anything about the purpose of drugs. 
However, we do not know about the patient knowledge after the physician 
consultation. Maybe pharmacies’ counselling had contributed to this level of 
information. 
 
Patients knew the duration of intake in 89% of all cases. Worst results could be found 
for ear, nose, and throat drugs. In this group only 67% answered correctly. 
Surprisingly, for antibiotics all of the patients knew how long to take them. Because of 
resistances it is pleasant to see that patients were good informed about this duration. 
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Tarn et al. found that physicians mentioned the duration of intake only in 34% of all 
cases. Overall, the frequency or timing (e.g. dermatologic medication) was known in 
96% of cases, and the number of tablets of all drugs in 84% of cases. 
 
Patients with urogenital drugs knew the correct number of tablets in 84%. Tarn et al. 
found that the physician mentioned the frequency or timing in 58% and the number of 
tablets in only in 55% of patients. The percentage in our study is high. One reason is 
certainly that patients were allowed to look at the package when answering and they 
probably could depict some information from the individualised etiquette, which in 
Switzerland always should be added to each newly dispensed package. 
 
From all of the five MCI-components the patients had least information about 
potential adverse effects. For antibiotics, cardiovascular, ear, nose and throat as well 
as for gastrointestinal drugs, nobody reported to be informed about adverse effects. 
Especially for antibiotics as well as for cardiovascular drugs it would be very 
important to be informed about possible adverse effects. Patients receiving 
psychiatric drugs were good informed about adverse effects (75%). Overall, 24% of 
the patients knew potential adverse effects of their drugs. Tarn et al. found that 
physicians informed about adverse effects in 25%. Perhaps, physicians and/or 
pharmacists mentioned the topic of adverse effects but the patients could not 
remember, or patients were actually not informed at all in order not to frighten the 
patient. It is not easy to talk and inform about adverse effects. Some patients could 
become scared and will not take the drugs at all or they think they will experience all 
of the adverse effects. 
 
Toren et al. [234] found 77% (out of 130) of patients who knew the purpose and 11% 
could remember adverse effects one week after discharge of the hospital. In our 
study more patients stated the correct purpose and they also had more information 
about adverse effects.  
 
This pilot had several limitations. When the patients were talking, it was difficult to 
document the answers and to listen at the same time. Perhaps, it would be better to 
audiotape the interviews in a further study. When the patients did not know the drug’s 
name, it was difficult to be able to relate which information of the patient refers to 
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which drug. Of course, with this study sample only tendencies can be shown. 
Because all patients live in the region of Basel the statements do not count 
throughout Switzerland. 
 
Home visits 
 
The most often detected risk factor was the risk for non-adherence (n=15; 75%). 
Sorensen et al. [170] found 53% of the patients with a risk for non-adherence. Many 
research groups try to find solutions to enable good adherence as for example with 
phone counselling [46]. Such phone counselling by a pharmacist improved 
adherence, reduced mortality, and reduced the use of healthcare resources in 
patients receiving polypharmacy. Our phone interviews aimed solely at investigation 
of patient knowledge. However, they could be used for a further counselling through 
pharmacists or for enabling patients to ask questions about their new drugs. 
Sorensen et al. named this risk factor ‘poor adherence’, however, we changed the 
wording into ‘risk for non-adherence’ because only due to some positive answers it 
seems to be daring to already talk about ‘poor adherence’. In our opinion, the 
Morisky questions are a tool to identify patients at risk for non-adherence enabling 
pharmacists to discuss this problem with a patient. 
 
The risk factors ‘no administration routine’ and ‘multiple medication storage locations 
used’ were each found in 55% (n=11). The pharmacist could ask such patients with 
several drugs if they would like to use a Dosette® or similar memory assistance to 
gain better adherence. Probably soon, the first kind of medication review, which will 
be paid by the healthcare system, will be implemented in Switzerland enabling 
pharmacists to perform a kind of concordance review (as described in the UK; [133]) 
in the pharmacy and to provide a pill box for 3 months after the review. This review 
would be performed without a referral of a physician. 
 
Most patients kept their drugs in the kitchen or the bathroom where it is often moist 
and warm. These are not the best places for medication storage. An alternative could 
be medicine cupboards which moreover allow a better overview. Furthermore, the 
presence of a medicine cupboard could help to detect quickly expired and hoarding 
of medications. However, none of the patients in this pilot used a medicine cupboard. 
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To decrease the amount of hoarding, pharmacists could give advice to the patients to 
pay attention to the presence of unused drugs. Expired medications can be brought 
to every pharmacy. All drugs at home should be periodically checked, either by the 
patient or by a pharmacist. 
 
In 25% of the home visits, patients reported to be confused of generic and trade 
names. Patients often do not know whether they take an original or a generic drug. 
This fact does not have to be a problem, but, if patients are not informed, the 
confusion could lead to therapeutic duplications (present in 15% of patients in this 
pilot). Thus, it seems to be important to better inform patients about original and 
generic drugs. 
 
Fourteen (70%) patients do not live alone. In these households the drugs were 
identified with different storage locations in 14%; and 43% reported that all people 
living in the household know the drugs. The remaining 6 (43%) patients do not have 
any system or have never thought about this risk factor. 
 
Two patients (10%) reported about any problems with application (e.g. big tablets), 
seven (35%) about supposed adverse drug effects. Considering that most of the 
patients are not informed about adverse effects and how to act in the case of adverse 
effects, this is a domain with a large room for improvement. Pharmacists, and 
physicians, should inform patients how to use the drugs correctly and also what to do 
in the case of an omitted drug intake or if experiencing supposed adverse drug 
effects. 
 
Sorensen et al. found that most frequently ‘confusion of generic and trade names’ 
was reported (56% vs. 25% in our study) while ‘risk for non-adherence’ was noted 
with the second highest frequency (53% vs. 75%). ‘Therapeutic duplications’ were 
identified in 25% (vs. 15% in our study), ‘expired medications’ were present in 20% 
as in our study, and ‘multiple medication storage locations’ were only used in 8% (vs. 
55% in our study). However, the patients included by Sorensen were chronically ill, 
i.e. more than four regular medications, suffering on more than two medical 
conditions or more than 11 doses of medication per day. This means that they 
already have taken their drugs for a longer time in contrast to our study with patients 
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taking a drug the first time and probably only for a limited time. Further, the home 
visits were performed by community pharmacists and general practitioners with more 
experience than the investigator of this pilot. 
 
The patients were good informed 2-3 days after getting their new prescribed 
medication about purpose of intake (92%) and dosage (number of tablets known in 
84% and frequency or timing of ingestion known in 96%). During the home visits, 
about 30 days after taking up the new prescribed drug in the pharmacy, 85% still 
knew the purpose and in 90% the dosage of all their drugs. However, for the phone 
interviews every drug was evaluated separately in contrast to the home visits where 
all drugs together were rated. This means that if the purpose of one drug was 
unknown in the home visit, the domain ‘purpose of drug’ was assessed as unknown. 
Because of rather good knowledge of patients with new prescribed drugs we decided 
to focus on chronically ill patients for the main study. 
 
The newly developed interview guide for home visits proved to be a useful tool. The 
pilot gave important information on improvements, which were incorporated in the 
following main study. These were amendments to the interview guide, such as 
questions about the intake of self-purchased over-the-counter (OTC) drugs (including 
herbal and traditional Chinese medicine (TCM) products), more detailed questions 
about the handling of drugs (e.g. use of pill organizers), actions in the case of a 
missed dose or a suspected adverse drug reaction (ADR), efforts to inform other 
healthcare professionals (HCP) about all drugs taken, knowledge about potential 
ADRs and interactions (drug-drug and drug-food), assessment of any concerns about 
the drugs, information on whether package inserts were read, the year of diagnosis 
of the diabetes or of the transplantation, and the number of pharmacies from which 
drugs are obtained. 
 
Most importantly, we recognised that such medication reviews pursues two different 
goals: Research and individualised patient service. To fulfil both, we will in future 
consider performing home visits by two persons of which one has the mandate to 
assess the data. 
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Conclusion 
 
Patients obviously had limited knowledge about adverse effects. The knowledge 
about dosage and frequency was satisfactory. Deficits could be avoided by concise 
and more subject-oriented written information. Confusion of generic and trade names 
could be avoided by informing patients about this subject. With this information, 
therapeutic duplications could probably be limited as well. The risk for non-adherence 
is difficult to be lowered. Home visits showed to be a feasible service, presumably 
also for community pharmacies. There is a potential to reduce MRRFs in patients’ 
homes and to improve patient knowledge. 
Opportunities for pharmaceutical care 
 172
Tables and figures 
 
 
Action: Prescription  Dispensed drugs  Drug use 
      
      
Intervention: Physician  Pharmacist  Patient 
Fig. 1: Prescribing, dispensing, and use of drugs 
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0% 20% 40% 60% 80% 100%
Risk for non-adherence
Multiple medication storage locations used
No medication administration routine
Hoarding of POM
Confused of generic and trade names
Expired medication present
Hoarding of OTC medicines
Therapeutic duplication present
Discontinued medication repeats retained
Percent of patients
At risk No risk Missing
 
Fig. 2: Prevalence of medication-related risk factors detected in home visits (n=20) 
 
  
Table 1: Results from phone interviews (n=70) stratified into medication class and medication type: over-the-counter (OTC) and prescription-only 
medicines (POM). Abbreviations: medication communication index (MCI); not applicable (NA). 
For dermatologic medication, the MCI is calculated by assigning 1 point to each of the topics: name, purpose or justification, duration, frequency or timing of use, and adverse 
effects 
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Abstract 
 
Objectives 
To get insight into the self-management of medications by diabetes type 2 (DM) and 
solid organ transplant (Tx) patients, to analyse drug-related problems (DRPs) and 
patients’ knowledge about the drugs, and to explore opportunities for pharmaceutical 
care. 
 
Setting 
Seventy-one Swiss community pharmacies offering internships for pharmacy 
students. 
 
Methods 
Diabetes and transplant patients were recruited in community pharmacies and were 
visited at home by the study investigator together with a fifth-year pharmacy student, 
using a specific interview guide developed for this study. 
 
Results 
In total, 24 (Tx patients) and 54 home visits (DM patients) were carried out. Mean 
age of visited patients was 71.4 ± 8.1 years (DM) and 52.6 ± 13.8 years (Tx). Overall, 
37.0% (DM) and 50.0% (Tx) of the participants were female. We identified 7.4 ± 2.4 
(mean ± SD) DRPs per visited patient, with significant differences between Tx and 
DM patients (6.3 ± 1.7 vs. 7.8 ± 2.5; p=0.010; Student t test). The most frequent 
DRPs were confusion of generic and trade names (DM: 74.1%; Tx: 27.3%), hoarding 
of over-the-counter (DM: 48.1%; Tx: 4.5%) and prescription-only medicines (DM: 
37.0%; Tx: 36.4%), and gaps in knowledge about potential interactions (DM: 
61.1%; Tx: 18.2%) and purpose of drugs (DM: 48.1%; Tx: 36.4%). Mean (SD) 
duration of the visits was 51.7 ± 21.4 min. 
 
Conclusion 
Visiting Tx and DM patients in their homes allowed the identification of specific DRPs 
which most probably would have escaped a medication review in the pharmacy. As 
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expected, Tx patients had fewer DRPs than DM patients because of their continuous 
care. 
 
Keywords  Pharmaceutical care · Home visits · Medication review · Community 
pharmacy · Diabetes type 2 · Solid organ transplantation · Medication management 
 
Impact of findings on practice 
 
- Home visits seem to be a useful service and allow assessing a wide range of 
drug-related problems which most probably would not have been detected in 
an interview in the pharmacy. 
 
- The interview guide developed specifically for the purpose of this study proved 
useful in the selected patient population. However, more tailored interview 
guides for different diseases would enable more efficient home visits. 
 
- The most frequently observed DRPs (e.g. confusion of generic and trade 
names, hoarding of medications, gaps in knowledge) are important 
shortcomings which easily can be solved by pharmacists. 
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Introduction 
 
Medication review by pharmacists is increasingly being implemented in the primary 
care setting and has been incorporated into the new pharmacy contract in the UK 
[235]. A medication review is defined as “a structured, critical examination of a 
patient’s medicines with the objective of reaching an agreement with the patient 
about treatment, optimising the impact of medicines, minimising the number of 
medication-related problems, and reducing waste” [235]. Regular performance of 
such reviews is prominent among methods that have been advocated to reduce the 
extent and seriousness of drug-related problems (DRPs) [55]. Recent studies 
indicated that pharmacist-led medication review and home visits are potentially 
beneficial [54, 142, 145, 206-208], but some randomised controlled trials failed to 
prove effectiveness [67, 146, 236, 237]. It is still an open question if tailored 
medication reviews by specifically trained pharmacists are needed. 
 
There are different levels of medication reviews described, such as in the UK by the 
National Health System (NHS): type 1 (prescription review), type 2 (concordance and 
compliance review), and type 3 (clinical medication review) [133]. The different 
review types are not hierarchical but each has a distinct purpose: prescription 
reviews address technical issues relating to the prescription (e.g. anomalies, 
changed items, cost effectiveness); concordance reviews address issues relating to 
the patient’s medicine-taking behaviour, and the clinical medication reviews address 
issues relating to the patient’s use of medicines in the context of their clinical 
condition. 
 
Systematic medication review carried out by pharmacists has been shown to be an 
effective cognitive service to identify DRPs [40, 54, 142, 170, 208, 238, 239]. 
However, not all DRPs can be detected by a review in the pharmacy [170]. To get 
more information about the patient’s medication management, it may be useful to 
visit them at home. Sorensen et al. [170] observed patients in their own home and 
screened for so-called medication-related risk factors (MRRFs). Most frequently, 
confusion by generic and trade names was observed while poor adherence was 
reported with the second highest frequency. Further common risk factors or DRPs 
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were therapeutic duplications, expired medications, multiple medication storage 
locations, and medication hoarding. These risk factors may be related to adverse 
drug events, hospitalisation due to adverse drug events, and hospital readmission 
[170]. 
 
Home visits allow conducting a prescription review and observing the patient’s 
medicine-taking behaviour. In this way, insight into all aspects of self-management of 
a drug regimen and the patients’ use of medicines in the context of their clinical 
condition may be possible [170]. 
 
Chronically ill patients, e.g. those suffering from diabetes type 2 (DM) or patients 
after solid organ transplantation (Tx) are often faced with complex 
pharmacotherapeutic regimens requiring intake of multiple drugs several times daily. 
Diabetic patients often suffer from hypertension, coronary heart disease, and/or 
hypercholesterolaemia. Transplant patients have a high risk of developing gout, 
hypertension, or hypercholesterolaemia [240-247] if not already present before 
transplantation. For these patients living in their own homes, self-management poses 
an important challenge and continuity of pharmaceutical care is a key issue to 
promote persistence with drug therapy and to avoid DRPs [235]. 
 
In Switzerland, the healthcare system allows physicians to issue repeat prescriptions, 
theoretically enabling patients to get their medications up to 12 months without 
further physician appointment. Within this period, the pharmacist is the only 
healthcare professional with whom patients have contact. If not well informed by the 
general practitioner (GP) and the pharmacy, patients may have a lack of knowledge 
leading to problems with their drug regimen. On the other hand, transplant patients 
are coached extensively before, during, and after transplantation for a long period of 
time. After this intensive care programme, most nephrological patients, for example, 
do not have a GP but continue to consult their nephrologist for any complaint, even if 
minor. Both, DM and Tx patients are reliable pharmacy visitors with regular 
attendance at the community pharmacy to get their drugs. 
 
Long-term treatment of diabetes and transplant patients varies substantially. 
Therefore, we selected these two patient populations for a comparison in order to 
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reveal opportunities for pharmaceutical care. We hypothesized that Tx patients are 
highly adherent and have a considerable knowledge about their drugs and disease 
because of their extensive instruction and counselling in the hospital, whereas DM 
patients may become less reliable over time leading to a risk for non-adherence and 
a decreased knowledge about their pharmacotherapy or the reason why they have to 
take their drugs. Taking into consideration the continuous care provided to transplant 
patients, we expected to observe important differences between DM and Tx patients 
in pattern and frequency of DRPs. 
 
The first objective of this study was to get insight into the self-management of 
medications by DM and Tx patients in the primary care setting. The second objective 
was to analyse DRPs and patients’ knowledge about the drugs and their 
management. The third objective was to explore opportunities for pharmaceutical 
care and the suitability of the interview guide developed specifically for home visits. 
 
Methods 
 
This prospective, cross-sectional, observational study was conducted in Switzerland 
from April 2007 to April 2009. We started with a pilot of 4 months and the 
development of an interview guide before conducting the main study. 
 
Development of the interview guide 
 
In the pilot study, we assessed patients’ knowledge about prescribed medications in 
a phone interview two days after visits in the pharmacy. These findings as well as 
results of a previous study of DRPs [248] and a literature review allowed developing 
a first draft of a structured interview guide whose usefulness was tested with patients 
who were recruited by the phone interviews. We carried out 70 phone interviews with 
patients who were recruited through a direct contact by fifth-year pharmacy students 
in community pharmacies in the region of Basel, Switzerland. Of the 70 contacted 
patients, 20 individuals agreed to be visited at home by the researcher. This pilot 
study resulted in important amendments to the interview guide, such as the intake of 
self-purchased over-the-counter (OTC) drugs (including herbal and traditional 
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Chinese medicine [TCM] products), more detailed questions about the handling of 
drugs (e.g. use of pill organizers), actions in the case of missed dose or a suspected 
adverse drug reaction (ADR), efforts to inform other healthcare professionals (HCP) 
about all drugs taken, knowledge about potential ADRs and interactions (drug-drug 
and drug-food), assessment of any concerns about the drugs, information on whether 
package inserts were read, the year of diagnosis of the diabetes or of the 
transplantation, and the number of pharmacies from which drugs are obtained. In 
addition, we recognised that home visits performed by one person alone results in 
poor quality of data. To ensure optimum reliability of information acquisition, we 
decided to conduct all home visits in the main study with two persons, i.e. the fifth-
year pharmacy student who had recruited the patient together with one of three 
specifically trained investigators. The final version of the interview guide comprised 
57 items. 
 
Outcome measures 
 
We assessed the patients’ knowledge about drug therapy (purpose and dosage of 
each drug) and the prevalence of MRRFs as defined by Sorensen et al. [170], i.e. 
risk for non-adherence using the self-reported medication-taking scale by Morisky 
[231], expired medications present, hoarding (one or more drugs no longer required 
but retained at home) of OTC drugs and prescription-only medicines (POMs), 
therapeutic duplications (two or more concomitant medications containing the same 
active ingredient), multiple locations of medication storage, no medication 
administration routine (e.g. no pill organizers used), discontinued medication repeats 
retained, and the patient’s confusion of generic and trade names. To avoid confusion 
with the generally used term DRP, we decided to rename MRRFs as DRPs 
according to the definition given by the Pharmaceutical Care Network Europe 
(PCNE), i.e. as events or circumstances involving drug therapy that actually or 
potentially interfere with desired health outcomes [128]. We assessed the self-
management of prescribed pharmacotherapy and additional problems (e.g. drugs 
belonging to other individuals living in the same household, any problems with using 
or handling the drugs, or any suspected ADR since taking the drug). Furthermore, we 
considered hazardous actions in the case of a suspected ADR (e.g. discontinuing the 
medicines; accepting minor ADR, e.g. skin modification; lowering the dosage). 
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Similarly, we addressed the patients’ actions in case of missed doses (e.g. missed 
dose taken later, missed dose just ignore, inconsistent action, next dose doubled). 
Overall, we evaluated the pattern and frequency of 25 different DRPs. Out of them 
we selected 11 DRPs that could probably not be assessed by a medication review 
performed in the pharmacy but would only be detected through home visits. These 
included multiple locations of medication storage, hoarding of OTC drugs, hoarding 
of POM, confusion of generic and trade names, absent administration routine, 
discontinued medication repeats retained, therapeutic duplication, expired 
medications present, intake of OTC drugs, intake of herbal products, and use of the 
same medication storage location by different people living in the same household. 
We always included self-medication and therapies outside the main treatment. In 
addition, we used pharmacy records and copies of prescriptions of the previous 12 
months to compare the currently taken medications with the prescribed drug therapy. 
 
Setting and participants 
 
A total of 79 Swiss community pharmacies offering internships for fifth-year 
pharmacy master students took part in the study. Inclusion criteria for the main study 
were: diabetes type 2 patients aged 60 years or older and solid organ transplant 
patients 18 years or older who took at least 4 prescribed drugs, were literate in the 
German language, lived in their own home without external support, and whose 
medication history for the previous 12 months was available at the internship 
pharmacy. 
 
Data collection 
 
Fifth-year pharmacy master students of the University of Basel had to recruit either a 
Tx or DM patient from the regular customers of their internship pharmacy. To prepare 
the home visit, the pharmacy record was used to establish a drug-use and drug-
interaction profile for each patient, thus gaining insight into the medication regimen, 
potential non-adherence gaps, as well as potential drug interactions. Any problems 
seen were later integrated in the discussion with the patient. 
 
Opportunities for pharmaceutical care 
 183
Potential drug-drug interactions were classified using Pharmavista® [232] which 
distinguishes five categories of severity. However, only those classified as ‘severe’ 
(life-threatening, intoxication, permanent harm) or ‘moderate’ (frequent therapeutic 
problems/combination can be administered but close monitoring required) were 
considered. 
 
Because this was not an intervention study, no recommendations were made directly 
to the patients, except in a few situations (e.g. the removal of expired drugs, 
explanations about possible purposes of drugs). For each patient, recommendations 
made because of relevant observations were summarised in a short note that was 
given to the responsible pharmacists who had to decide whether intervention was 
needed or not. The interviews were tape-recorded to ensure that patients’ statements 
were assessed correctly. All documents were made anonymous. 
 
The study was approved by the Ethics Committee of Basel, Switzerland. Patients 
gave their written informed consent to participate in the study. If necessary, we 
informed the patient’s responsible pharmacies of any relevant findings or patient’s 
statements in the interest of the patient’s safety. 
 
Statistical analysis 
 
Results are expressed in frequencies and means ± standard deviations (SD) for 
normally distributed and interval-scaled variables, and as medians with the 
corresponding interquartile range (IQR) for non-normally distributed and ordinally 
scaled variables. The non-parametric Mann-Whitney test was used for unpaired two-
sample comparisons, and if data were normally distributed with Student’s t test and 
analysis of variance (ANOVA). To check for possible correlations, McNemar’s chi-
square test and bivariate correlation (Pearson) were used. Statistical significance 
was defined as a p value <0.05. Statistical analyses were performed using SPSS for 
Windows version 15.0 (SPSS Inc., Chicago, IL, USA). 
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Results 
 
During the study period (April 2007 to April 2009), 23 home visits (Tx patients) and 
56 home visits (DM patients) were carried out. Three cases did not fulfil the inclusion 
criteria (one patient had only 3 prescribed drugs, two DM patients were younger than 
60 years), resulting in a sample of 76 home visits. Table 1 shows the basic study 
characteristics. 
 
From the drug list of the DM patients, we deduced the most frequent diseases in 
addition to diabetes. These were hypertension in 45 (83.3%) patients, dyslipidaemia 
(n=28; 51.9%), coronary heart disease (n=14; 25.9%), pain (n=10; 18.5%), and 
arthrosis (n=5; 9.3%). For Tx patients, the most frequent concomitant diseases were 
hypertension (n=10; 45.5%), gastro-intestinal diseases (n=3; 13.6%), and cystic 
fibrosis, dyslipidaemia, gout, osteoporosis, and risk for thrombosis (n=2 each; 9.1%). 
 
Drug-related problems 
 
We identified a mean of 7.4 ± 2.4 DRPs per visited patient, with significant 
differences between Tx and DM patients (6.3 ± 1.7 vs. 7.8 ± 2.5; p=0.010; Student t 
test). All patients had at least one DRP. Table 2 summarises the results for all items 
of the interview guide. 
 
Transplant patients stored drugs either in the kitchen (n=9; 40.9%), the living room 
(n=8; 36.4%), or the bathroom (n=5; 22.7%). All Tx patients kept their drugs in a 
medicine cupboard. Most DM patients stored their drugs in the kitchen (n=22; 40.7%) 
or the bathroom (n=13; 24.1%). Forty-four (81.5%) DM patients used a specific 
cupboard. Four (18.2%) Tx patients reported to have forgotten at least once to 
prepare enough drugs for the holidays whereas 14 (25.9%) DM patients reported 
such a mistake. With respect to self-reported non-adherence, 17 (77.3%) Tx patients 
and 33 (61.1%) DM patients gave at least one positive answer to the Morisky 
questions indicating a risk for non-adherence. Among these, there were 2 (9.1%) Tx 
patients and 17 (31.5%) DM patients who gave two or more positive answers. 
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Among all patients, 11 (14.5%) reported to have problems with their drugs (e.g. 
swallowing, opening of a bottle, use of a pipette). A total of 19 (86.4%) Tx patients 
and 26 (48.1%) DM patients stated that they had experienced one or more adverse 
drug events since the start of the drug therapy (p=0.002). History of allergies (active 
ingredients or excipients) was reported by 9 (40.9%) Tx and 12 (22.2%) DM patients. 
 
If interviews had been conducted at the pharmacies rather than the patients’ homes, 
we most probably would have detected only 3.6 ± 1.5 (48.6%) DRPs. Thus, we 
reason that 51.4% of all DRPs were only identified because we performed visits at 
the patient’s home. 
 
Discussion 
 
This study provides insight into the self-management of drug therapies by transplant 
and diabetes patients. We observed a total of 7.4 ± 2.4 DRPs per visited patient, with 
significant differences between transplant and diabetes patients. 
 
For this study, we developed a specific interview guide for home visits which was 
tested within a large pilot study. We used the MRRFs described by Sorensen et al. 
[170] and carefully assessed further DRPs. In addition, we used integrated questions 
with respect to knowledge resulting in a comprehensive 57-item interview guide. A 
total of 17 items were specifically included for the purpose of home visits. 
 
Other studies of home visits used the term ‘pharmaceutical care issues’ (PCIs) 
without differentiation between MRRFs and DRPs. In our study, we used the term 
DRP for both the MRRFs defined by Sorensen [170] and the other DRPs. We feel 
that risk factors can easily be attributed to circumstances that actually or potentially 
interfere with desired health outcomes, as stipulated by the definition of a DRP [128].  
 
The interview guide was designed to provide the basis for pharmacist-led home visits 
of patients and to screen for opportunities for pharmaceutical care. The median (IQR) 
duration of visits was 60 (30) min and 45 (25) min for Tx and DM patients, 
respectively. Other studies reported similar durations of medication reviews at 
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patients’ homes, ranging from 15 to 120 min [54, 58, 206, 208, 237, 238, 249], 
illustrating that home visits represent a time-consuming process for both the health 
professional and the patient. In our study, pharmacy master students visited the 
patients and therefore, no on-site interventions were performed. The interviewers had 
to document opportunities for intervention for discussion with the responsible 
pharmacist who then decided upon the need for action. The concept of conducting 
the home visits with two investigators resulted in very complete data sheets with no 
missing data. 
 
Our study revealed a higher number of DRPs compared to earlier studies [80, 208, 
238, 250]. Other studies involving home-dwelling residents reported DRPs ranging 
from 2.2 [251] to 4.1 [238] per person, with 81% of DM patients having at least one 
DRP. Similarly, studies in residents of care facilities reported between 2.4 [239] and 
3.5 [208] DRPs per patient. A European study conducted in 2004 documented 5.9 
potential DRPs per patient [80]. However, Krska et al. [40] conducted home visits and 
found 8.4 and 7.2 PCIs per patient. If we compare our results with the study by 
Sorensen [170], the prevalence of DRPs is similar, and both studies revealed the risk 
for non-adherence (52.5% vs. 65.8%) and the confusion of generic and trade names 
(55.9% vs. 60.5%) as the most frequent DRPs. 
 
To identify patients at risk for non-adherence, we used the self-reported 4-item 
medication-taking behaviour scale by Morisky [231]. According to the definition of 
Soerensen [170], only one criterion had to be met for a patient to be considered at 
risk for non-adherence. While our study was in process, Morisky published a revised 
tool to determine medication adherence containing 8 questions [252]. This 8-item 
instrument had a higher sensitivity (93%) and specificity (53%) than the original 4-
item scale (81% and 44%) and was designed to function as a screening tool to 
identify patients who are at risk for non-adherence [252]. However, because the 
original instrument is short and has proven useful in practice [249, 253], we feel that 
the 4-item Morisky score is a suitable and simple tool for home visits to identify 
patients at risk for non-adherence and to address any problems and other factors 
jeopardising the adherence to therapeutic regimens. 
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Nevertheless, if the patient reports very good adherence to his or her therapeutic 
regimen, this may not be true objectively. Even if patients are told that it is ‘human’ to 
forget a dose or to be careless with drug intake, it is reasonable to assume that 
patients may not be entirely honest. Thus, non-adherence levels would be expected 
to be higher than reported. This is a potential source of bias which is well known 
[216-218]. However, if patients confess that they occasionally forget to take a dose, 
this scale would provide a basis for discussion with the patient about non-adherence 
in general. 
 
In 2008, Vuong et al. [249] reported a risk for non-adherence of 59% which the 
authors had determined on the basis of slightly modified Morisky questions. We 
found more patients hoarding drugs (50.0% vs. 21.5%), not apply any medication 
administration routine (36.8% vs. 27.8%), and using multiple medication storage 
locations (34.2% vs. 8.3%). However, in our study fewer patients kept expired 
medications (9.2% vs. 19.3%) or retained discontinued medication repeats (10.5% 
vs. 21.4%) than in the study by Vuong et al. [249]. 
 
Thus, the results of this study show that a) the prevalence of DRPs in both patient 
groups was similar or even higher than those previously described in the literature, 
and b) the extension of our interview guide for home visits resulted in detection of a 
higher number of DRPs. Several reasons may explain this higher number in our 
study. First, students may be more eager to find as many DRPs as possible. In 
addition, students tend to have much more time than employed pharmacists for 
conducting home visits. Furthermore, it is reasonable to assume that patients are 
more willing to talk to students than to pharmacists or physicians about their disease, 
drugs, and concerns. Furthermore, our interview guide with 57 items was very 
comprehensive. The more items there are, the higher the probability to detect any 
DRPs. Another reason for the discrepant prevalence of DRPs in the various studies 
may be the use of different coding systems, different data collection methods, and 
different education levels of the persons collecting the data [127]. 
 
Comparison of the pattern and prevalence of DRPs between Tx and DM patients 
revealed similarities but also interesting differences. Diabetes patients were at a 
significantly higher risk of hoarding any OTC drugs (p=0.001) and were significantly 
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more often confused by generic and trade names (p<0.001) than transplant patients. 
However, these two findings can be partially explained because of the higher mean 
age of diabetes patients (Table 1Table ). 
 
Most Tx patients did not live alone (86.4%) and had support by a family member. 
Overall, 63.6% of them were still employed with daily routine and were younger than 
many DM patients (mean age 52.6 years vs. 71.4 years) because the need for 
transplantation does not have to be associated with greater age. Many diabetes 
patients had no basic knowledge about potential interactions (61.1%), but only 18.2% 
of Tx patients knew little about interactions. If a dose was missed, Tx patients 
reported that they would ask their physician in 40.9%, while only 5.6% of DM patients 
would contact their GP; 61.1% of DM patients would just ignore it (vs. 27.3% of Tx 
patients). During home visits, many Tx patients reported that they tolerated certain 
ADRs and were highly appreciative of their ‘second life’ after transplantation, in 
particular if they received an organ from a living donor. In contrast, DM patients often 
regarded their disease as a burden and found their drug regimen cumbersome 
because of the increasing complexity over the years and their dependence on 
medication for the rest of their lives. 
 
The differing perception of the medical condition in the two patient groups could have 
important consequences for several DRPs (e.g. non-adherence, concerns, and little 
knowledge) which could be a topic for further research. The different numbers and 
patterns of DRPs in Tx and DM patients can be explained by variable pre-conditions, 
monitoring, and medical support. Hence, these differences raise the question if, for 
implementation in routine pharmacy practice, more tailored interview guides are 
needed to perform home visits efficiently in other medical conditions. 
 
The potential risk for non-adherence was the most frequent risk factor with 65.8% 
and even more frequently expressed in Tx patients (77.3% vs. 61.1%). Jansà et al. 
[36] used the same Morisky questions with the same cut-off (≥1 question positively 
answered) for patients with multiple chronic conditions and revealed 82% of patients 
at risk for non-adherence. Looking at the first two Morisky questions reveals that Tx 
patients reported to forget to take a drug significantly less frequently than DM 
patients (13.6 vs. 44.4%) but they seemed to be much more cautious with respect to 
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adherence to timing (‘careless at times about taking your medicine’; 
72.7% vs. 35.2%). Thus, we have some doubts about the appropriateness of the 
assessment of the ‘risk for non-adherence’ as defined by Sorensen [14] and we 
presented detailed data for all Morisky questions as Jansà et al. [36] did.  Such 
analysis of the pattern of answers to the Morisky questions results in very important 
information for tailored counselling.  
 
Overall, the home visits revealed a large number of opportunities for pharmaceutical 
care. Important issues which a pharmacist could solve on-site and which he or she 
should review regularly were confusion about generic and trade names, hoarding of 
OTC and prescription-only medicines, gaps in knowledge about interactions and 
purpose of drugs, problems with the use of medicines, and the taking of OTC 
medicines or herbal products. To our knowledge, this is the first pharmaceutical care 
study observing patients at their homes in Switzerland. Therefore, this work could be 
seen as a starting point for further research in Switzerland. 
 
The advantage of home visits is the possibility to get insight into the patient’s 
management of his/her drug therapy at the place where it happens, and to detect 
DRPs which most probably would not be picked up by interviews in the pharmacy, 
even if the so called ‘brown bag’ method is used [183, 254-256]. Therefore, we tried 
to tag items of our interview guide which could only be assessed by home visits. Our 
evaluation resulted in an important fraction of DRPs (51.4%) that were identified only 
because we performed visits at the patient’s home. Thus, our results clearly 
underline the value of home visits in chronically ill patients. 
 
There are several limitations to our study. First, we were only able to recruit willing 
patients who were motivated to be visited at home by a researcher leading to a 
potential selection bias. Probably, pharmacotherapy management by such patients is 
better than by randomly selected patients. Second, the data analysed in this study 
were collected with the aid of a standardised interview guide, but we conducted the 
home visit for research purposes. If a DRP was not part of the interview guide, the 
problem was probably not picked up by the less experienced students because of 
their faith in the present interview guide. The task was not to find as many DRPs as 
possible but to deliver a complete data sheet. These visits may therefore not 
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accurately represent what they could if performed in practice by a trained pharmacist. 
Third, DRPs were reported only by the patient and were based on the information 
available from the pharmacy. Medical records (laboratory data, medical reports, 
therapy plans, etc.) were not consulted and the prescriber was not involved. Clearly, 
such a multidisciplinary approach would allow a more complete assessment and 
would minimise the risk of researchers to identify any DRPs that had already been 
addressed by the GP.  
 
We could not definitively identify any erroneous dosages of patients but could only 
check if a dosage was plausible and if the timing of taking the medication was 
appropriate. Therefore, we only checked the appropriateness of dosages (e.g. timing, 
frequency). Therapy failure was not part of the interview guide and was therefore not 
detected. In addition, the large number of different persons collecting the data may 
question the reliability of data collection. However, all participating fifth-year 
pharmacy students had been trained to collect data and each student was 
accompanied by a master student. 
 
Conclusion 
 
Home visits of transplant and diabetes patients allowed us to assess more drug-
related problems than would have been detected with a medication review in the 
pharmacy. As expected, transplant patients had fewer drug-related problems than 
diabetes patients. In diabetes patients, confusion about generic and trade names, 
hoarding of drugs, and gaps in knowledge about interactions and purpose of drugs 
were most frequently observed. These aspects represent important opportunities for 
pharmaceutical care. 
 
The interview guide developed specifically for the purpose of this study proved useful 
in the selected patient populations. More tailored interview guides for different 
diseases would enable more efficient home visits. 
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Tables and figures 
 
Table 1: Basic study characteristics of transplant (Tx; n=22) and diabetes (DM; n=54) patients 
 Transplant patients Diabetes patients Total p-values  
(Tx vs. DM) 
 n (%) n (%) n (%) 95%; 2-tailed 
Home visits 22 (28.9) 54 (71.1) 76 - 
Age − mean ± SD years 
(range, years)  
52.6 ± 13.8 
(23−75) 
71.4 ± 8.1 
(58−91) 
66.0 ± 13.2 
(23−91) 
p<0.001a 
Female − n (%) 11 (50.0) 20 (37.0) 31 (40.8) p=0.297b 
No. of patients living alone − n (%) 3 (13.6) 25 (46.3) 28 (36.8) p=0.007b 
No. of patients still employed − n (%) 14 (63.6) 10 (18.5) 24 (31.6) p<0.001b 
No. of chronic medical conditions† – mean ± SD 
- self report of patient (during the visit) 
- deduction from drug list (after the visit) 
 
2.3 ± 1.6  
4.3 ± 1.6 
 
3.5 ± 1.3 
4.5 ± 1.3 
 
3.2 ± 1.5 
4.5 ± 1.4 
 
p<0.001b 
p=0.362b 
     comparison within each  patient group (self report vs. deduction) p=0.018d p<0.001d p<0.000d - 
No. of medications – mean ± SD 
- self report of patient (during the visit) 
- deduction from drug list (after the visit) 
 
10.2 ± 4.9 
12.5 ± 4.4 
 
9.8 ± 3.5 
13.9 ± 5.4 
 
10.0 ± 4.0 
13.5 ± 5.1 
 
p=0.331c 
p=0.708a 
     comparison within each patient group (self report vs. deduction) p=0.834d p<0.001d p=0.011d - 
continued next page 
  
 
 Transplant 
patients 
Diabetes patients Total p-values  
(Tx vs. DM) 
Years since diagnosis of type 2 diabetes or since transplantation  –  
mean ± SD 
median (IQR) 
 
7.5 ± 5.5 
6.5 (7.25) 
 
14.2 ± 10.6 
10 (13.25) 
 
12.0 ± 9.7 
10.0 (11) 
 
p=0.009c 
Duration of visits (minutes) − mean ± SD 
median (IQR) 
60.0 ± 26.0 
60.0 (30) 
48.3 ± 18.4 
45.0 (25) 
51.7 ± 21.4 
50.0 (25) 
p=0.039c 
 
a) Student t test 
b) Chi-square 
c) Mann-Whitney u test 
d) analysis of variance (ANOVA) 
‡ insufficient data to calculate statistical comparisons 
† number of chronic medical conditions including transplantation or diabetes (with treatments >3 months) 
  
Table 2: Drug-related problems identified in transplant (Tx; n=22) and diabetes type 2 (DM; n=54) patients 
 Transplant patients  
(n=22) 
Diabetes type 2 
patients  
(n=54) 
Total  
 
(n=76) 
p-values  
 
(Tx vs. DM) 
 n (%) n (%) n (%) 95%; 2-tailed 
Uncertainty about one or multiple purposes or justification of all drugs 8 (36.4) 26 (48.1)  32 (42.1) p=0.101a 
Uncertainty about one or multiple dosages (drug amount and timing) 1 (4.5) 2 (3.7) 3 (3.9) p=0.367a 
Uncertainty about potential adverse effects 7 (31.8) 27 (50.0) 12 (44.7) p=0.063a 
No. of severe potential interactions 
No. of moderate potential interactions 
1 (4.5) 
15 (68.2) 
3 (5.6) 
41 (75.9) 
4 (5.3) 
56 (73.7) 
p=0.859c 
p=0.013c 
No basic knowledge about potential interactions (e.g. grapefruit, St. 
John’s wort; beta-blockers) 
 
4 (18.2) 
 
33 (61.1) 
 
37 (48.7) 
 
p=0.027a 
Multiple pharmacies visited to receive drugs 0 (0.0) 1 (1.9) 1 (1.3) p=0.527d 
Drugs belonging to other people living in the same household † 17 (77.3) 28 (51.9) 45 (59.2) p=0.031a 
Concerns about medicines 7 (31.8) 9 (16.7) 16 (21.1) p=0.118a 
Any problems with the use of drugs 3 (13.6) 8 (14.8) 11 (14.5) p=0.896a 
No efforts to inform other HCP about all drugs taken if receiving an 
OTC drug or a prescription for a POM 
 
9 (40.9) 
 
9 (16.7) 
 
18 (23.7) 
 
p=0.277a 
    Hazardous actions in the case of suspected ADR 
 discontinuing the medicines 
 accepting minor ADR  (e.g. skin modifications) 
     lowering the dosage 
0 (0.0) 
1 (4.5) 
0 (0.0) 
3 (5.6) 
0 (0.0) 
1 (1.9) 
3 (3.9) 
1 (1.3) 
1 (1.3) 
p=0.083a 
p=0.329a 
p=0.527a 
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 Transplant patients  
(n=22) 
Diabetes type 2 
patients (n=54) 
Total  
(n=76) 
p-values  
(Tx vs. DM) 
Hazardous actions in the case of missed doses     
     missed dose taken later 
     missed dose just ignore 
     inconsistent action 
     next dose doubled 
12 (54.5) 
6 (27.3) 
5 (22.7) 
1 (4.5) 
29 (53.7) 
33 (61.1) 
14 (25.9) 
0 (0.0) 
41 (53.9) 
39 (51.3) 
19 (25.0) 
1 (1.3) 
p=0.948a 
p=0.006a 
p=0.774a 
p=0.329a 
Package insert not read 6 (27.3) 7 (13.0) 13 (17.1) p=0.613b 
Any suspected ADR since start of drug intake 19 (86.4) 26 (48.1) 45 (59.2) p=0.002b 
No. of patients taking OTC drugs* † 
(purchased by themselves) 
 
10 (45.5) 
 
31 (57.4) 
 
41 (53.9) 
 
p=0.716b 
No. of patients taking herbal, homeopathic or TCM products † 6 (27.3) 20 (37.0) 26 (34.2) p=0.896b 
Therapeutic duplication present° † 2 (9.1) 4 (7.4) 6 (7.9) p=0.805b 
Expired medications present° † 2 (9.1) 5 (9.3) 7 (9.2) p=0.656b 
Discontinued medication repeats retained° † 4 (18.2) 4 (7.4) 8 (10.5) p=0.302b 
Multiple medication storage locations used° † 9 (40.9) 17 (31.5) 26 (34.2) p=0.432b 
Hoarding of OTC medicines° † 1 (4.5) 26 (48.1) 27 (35.5) p=0.001b 
No medication administration routine° † 8 (36.4) 20 (37.0) 28 (36.8) p=0.956b 
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 Transplant patients  
(n=22) 
Diabetes type 2 
patients (n=54) 
Total  
(n=76) 
p-values  
(Tx vs. DM) 
Hoarding of prescription only medicines° † 8 (36.4) 20 (37.0) 28 (36.8) p=0.956b 
Confusion of generic and trade names° † 6 (27.3)  40 (74.1) 46 (60.5) p<0.001b 
Risk for non-adherence° 17 (77.3) 33 (61.1) 50 (65.8) p=0.178b 
      Do you ever forget to take your medicine? 
      Are you careless at times about taking your    
         medicine? 
      When you feel better do you sometimes  
         stop taking your medicine? 
      Sometimes if you feel worse when you  
         take the medicine, do you stop taking it? 
3 (13.6) 
 
16 (72.7) 
 
0 (0.0) 
 
0 (0.0) 
24 (44.4) 
 
19 (35.2) 
 
5 (9.3) 
 
5 (9.3) 
27 (35.5) 
 
35 (46.1) 
 
5 (6.6) 
 
5 (6.6) 
p=0.011b 
 
p=0.003b 
 
p=0.140b 
 
p=0.140b 
 
a) Student t test 
b) Chi-square 
c) Mann-Whitney u test 
d) analysis of variance (ANOVA) 
‡ insufficient data to calculate statistical comparisons 
* Tx patients: paracetamol (40.9%), ‘drops for cough’ (9.0%) 
DM patients: vitamins (13.0%), paracetamol (11.1%), ibuprofen, diclofenac and loperamide (each 7.5%), aspirin (3.7%), codeine/guaifenesin (1.9%) 
○ These drug-related problems have been retrieved from the study of Sorensen et al. [170] who named them medication-related risk factors 
† These drug-related problems could probably not be assessed by a medication review performed in the pharmacy but only through home visits 
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5 General discussion and conclusions 
In this thesis we evaluated different aspects of pharmaceutical care including self-
assessment of its provision, documenting community pharmacists’ activities, and 
opportunities for new community pharmacy services. 
 
In project A the provision of pharmaceutical care by community pharmacists across 
Europe was investigated and factors that could affect its implementation were 
examined. Pharmacies in all regions are adequately equipped to provide 
pharmaceutical care. However, its provision in a comprehensive fashion seems to be 
still limited within Europe. Pharmacists rarely documented activities related to patient 
care, evaluated patients’ perceived status or engaged in implementing therapeutic 
objectives, and monitoring plans. In Denmark, similar results have been revealed by 
Rossing et al. [159] in 2003. One important barrier of the implementation and 
provision of pharmaceutical is most probably reimbursement [20]. In Australia, for 
example, pharmacists are reimbursed for several types of cognitive services [257] 
and in Portugal, community pharmacists obtain reimbursement for diabetes disease 
management [20]. The basic pharmaceutical activities (e.g. documentation of 
medical condition, establish a follow-up plan) which the BPCS study asked for, are 
generally not remunerated. Further, not all countries have specifically appointed 
professors to educate pharmacy students in this area of pharmacy practice [20]. 
Overall, much room for improvement in different activities is evident. Results should 
stimulate further research and efforts at local level to achieve a higher extent of 
provision of pharmaceutical care. 
 
The objective of project B was an in-depth analysis of data from Switzerland and 
Germany which had been collected for the European BPCS study for an additional 
comparison with specialised quality circle pharmacists and Danish BPCS data. The 
specialised quality circle and Danish pharmacists reached significantly lower scores 
than Swiss and German pharmacists. This was surprising because quality circle 
pharmacists meet each other regularly with the aim to implement and improve 
pharmaceutical care activities in a way that patients realize the desire of pharmacists 
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to optimise care of chronically ill patients. In Denmark, several pharmaceutical care 
services have already been implemented such as medication review and home visits 
with clinical interventions related to assessment of individuals’ drug therapy at the 
pharmacy or in their homes. Keeping in mind these facts, the results of this study 
casts doubt on the results of the whole BPCS study, and the question arises if the 
BPCS scale is sensitive enough to enable a conclusion about the extent to which 
pharmaceutical care is provided to patients. We suggest one explanation for the low 
scoring of pharmacists, who in our view were well placed to perform pharmaceutical 
care activities. Both, quality circle and the Danish pharmacists follow regularly 
professional continuing education and advanced training in the topic of 
pharmaceutical care. They know the concept of pharmaceutical care and the process 
of solving DRPs while other pharmacists probably think that their ‘standard’ care yet 
represents pharmaceutical care and thus reported much higher frequency of 
corresponding activities. A difference in quality consciousness might represent a 
major bias. Therefore, such a questionnaire based survey needs much more 
emphasis on good explanation and definition of what is meant with ‘pharmaceutical 
care services’ as well as key questions to assess responders’ knowledge of the 
concept of pharmaceutical care. Thus, further efforts are needed to develop valid 
assessment tools including indicators for pharmaceutical care activities. 
 
Project C aimed to explore the occurrence of clinical and technical DRPs with new 
primary care and hospital discharge prescriptions in community pharmacies, to 
analyse possible differences between new primary care and hospital discharge 
prescriptions as well as differences between electronically printed and handwritten 
prescriptions, and to evaluate the applicability of the modified classification system. 
We found a high occurrence of clinical and, in particular, of technical DRPs. The 
occurrence was only influenced by the number of prescribed drugs. More than the 
half of all prescriptions showed a clinical or a technical DRP or both. Compared to 
other studies our numbers are quite high, but in this study we set out to use 
prescriptions which we considered likely to have a high prevalence (i.e. newly started 
drugs and prescriptions with at least two drugs). Most of DRPs could be managed by 
the pharmacist alone or after discussion with the patient. These results show that the 
management of DRPs with new prescriptions is a very important activity in the 
community pharmacy which should be explored in further studies with respect to 
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indicators for good counselling and outcomes for the patient. The modified PCNE 
classification system, especially the amendment with a technical DRP category, 
proved to be useful and allowed the classification of all DRPs, but still rather 
complicated to apply in pharmacy practice. Although users agreed that it is important 
to have an opportunity to classify the effort of pharmacies and pharmacists, they 
most probably would not use this classification system in the future. Because of the 
complex nature of many DRPs and the use of classification systems in various 
settings, it seems to be very difficult to achieve a system which fulfils all 
requirements. For future research in development of a classification system for use in 
daily practice, our study clearly indicates that technical problems need to be 
incorporated. 
 
With a pilot we set the goal in project D to explore the knowledge of patients shortly 
after reception of newly prescribed drugs by a community pharmacy and to gain first 
experiences in performing home visits. Patients had little knowledge about adverse 
effects and the name of the drugs. However, they were good informed about dosage, 
frequency, duration of intake, and purpose of drugs. Phone interviews could also be 
used to improve adherence or knowledge about drugs or diseases. Wu et al. [46] 
showed that periodic phone counselling by a pharmacist enables an improvement of 
adherence and a reduction of mortality. However, we used the interviews only for the 
assessment of knowledge and to recruit patients for following home visits which 
showed to be a feasible service. The results of this pilot study are based on a rather 
big number of individuals compared to the main study. This enabled important 
amendments of the structured interview guide, which proved to be very valuable in 
the subsequent main study. 
 
In project E we performed home visits to get insight into the medication 
management of transplant and diabetes patients. We aimed to analyse DRPs and 
patients’ knowledge, to explore opportunities for pharmaceutical care, and to 
evaluate the suitability of the interview guide developed specifically for home visits. 
Home visits allowed assessing most probably more DRPs than would have been 
detected with an interview in the pharmacy. The results show that the prevalence of 
DRPs in both patient groups was similar or even higher than previously described in 
the literature and that the extension of our interview guide for home visits resulted in 
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detection of a higher number of DRPs. Most frequently observed DRPs (e.g. 
confusion of generic and trade names, hoarding of medications, gaps in knowledge) 
represent important shortcomings which are easy to be solved by community 
pharmacists. Limitations of this study were that no medical records were available 
and the prescriber was not involved and we could only check if a dosage was 
plausible and if the timing of taking the medication was appropriate.  
Presumably due to continuous care, transplant patients showed significantly less 
DRPs than diabetes patients. The interview guide developed specifically for the 
purpose of this study proved to be useful in the selected patient population. However, 
differences in the investigated samples raise the question if for implementation in 
routine pharmacy practice more tailored interview guides are needed to perform 
home visits efficiently in other medical conditions. This first study in Switzerland on 
home visits represents an important starting point for future research. First, the 
procedure needs to be optimised to be feasible in daily practice. For this purpose 
focus group discussions with practitioners are important. Second, this service must 
be further developed in cooperation with other healthcare providers to assure 
complementarity of services, Third, an improved procedure, considering these 
aspects, needs a proof of concept and studies looking at clinical, humanistic and 
economic outcomes. 
 
In conclusion this thesis shows that: 
 
- The provision of pharmaceutical care in a comprehensive fashion is still limited 
within Europe. Pharmacists routinely screened patient records and verified 
patient understanding but rarely documented activities related to patient care, 
evaluated patients’ perceived status, engaged in implementing therapeutic 
objectives and monitoring plans or self-evaluated their performance in 
providing pharmaceutical care on regular basis. There is a large room for 
improvements. 
 
- Pharmacies are adequately equipped to provide pharmaceutical care. 
However, the provision of pharmaceutical care mainly occurs when 
pharmacists were supported by their computer system. If the results of such a 
survey are presented in detail, they are much more meaningful than when 
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aggregated in domains and dimensions. However, the question arises if the 
BPCS tool is sensitive enough to enable a conclusion about the extent to 
which pharmaceutical care is provided to patients. Thus, further efforts are 
needed to develop valid assessment tools including indicators for 
pharmaceutical care activities. 
 
- Clinical and technical DRPs are frequently observed in new primary care and 
in hospital discharge prescriptions and the occurrence was only influenced by 
the number of prescribed drugs. Therefore, the management of DRPs in 
community pharmacies is a very important activity. The modified PCNE 
classification system proved to be useful and allowed the classification of all 
DRPs, but still rather complicated to apply in pharmacy practice. 
 
- The knowledge of patients few days after reception of newly prescribed drugs 
was rather good (except for drug names and knowledge about potential 
adverse effects), indicating that patients who get their drugs in a pharmacy 
were well informed. Home visits of such patients showed to be a feasible 
service, presumably also for community pharmacists. 
 
- Home visits of chronically ill patients allowed assessing most probably more 
DRPs than would have been detected with an interview in the pharmacy. 
Transplant patients showed significantly less DRPs than diabetes patients 
who were often confused of generic and trade names, hoarded drugs, and had 
gaps in knowledge about interactions and purpose of drugs. These aspects 
represent important opportunities for pharmaceutical care. The interview guide 
developed specifically for the purpose of this study proved useful in the 
selected patient population. More tailored interview guides for different 
diseases would enable more efficient home visits.General introduction. 
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7.1 Data dictionary for the European BPCS study 
 
Section A 
 
A1i  Gender 
  1 = Male 
  2 = Female 
 
A1ii  Year of Registration as Pharmacist 
 
A2  Type of Pharmacy  
  1 = Independent  
  2 = Small Multiple (>4 pharmacies)   
  3 = Large Multiple (10+ pharmacies) 
 
A3  Location of Pharmacy  
  1 = Rural 
  2 = Suburban 
  3 = City or Town Centre 
  4 = Out of Town 
  5 = Health Centre 
 
A4 No. of full time equivalent pharmacists who work in the pharmacy 
 
A5  No. of ancillary, skilled staff involved in the dispensing process 
(excluding pre-registration student) 
 
A6  Pre-registration student employed? 
  1 = Yes 
  2 = No 
 
A7 Approximate number of prescription items dispensed in the pharmacy 
in an average day 
 
A8 Do you participate regularly in continuing education programmes/ 
continuing professional development to maintain and improve your 
competency? 
  1 = Yes 
  2 = No 
 
A9 Do you have a postgraduate qualification in clinical pharmacy? 
 1 = Yes 
 2 = No 
 
A10 Do you participate in regular local multi-disciplinary team meetings, e.g. 
GP, community nurse, social workers? 
 1 = Yes 
 2 = No 
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A11  Does your pharmacy have a private consultation area? 
 1 = Yes 
 2 = No 
 
A12 What pharmacy practice-related software do you use in your practice? 
 
A13  What do you use this software for? 
 
A14 If you need medical/clinical information about patients to whom you 
provide care, do the GPs make this information available to you? 
 1 = Yes 
 2 = No 
 
Do you participate in the following activities? 
 
A15i Health screening 
 1 = Yes 
 2 = No 
                               
A15ii  Patient monitoring                             
 1 = Yes 
 2 = No 
 
A15iii  Domiciliary visiting                             
 1 = Yes 
 2 = No 
 
A15iv  Health promotion/education 
 1 = Yes 
 2 = No 
 
Section B 
 
Indicate how many of the last five patients, who presented a NEW prescription used 
to treat a chronic condition, you provided the following activities to (0-5 patients). 
 
B1  Asked the patient to describe his or her medical condition, including a 
description of medical problems and symptoms. 
 
B2 Documented information about the patient’s medical condition(s) on 
written records or computerised patient medication records or by other 
formal mechanisms in a form that could be read or interpreted by 
another healthcare professional in my absence. 
 
B3 Documented all medications currently being taken by the patient on 
written records or computerised patient medication records or by other 
formal mechanisms in a form that could be read or interpreted by 
another healthcare professional in my absence. 
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B4 Asked the patient what he or she wanted to achieve from the drug 
therapy. 
 
B5 Documented the desired therapeutic objectives for the patient. 
 
B6 Checked the patient’s records for potential drug-related problems (e.g. 
interactions, side-effects, poor compliance) 
 
B7  Discussed the patient’s drug therapy with him or her. 
 
B8 Verified that the patient understood the information I presented to him 
or her. 
 
Indicate how many of the last five patients, who presented a REPEAT prescription 
used to treat a chronic condition, you provided the following activities to (0-5 
patients). 
 
B9 Asked the patient questions to assess actual patterns of use of the 
medication. 
 
B10 Asked the patient questions to find out if he or she might be 
experiencing drug-related problems (e.g. interactions, side-effects, poor 
compliance). 
 
B11 Asked the patient questions to find out about the perceived 
effectiveness of drugs he or she was taking. 
 
B12 Asked the patient questions to ascertain whether the therapeutic goals 
were being reached. 
 
 
Question B12.5 does not form part of the questionnaire total score. 
 
B12.5 Was a drug-related problem uncovered? 
1 = A drug-related problem was detected in any of these ten patients 
(i.e. neither box is ticked). 
 2 = I do not check for drug-related problems in my patients (i.e. the top 
box is ticked). 
 3 = I routinely check for drug-related problems, but these 10 patients 
did not experience any (i.e. the bottom box is ticked). 
 
 
Indicate how many of the last five patients who you discovered were experiencing 
drug-related problems you provided the following activities to (0-5 patients). 
 
B13 Documented the drug-related problem(s), potential or actual on written 
notes on patient medication records. 
 
B14 Documented the desired therapeutic goal(s) for each drug-related 
problem(s) identified. 
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B15 Implemented a strategy to resolve (or prevent) the drug-related 
problem(s). 
 
B16 Carried out the follow-up plans established for the patient’s progress 
towards his or her therapeutic objectives. 
 
B17 Documented any intervention made on the patient’s file or patient 
medication records in a form that could be read and interpreted by 
another healthcare professional. 
 
 
In general, considering all the patients with chronic conditions that you have seen in 
the last six weeks, please indicate the extent to which you provided pharmaceutical 
care to these patients (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). 
 
Questions B18 and B19 do not form part of the questionnaire total score. 
 
B18 How often did you try to provide pharmaceutical care to these patients? 
 
B19 How often did you consciously decide and make the effort to provide 
pharmaceutical care to these patients? 
 
 
In general, considering all the patients you saw in the last two weeks, please 
indicate how often you carried out the following activities (1=never, 2=rarely, 
3=sometimes, 4=often, 5=always). For questions that deal with communication, 
we are referring to communication that the pharmacist initiates. 
 
B20 Consulted with other pharmacists in my practice group about difficult or 
unusual patient problems. 
 
B21 Made referrals to other pharmacists whenever it was in the best interest 
of the patient. 
 
B22  Made referrals to a GP when necessary. 
 
B23 Communicated patients’ progress on their drug therapy, good or bad, 
to their GP. 
 
B24 Initiated discussion with GPs whenever I believed one of their patients 
was experiencing a drug-related problem or might experience a drug-
related problem. 
 
B25 Provided the GP with a written summary of the patient’s medication 
history and any related problems when referring a patient. 
 
B26 Referred patients with social problems to appropriate help groups. 
 
B27  Used a quiet location for patient counselling. 
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B28 Double checked each prescription prepared by another person before 
giving the medication to the patient. 
 
B29 Used appropriate information services, e.g. personal reference library, 
Drug Information Unit at Royal Victoria Hospital, to assist me in my 
practice when necessary. 
 
B30 Enquired of patients about their satisfaction with my services in order to 
evaluate my work. 
 
B31 Participated regularly in continuing education programmes to maintain 
and improve my competency. 
 
B32 Used the clinical outcomes of my patients to evaluate my work. 
 
B33 Provided written copies of relevant patient information to professional 
colleagues authorised to have such information for the purpose of 
solving or preventing specific drug-related problems. 
 
B34  Provided general medical information to patients. 
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7.2 BPCS questionnaire for Switzerland 
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7.3 BPCS questionnaire for Germany 
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